Identification of a 40KD Protein Increased by HSV-2 Infection by Lucasson, Jean-Francois
Identification of a 40KD protein increased 
by HSV-2 infection.
by
Jean-Francois LUCASSON
A Thesis Presented For the Degree of Doctor of Philosophy
in the
Faculty of Science, University of Glasgow
Institute of Virology, 
University of Glasgow August 1992
ProQuest Number: 13815504
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13815504
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW
UNIVERSITY
i l ib r a r y
ACKNOWLEDGEMENTS.
I am grateful to Professor J.H. Subak-Sharpe for 
allowing me to carry out this work and for providing the 
facilities of the Institute of Virology. I would like to 
thank Dr Joan Macnab for supervising my project and for her 
critical reading of the manuscript of this thesis.
I would very much like to thank Dr Graham Hope, Mr David 
McNab, Mrs Morag Grassie and Mr David Miller for practical 
help during these studies.
I am particularly indebted to Dr Anne Cross, Hilka 
Lankinnen, Joe Conner, Alan Darling and Howard Marsden for 
their helpful advices. Thanks are also due to Mr8 Mary 
Murphy for supplying the virus stocks and Mr8 Leila Brown 
and her colleagues for supplying sterilized glassware.
I thank Dr Maggie Cusack and Gordon Currie of the 
Department of Geology of the University of Glasgow for 
obtaining N-terminus sequences of the proteins and Dr Jeff 
Keen from the department of Biochemistry of the University 
of Leeds for sequencing the peptides.
I thank Dr Howard Jacobs of the Department of Genetics 
of the University of Glasgow, Dr Malcolm. Finbow of the 
Beatson Institute for Cancer Research, Glasgow and Dr B. 
Dunbar of the Department of Biochemistry of the University 
of Aberdeen for their advices
I am grateful to Professor Joseph R. Mattingly of the 
School of Basic Life Sciences, University of Missouri-Kansas 
City (USA), Dr Masahiro Asaka of the Third Department of 
Internal Medicine, University of Sapporo (Japan) and Dr 
Jamboor K. Vishwanatha of the University of Nebraska Medical 
Center (USA) for kindly giving me antisera.
Unless stated otherwise, the work described in this 
thesis was carried out by the author.
Abbreviations.
The following abbreviations are used in this thesis.
AA
Ad
AEV
Aldolase A 
alpha TIF 
Bis
Bi stris
BHK 
BLV 
b. p.
BPV
cAMP
CAPS
cAspAT
CEF
CIN
’’COLUMN 40”
c-onc
CRPV
DATD
DNA
DMP
ds
DPT
DW
E
EBV
EBNA
EDTA
EGF
FGF
FLV
amino acid 
adenovi rus
avian erythroblastosis virus 
fructose 1-6 diphosphate aldolase A 
alpha transinducing factor 
N - N ’-methylene bisacrylamide 
2[bi s (2-hydroxyethyl)amino]-2- 
(hydroxymethyl)propane-l,3-diol 
baby hamster kidney 
bovine leukemia virus 
base pair
bovine papilloma virus
cyclic adenosine monophosphate
3-[cyclohexylamino]-l-propane-sulfonic acid
cytoplasmic aspartate aminotransferase
chick embryo fibroblast
cervical intra epithelial neoplasia
40KD polypeptide retained on the Mono Q
column at p H .9.5 (buffer C) and eluted by
7.5% buffer D.
cellular oncogene
cotton tail rabbit papillomavirus
N , N ’-diallyltartramide
deoxyribonucleic acid
N-dimethyl-N’-phenylthiourea
double stranded
N - N ’diphenylthiourea
distilled water
early gene
Epstein-Barr virus
Epstein-Barr nuclear antigen
ethylenediamide tetra acetic acid di-sodium 
salt
epidermal growth factor 
fibroblast growth factor 
feline leukemia virus
FPLC fast protein liquid chromatography
FPLC:40 40KD polypeptide eluting in the void volume
of the Mono Q at p H .8 (buffer A) 
g gramme
G 10m/s2
GAP GTPase activating protein
GDP/GTP guanosine di/triphosphate
h. hour
HAT hypoxanthine, aminopterin and thymidine
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCMV human cytomegalovirus
HGPRT hypoxanthine guanine phosphorit^syl
transferase
HPLC high performance liquid chromatography
HPV human papilloma virus
HRP horseradish peroxidase
HSP heat shock protein
HSV herpes simplex virus
HSV-1 herpes simplex virus type 1
HSV-2 herpes simplex virus type 2
HT ! hypoxanthine and thymidine
HTLV-1 humam T lymphotropic virus 1
IE immediate early HSV genes
i .p . immunoprecipitation/immunoprecipitated
k 'b ' kilobase ^  Dalton is i/12th of the mass
KD kilodalton i
|of a mole of the atom 12C).
L 1 ate (gene )
LAT latency associated transcripts
LMP latent membrane protein
LTR long terminal repeat
Mab monoclonal antibody
mAspAT mitochondrial aspartate aminotransferase
mDBP major single stranded DNA binding protein
min. minute
mRNA messenger ribonucleic acid
MTR morphological transformation region
m .u . map uni t
MW molecular weight
MDHV Marek disease herpes virus
TG7A Mouse monoclonal antibody raised by Dr N.
LaThangue against DNA binding proteins of 
BHK cells clone C13 infected by HSV-2 
strain 333 (Macnab et a l .. 1985; LaThangue 
and Latchman, 1988).
MMTV murine mammary tumor virus
NPC naso-pharygea] care i noma
npt. non permissive temperature
ORF open reading frame
ori origin of replication
PCNA proliferating cell nuclear antigen
PDGF platelet derived growth factor
PEG polyethylene glycol
PGK phosphoglycerate kinase
p.i. post infection
pH. hydrogen potential
pi isoeiectric point
PK protein kinase
pKa cologarithm of the equilibrium constant
PVDF polyvinyl difluoride
RE rat embryo
RB retinoblastoma gene
RNA ribonucleic acid
r.p.m. revolution per minute
RR ribonucleotide reductase
Rl long repeat segment
Rs short repeat segment
RSV Rous sarcoma virus
RT room temperature
s Svedberg
SDS sodium dodecvl sulfate
SDS-PAGE sodium dodecyl sulfate polyacrylamide
gel electrophoresis
SV simian virus
TBS tumour bearing serum
TBS: 40 40KD polypeptide i.p. by TBS
TBS:90 90KD polypeptide i.p. by TBS
■T Cf 7
TG7A:40 40KD polypeptide i.p. by TG7A
TG7A:90 90KD polypeptide i.p. by TG7A
TBuS tris buffered saline.
TCA trichloracetic acid
TEMED N,N,N’,N ’-tetramethvlenediamine
TES 2-2 {(2-hydroxy-1 ,1-bis(hydroxymethy1 ) ethyl ]
ami nojethanesulfonic acid 
TFA tri fluoroacet ic acid
TTBuS tris buffered saline with 0.5% Tween 20
"Void Volume" is used as a synonym of flow through in this 
thesis.
TK 
TPA 
tris 
t s 
TS
TTT3o-S
U L , Ul
US, Us
’’V OID VOLUME 4 0'
VZV
Vmw
v-on c
w
wt
uC i
ug
ul
thymidine kinase
12-0-tetradecanovl-phorboI-14 acetate
tr i s ( hydroxymethyl ) aminomet.hane
temperature sensitive (mutant)
tris sali ne
unique long segment
unique short segment
volume
ultra violet 
uridine triphosphate
40KD polypeptide eluting in the void volume 
of the Mono 0 column at p H .9.5 (buffer C) 
varicella zoster virus
virus specific polypeptide of apparent
molecular weight (X)
viral oncogene
wei ght
wild type
microCurie
m i c rog ramme
m i cro.1 i t re
THREE AND ONE LETTER AMINO ACID CODES
AMINO ACID THREE LETTERS CODE ONE LETTER CODE
alanine Ala A
arginine Arg R
asparagine Asn N
aspartic acid Asp D
c yste i ne Cys C
glutamic acid Glu E
glutamine Gin Q
glycine Gly G
histidine His H
i soleuc i ne H e I
leuc ine Leu L
1ys i ne Lys K
methionine Met M
phenylalanine Phe F
proline Pro P
serine Ser S
threonine Thr T
tryptophane Trp W
tyros i ne Tyr Y
valine Val V
SUMMARY.
Herpes simplex virus (HSV) has been implicated in the 
etiology of human cancer, but its role in the transformation 
process is not well understood.
A set of cellular polypeptides of 200KD, 90KD (a doublet 
U90 and L 9 0 ) and 40KD (TBS:40) was previously detected by 
immunoprecipitation (i.p.) with tumour bearing serum in the 
Bn5T cell line. The Bn5T cell line is derived from rat
embryo fibroblast transformed by a fragment of the HSV type 
2 (HSV-2). These polypeptides were detected in cell lines 
transformed by other agents and were not detectable in 
control rat embryo (RE) cells (Macnab et a l .. 1985).
The aim of the project was to purify and obtain amino 
acid sequence for the TBS:40. The 40KD polypeptide was
characterized by its digestion pattern with the enzyme 
St.anh. aureus V8 protease. The U90 and the TBS: 40 were 
increased upon infection with HSV (Macnab et a l .. 1992) but 
this was not known at the start of this thesis. The 40KD
protein was purified from Bn5T cells and notfrom infected
cells.
Attempts to raise antibodies in mice and rabbits were 
carried out. In rabbit there was no immunological response. 
To raise monoclonal antibodies (Mab) twelve mice were 
immunized against Bn5T tumour cells. The 90KD polypeptide
i.p. by mouse antisera and the U90 i.p. by TBS were similar, 
in respect of the Staph, aureus V8 protease peptide map. By 
contrast the 40KD polypeptide i.p. by the serum of the mice 
and the TBS:40 had different peptide maps. Therefore, in 
this instance, the immune system of the rat and the mouse 
recognized different 40KD proteins. Unfortunately attempts 
to raise Mabs against the 90KD and the 40KD polypeptides 
failed. Although the 40KD polypeptide did initially raise 
Mabs, these were unfortunately subsequently lost.
The TBS:40 was purified by biochemical methods. In these 
experiments TBS was found to i.p. more than one polypeptide. 
It was decided to purify and identify each polypeptide in 
turn and lastly to test the effect of HSV-2 infection on its 
expression.
Ammonium sulphate fractionation separated two 40KD 
proteins i.p. by TBS. One was mainly insoluble, the other 
was soluble in a 70% saturated ammonium sulphate solution. 
The Staph, aureus V8 peptide map of the TBS:40 and the 40KD 
protein soluble in a 70% saturated ammonium sulphate 
solution were undistinguishable. Therefore it was decided to 
purify the soluble 40KD protein.
The 40KD protein was further purified by anion exchange 
chromatography at p H . 8. The 40KD protein eluted in the void 
volume. The pH. of the void volume was increased to p H .9.5 
and anion exchange chromatography at p H . 9.5 separated two 
40KD polypeptides, one eluted in the void volume and was 
called the "VOID VOLUME 40” ; the other was eluted from the 
columm and was called the ’'COLUMN 40" .
Both had a Staph, aureus V8 peptide maps different from 
the TBS:40 peptide map suggesting that the TBS:40 peptide 
map was produced when both proteins interact with each 
other. The "COLUMN 40" was i.p. by TBS but not the "VOID 
VOLUME 40", these results suggested that the "VOID VOLUME 
40" is i.p. as part of a complex.
The amino acid sequences obtained from the "VOID VOLUME 
40" matched the sequence of the mitochondrial aspartate 
aminotransferase (mAspAT). The "VOID VOLUME 40" was also 
immunologically related to the mAspAT in a Western blotting 
experiment. Expression of polypeptides immunologically 
related to the mAspAT were increased upon infection with 
HSV-2.
Two peptides obtained by digestion of the "COLUMN 40" 
were successfully sequenced. The sequence of one matched the 
sequence of the rat fructose 1-6 diphosphate aldolase, and 
the sequence of the second peptide matched the sequence of 
the rat phosphoglycerate kinase-1. The experiment was 
repeated and the sequence data obtained suggested that the 
"COLUMN 40" was also related to the mAspAT were obtained in 
the second experiment. Further experiments must be set up to 
confirm this result.
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PART 1 
INTRODUCTION.
1.1. HERPESVIRUSES.
1.1.1. CLASSIFICATION.
The human herpesviruses belong to the family or Genus 
Herpesviruses. The family herpesvirus comprises at least 80 
members infecting a wide range of animals, mainly mammals, 
including man. They are large (150-200 nm), icosahedral, 
enveloped viruses containing double stranded (ds) DNA. Their 
replicative cycle is intranuclear and all can infect their 
host latently. They are classified according their 
biological properties into alpha, beta and gamma 
herpesviruses.
Alpha herpesviruses have experimentaly a variable host 
range in vivo and in vitro and a short replicative cycle. 
They spread rapidly with efficient destruction of infected 
cells and they establish latency primarily in neural 
ganglia, . Examples of alpha
herpesviruses are herpes simplex virus type 1 (HSV-1),
herpes simplex virus type 2 (HSV-2), varicella zoster virus
(VZV), equine herpesvirus 1 and bovine herpesvirus 2.
Beta herpesviruses have a narrow host range and a long 
reproductive cycle. The viruses spread slowly in tissue 
culture and the cells frequently become enlarged and a 
carrier culture can be established, i.e. the cytopathology 
is so slow that sufficient regeneration occurs to maintain 
the culture alive. Latent infections can be established in 
secretory glands, lymphoreticular cells and kidneys. 
Examples of vbeta herpesviruses : Human cytomegalovirus
(H C M V ), murine herpesvirus 1 and probably human herpes virus 
7 (Frenkel et a l .. 1990).
Gamma herpesviruses host range is restricted in vivo to 
the family or order to which the natural host belongs. The
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viruses are specific either for B or T lymphocytes, but the 
infection is frequently abortive with either establishment 
of a latent infection, or cell death without production of a 
complete virion. Latent virus is frequently demonstrated in 
lymphoid tissues. Examples of gamma herpesviruses : Epstein- 
Barr virus and gallid herpesvirus 2.
1.1.2,HUMAN HERPESVIRUSES.
Seven human herpesviruses have been isolated. Human 
infections are widespread, producing usually no clinical 
manifestation or, a mild disease, except for the recently 
isolated RK virus which is not well known.
Herpes simplex virus 1 Human herpesvirus 1
Herpes simplex virus 2 Human herpesvirus 2
Varicella zoster virus Human herpesvirus 3
Epstein-Barr virus Human herpesvirus 4
Cytomegalovi rus Human herpesvirus 5
Herpesvirus 6 Human herpesvi rus 6
RK virus Human herpesvi rus 7
1.1.2.1. HERPES SIMPLEX VIRUS 1 AND 2.
Primary-infection occurs very early in life with HSV-1, 
and may occur in over 90% of the population causing a 
variety of conditions from the mild to the fatal. Acute
herpetic gingivostomatitis is the most common clinical
manifestation of primary infection with HSV-1, it usually 
occurs in young children (1-3 years of age). In some
individuals, reactivations occur, the most frequent clinical
manifestation is also acute gingivostomatitis.
The clinical manifestations • of HSV-2 are 
undistiguishable from those caused by HSV-1, but HSV-2 has a 
tropism for the genitalia, it frequently is the agent of 
genital herpes and neo-natal herpes infections.
In vitro infection of permissive cells results in the 
lysis of cells within 24-48 hours and generation of progeny 
virus.
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1.1.2.2.VARICELLA ZOSTERVIRUS (V Z V ).
Varicella is a mild , very infectious disease of 
children. It is also called chicken pox and is characterized 
by a vesicular eruption of the skin and mucous membranes. 
VZV infection can be lethal for immunocompromised 
individuals.
Herpes zoster is the reactivation of VZV in a specific 
ganglion. Shingles occur in one fifth of the population 
reaching the age of 75, and is frequent in immunosuppressed 
patients. The clinical lesions are indistinguishable from 
those of chicken pox but are localized in the dermatome 
innervated by the sensory ganglion where reactivation occurs 
and are painful. Scarring and severe pain can remain as 
sequellae.
1 . 1 . 2. 3. CYTOMEGALOVIRUS ( HCMV ) .
HCMV is an beta herpesvirus. Acquired infection is 
usually inapparent. Congenital infection may result in the
death of the foetus in utero or produce a severe disease of
the foetus. Prematurity, malformation and somatic and mental 
retardation are potential sequellae. Inapparent intra
uterine infection seems to occur frequently.
1 . 1.2.4.EPSTEIN-BARR VIRUS (E B V ).
EBV is a gamma herpes virus. Most childhood infections 
are inapparent. In young adults EBV causes infectious 
mononucleosis. EBV has been involved in the etiology of 
Burkitt’s lymphoma (B L ) and naso-pharyngeal carcinoma (N P C ). 
Primary infections of pregnant women can result in foetal 
damage. In immunocompromised patients, EBV reactivation may 
trigger the production of B cell lymphomas (Reviewed by 
Grif f iths, 1990 ) .
1.1.2.5.HUMAN HERPESVIRUS 6 (HHV-6).
HHV-6 was first isolated from a patient with
lymphoproliferative disorders (Salahuddin et a l .. 1986). It 
is found associated with exanthem subitum (Yamanishi et 
al . . 1988) and interstitial pneumonitis (Carrigan, et a l . . 
1991). The seroprevalence in the normal population is over
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Figure 1.1. Structure of HSV.
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80 % (Levy et a l .. 1990). HHV-6 DNA can be detected by PCR 
from healthy adult from peripheral mononuclear cells (Kondo 
et a l ., 1991).
1.1.2.6.RK virus (HHV-7).
A seventh human herpes virus, called RK virus, has 
recently been isolated from CD4+ T cells of a healthy 
subject (RK). Its DNA shows partial homologies with HHV-6 
DNA in blotting experiments (Frenkel et a l .. 1990). It has 
not been connected with any disease yet.
The properties of herpes simplex viruses will be 
discussed in more detail.
1.1.3.STRUCTURE OF THE VIRION.
(Figure 1.1.)
1 .1 . 3 . 1. ENVELOPE.
The HSV envelope is a lipid membrane which forms the 
outer margin of the virus particle. It is derived from the 
nuclear membrane of cells (Darlington and Moss, 1968). HSV-1 
encodes at least eight glycoproteins, designated gB to g J , 
which are on the surface of the virion. The glycoproteins 
gB, gC and gD were shown to be components of the envelope 
spikes (Stannard et a l .. 1987).
1.1.3.2. TEGUMENT.
The tegument is an amorphous layer between the capsid 
and the envelope (Roizman and Furlong, 1974). It makes up 
65% of the volume of the virion (Schrag et a l . . 1989). It 
contains among other proteins Vmw 65 the alpha transinducing 
factor (alpha TIF), and UL 41, the virion host shut off 
(VHS) protein.
1 .1 . 3 . 3. NUCLEOCAPSID.
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Schrag et a l . . (1989), proposed the following model for 
the nucleocapsid. The nucleocapsid is made of three layers. 
The outer layer is icosahedral and made of 162 capsomeres
AVV
with a 5:3:2 cubic symetry. The protein VP 5 and VP 23 are 
the main components of the outer layer. The intermediate 
layer is also icosahedral, its constitution is not defined. 
The inner layer contains DNA associated with spermine which 
allow a dense packaging of DNA and other proteins. However 
in the latest jhypothesis, the DNA and associated proteins 
the outside layer of the capsid entirely. (Rixon, 
F.J., personal communication).
Three types of capsids are described.
A capsids are intranuclear, lack DNA and are not 
enveloped. They are made of five polypeptides, VP 5 
(155KD), VP 19C (53KD), VP 23 (36KD), VP 24 (24KD) and a
component of 12 KD. These capsids do not seem to contain 
DNA.
B capsids are also intranuclear, They do not contain 
DNA, but they contain two more proteins, VP 21 (45KD) and VP
22a (38KD) which are also involved in DNA packaging.
SL
C capsids are obtained by chemicaly stripping the 
envelope and the tegument off the mature virion. They 
contain the same proteins as capsid B except VP 22a.
1.1.4. THE LYTIC CYCLE OF HSV.
1.1.4.1. ADSORPTION AND PENETRATION.
Adsorption of HSV to the cell surface occurs maximally 
within 30 minutes (min.) of addition of the virus to the 
cells. HSV-1 binds to the cell surface through an 
interaction with heparin like cell associated 
glycosaminoglycans (Wu Dunn and Spear, 1989). The sequence 
of the events is thought to be the following. The viral 
envelope fuses with the plasma membrane (Morgan et al.. 
1968; Fuller and Spear, 1987) and releases the viral 
nucleocapsid inlcthe cytoplasm of the cell (Vahlne et a l . . 
1979). It was reported that HSV-1 penetration qE the cells 
is mediated by basic fibroblast growth factor (Baird et a l .. 
1990), but this result was not confirmed in our department
5
(L. Wood, personal communication).
It is unclear which viral proteins are involved in 
binding to the cells. Of the identified glycoproteins, only 
gB (Sarmiento et a l , , 1979; Little et a l .. 1981), gD (Ligas 
and Johnson, 1988) and gH (Weller et a l .. 1983; McGeoch and 
Davison, 1986; Gompel and Minson, 1986; Desia et a l . 1988) 
are essential for infectivity. Glycos\Jlation was shown 
unnecessary for adsorption (Campadelli-Fiume, 1982). Mutants 
in gB and gD retain the ability to adsorb to the surface but 
fail to synthesise viral polypeptides (Ligas and Johnson, 
1988). Only gH may be essential for adsorption (Buckmaster 
et a l .. 1984).
HSV-1 infection interferes with the superinfection by 
other HSV-1 strains but not by HSV-2. These results 
suggested that HSV-1 and HSV-2 have different receptors on 
the cell surface (Vahlne et a l .. 1979; Addison et a l ..
1984) .
HSV-1 adsorption to the cellular receptor was found to 
be selectively inhibited by neomycin and the polyamino acid 
polylysine whereas HSV-2 infection is unaffected (Langeland 
et a l .. 1987, 1988). The DNA region of HSV responsible for 
the different sensitivity of HSV-1 and HSV-2 to polylysine 
and neomycin was mapped by two different groups (Langeland 
et a l .. 1990; Campadelli-Fiume et a l .. 1990) .
Using intertypic recombinants, Langeland et a l .. (1990)
mapped the proteins affecting the binding of the virion 
between coordinate 0.580 and 0.687 m.u.. This region
contains two partial and eight complete genes including the 
glycoprotein gC gene, and three proteins with potential 
transmembrane sequences (McGeoch et a l ., 1988a). The
adsorption of a HSV-1 mutant in gC was prevented by 
polylysine and neomycin showing that HSV-1 is not 
responsible for the sensitivity of HSV-1 to these chemicals. 
However gC-1 is involved in the adsorption of HSV-1 to the 
cell surface because the kinetics of adsorption of the gC-1 
virus is slower than the wild type and because adsorption 
can be blocked by Mabs specific to gC-1.
Campadelli-Fiume et a l .. (1990) defined the genome
fragment which encodes the lack of sensitivity of HSV-2 to 
neomycin and polylysine. It is a Sal 1 DNA fragment encoding 
the entire gC UL44 open reading frame (ORF), and part of the
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UL43 and UL45 ORFs. HSV-1 and HSV-2 gC- mutants adsorption 
was blocked by neomycin and polylysine. They concluded that 
HSV-2 could mediate adsorption to the cells by two 
mechanisms. One pathway blocked by neomycin and polylysine, 
a second pathway gC-2 dependent, unaffected by neomycin and 
polylysine, which was found effective with BHK cells but not 
with Vero cells and Hep2 cells.
1.1.4.2. UNCOATING OF VIRAL GENOME.
Following penetration the viral capsids are translocated 
to the nucleus, where, after uncoating, the viral DNA then 
enters the nucleus at a nuclear pore. Release of the viral 
DNA into the nucleoplasm requires a viral function. A 
temperature sensitive (t s ) mutant in UL36 (McGeoch et a l .. 
1988a) (m.u. 0.501-0.503) cannot release the DNA in the 
nucleoplasm at non permissive temperature (npt)(Knipe et 
a l .. 1981; Batterson et a l .. 1983).
1.1.4.3.TRANSCRIPTION, TRANSLATION AND REPLICATION.
Virus DNA replication and transcription of virus DNA 
occurs in the nucleus. Immuno-fluorescence microscopy has 
identified replication compartments in the nucleus where 
virus DNA is synthesized at the same site where DNA 
polymerase ( UL30) is visualized (Quinlan et a l .. 1984). 
These processes are described in detail below.
1.1.4.4.ASSEMBLY AND RELEASE.
Herpesvirus capsids are assembled in the cell nucleus 
(Morgan et a l . 1954 ). Virus DNA is packaged into preformed 
capsids. In late infection, reduplicated membranes and thick 
patches appear particularly in nuclear membranes. It is 
likely that these patches represent aggregation of viral 
membrane proteins. There is general agreement that the inner 
lamellae are the site of initial envelopmemt (Reviewed by 
Roizman and Sears, 1990). Capsids containing fragments less 
than the standard genome length are retained in the nucleus 
(Vlazny et a l . 1982). The exact mechanism of the release of
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the virus is unknown, but cytoplasmic transit is associated 
with maturation of the glycoproteins. This supports a role 
for the Golgi apparatus (Reviewed by Campadelli-Fiume and 
Serafini-Cessi, 1985).
1.1.5. GENOME STRUCTURES.
Genome structures have been studied most extensively in 
HSV-1. Intertypic recombination and complementation data 
(Timbury and Subak-Sharpe, 1973; Marsden et a l .. 1978), and 
DNA/DNA hybridisation studies (Davison and Wilkie, 1983) 
showed that HSV-1 and HSV-2 genomes are essentially colinear 
with viral genes mapping at equivalent positions on both 
genomes.
1 . 1 . 5 . 1. CHEMICAL COMPOSITION.
The HSV-1 genome is a dsDNA whose molecular weight is 
95.1xl06 Daltons (Becker et a l .. 1968), The G+C composition
is 68.3% (McGeoch et a l .. 1988a). The entire nucleotide 
sequence of HSV-1 strain 17 has been determined. It contains
number of "a" sequences and short tandem reiterations 
(McGeoch et a l .. 1988a).
1.1.5.2. LONG AND SHORT SEGMENT.
Electron microscopy studies of structures produced by
intra-molecular hybridization of single stranded (ss) DNA
have shown that the HSV genome is made of two covalently
linked components, long (L) and short (S) (Sheldrick and
Berthelot 1974), which can invert relative to each other
creating four genomic isomers functionally equivalent and
present in equimolar amounts (Hayward et al .t 1975; Clements
et a l . , 1976; Delius and Clements 1976 Wilkie and Cortini,
1976). Each component is made of an unique segment flanked ^
by two repeat sequences inverted relative to each other. The 
unique long segment (Ul ) is 110 Kbp, and the internal and 
terminal long repeats (Rl or IRl and TRl ) are each 9.2 Kbp. 
The unique short (U s ) segment is 13 Kbp long and is also 
flanked by internal and terminal short repeats (Rs or IRs 
and TRs) of 6.6 Kbp.. (Figure 1.2).
but this number may vary according the
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An additional gene UL26.5 is entirely contained within 
the coding sequences of UL26 (Liu and Roizman, 1991)..
1.1.5.3.THE "a” SEQUENCE.
The Ma M sequences are short direct repeats observed at 
the termini of the HSV genome (Grafston et a l ., 1974) At 
least one copy of the "a" sequence is also located at the 
junction of the long and short component (Wadsworth et a l . 
1976; Wagner and Summer, 1978; Davison and Wilkie, 1981). 
The HSV-1 "a" sequence 250-500 bp varies depending on the 
strain , because of the different numbers of repeat 
elements. (Davison and Wilkie 1981; Mocarski and Roizman, 
1981; Varmuza and Smiley 1985). Each terminal "a" sequence 
has a overhanging residue with a free 3 ’ OH group (Mocarski 
and Roizman, 1982).
The "a" sequences mediate the circularization of the 
genome (Davison and Wilkie, 1983b), cleavage and packaging 
of the DNA (Stow et a l .. 1983, Varmuza and Smiley 1985) and
isomerization of the genome. (Mocarski et a l .. 1980,
Mocarski and Roizman, 1981; Varmuza and Smiley 1985).
The "a" sequence contains the promoter for a gene 
involved in HSV neurovirulence (Ackermann et a l .. 1986a; 
Chou and Roizman, 1986; Chou et a l ., 1990; Taha et a l .. 1988 
and 1989; McLean et al.. 1991; McGeoch et a l .. 1991).
1.1.5.4. SHORT TANDEM REITERATIONS.
Short tandem reiterations are found in U s , in Rs and in 
Rl . They range from five to 54 bp long (Rixon et a l .. 1984; 
McGeoch et a l .. 1985) and may increase the level of genetic 
exchange between the repeat regions (Rixon et a l ., 1984). It 
is notable that one set in the Rs has homology with 
sequences of the Ig class switch recombination sites (Gomez 
Marquez et a l ♦. 1985).
1.1.5.5.ORGANIZATION OF THE GENES.
HSV-1 genome encodes 72 genes (McGeoch et a l .. 1989), 
found in both orientation and encoding 70 distinct proteins. 
A gene whose product is designated ICP 34.5 has been 
identified in Rl between the "a” sequence and the immediate 
early gene 1 (IE-1)(Chou and Roizman, 1986; McLean et a l ..
9
TABLE 1.I
The HSV-1 genes encoding proteins. 
(Fareed, 1992)
Gene No. of M t 1 Properties or Status4 Reference5
residues functions
RL1 263 435002 ICP34.5 protein; ne Ackerman et a l, 1986; Chou and Roizman,
248 281843 Neurovirulence factor 1986,1990; Chou et al.. 1990; MacLean,
A.R. et al., 1991; McGeoch et al.. 1991; Dolan et al., 1992
RL2 (19)
(222)
(534)
IE transcriptional 
regulatory protein ne 
(IE110; IE-1)
775 Total 78452
UL1 224 24932 Hydrophobic N terminus; e 
proposed virion glycoprotein L
Hutchinson et al., 1992
UL2 334 36326 DNA repair enzyme; ne 
Uracil DNA glycosylase
Mullaney et al., 1989
UL3 235 25607 Hydrophobic N terminus ne Baines and Roizman, 1991
UL4 199 Unknown ne Baines and Roizman, 1991
UL5 882 98710 DNA replication; e
possibly responsible for the DNA helicase activity
UL6 676 74087 Virion protein; e 
possible role in DNA packaging
UL7 296 33057 Unknown
UL8 750 79921 DNA replication e
UL9 851 94246 DNA replication; OBP e
UL10 473 51389 Multiply hydrophobic; ne Baines and Roizman, 1991;
possible membrane-inserted protein MacLean, C. A. et al., 1991
UL11 096 10486 Myristylated virion protein ne MacLean, C.A. et al., 1989; MacLean, 
C.A. et al., 1992
UL12 626 67503 Deoxyribonuclease; ne Weller et al., 1990
possible role in DNA packaging or processing
UL13 518 57193 Predicted protein kinase ne L Coulter, personal communication
UL14 215 23454 Unknown
UL15 (343)
(392)
Possible rolejn packaging - 
nascent DNA into capsids
Dolan et al., 1991
735 Total 80918
UL16 373 40440 Unknown ne Baines and Roizman. 1991
Gene NQ.Qt M £1 Prooerties or Status4 Reference5
residues functions
UL17
UL18
UL19
UL20
UL21
UL22
UL23
UL24
UL25
UL26
UL26.5
UL27
UL28
UL29
UL30
UL31
UL32
UL33
UL34
UL35
UL36
UL37
703 74577 Unknown
318 34268 Virion capsid protein; VP23- Rixon et al., 1990
1374 149075 Major capsid protein e
222 24229 Multiply hydrophobic; ne* Baines ef al., 1991
possible role in viral egress 
535 57638 Unknown
838 90361 Virion glycoprotein H e
376 40918 Thymidine kinase ne
269 29474 Unknown ne
580 62666 Virion protein; possible e Preston, V. G. 1990
role in the formation of full capsids & virus entry into cells 
635 62466 Capsid protein?; e Liu and Roizman,1991a, b;Preston, V.G.
Protease; role in DNA packaging et al., 1992 
329 Substrate of the UL26 - Liu and Roizman,1991a
gene product; located entirely within the UL26 ORF  
904 100287 Virion glycoprotein B e
785 85573 Probably structural; e Addison et al., 1990
possible role in the formation of mature capsids 
1196 128342 DNA replication; MDBP e
1235 136413 DNA polymerase e
306 33951 Unknown
596 63946 Locus of immune e
cytolysis resistance mutation; structural protein 
130 14436 Structural protein; e Al-Kobaisi et al., 1991
involved in DNA packaging 
275 29788 Virion protein;
hydrophobic C terminus;
Probable substrate of the viral protein kinase Purves et al., 1991
112 12095 Possible capsid protein - McNabb and Courtney, 1992
3164 335841 Virion protein; large e
tegument protein 
1123 120549 Unknown
Gene No. of M r1 Properties or Status4 Reference5
residues functions
UL38 465 50260 Virion protein; required e
for capsid assembly; VP19C  
UL39 1137 124043 Large subunit of ne*
ribonucleotide reductase 
UL40 340 38017 Small subunit of e
ribonucleotide reductase 
UL41 489 54914 Virion host shut-off protein ne
UL42 488 51156 DNA replication; DBP (65K) e
UL43 434 44905 Multiply hydrophobic ne
UL44 511 54995 Virion glycoprotein C; ne
possible role in virus adsorption to cells 
UL45 172 18178 Hydrophobic N terminus ne
UL46 718 78239 Unknown; May modulate ne
activity of UL48 protein 
UL47 693 73812 Possible tegument ne
protein
UL48 490 54342 Major tegument protein;
activator of IE genes 
UL49 301 32252 Virion protein; VP22
UL49.5 091 membrane inserted e
or UL49A protein
UL50 371 39125 Deoxyuridine triphosphatase ne
UL51 244 25468 Unknown ne
UL52 1058 114416 DNA replication; e
possibly responsible for the DNA primase 
UL53 338 37570 Multiply hydrophobic; syn -
locus; proposed virion glycoprotein K 
UL54 512 55249 IE transcriptional e
regulatory protein (IE63; IE-2)
UL55 186 20491 Unknown ne
UL56 197 21182 Unknown ne
IE175 1298 132835 IE transcriptional e
regulatory protein(IEl75; IE-3)
Pertuiset et al., 1989; Rixon et al., 1990
Fenwick and Everett, 1990
MacLean, C. et al., 1991
Herold et al., 1991 
Visalli and Brandt, 1991 
Barker and Roizman, 1990
Barker and Roizman, 1990; McLean et al., 
1990
Elliott and Meredith, 1992 
Barker and Roizman, 1992;
Barnett et al., 1992
Barker and Roizman,~l 990
activity
Hutchinson et al., 1992; Ramaswamy and 
Holland, 1992
gene No. of M^1 Properties or
residues functions
Status4 Reference5
US1 420 46521 IE protein (IE68; IE-4) ne
US2 291 32468 Unknown ne*
US3 481 52831 Protein kinase ne
US4 238 25236 Virion glycoprotein G ne
US5 092 09555 Putative glycoprotein e
US6 394 43344 Virion glycoprotein 0 e
US7 390 41366 Virion glycoprotein I ne
US8 550 59090 Virion glycoprotein E ne
US9 090 10026 Tegument phosphoprotein ne
US10 312 34053 Virion protein ne
US11 161 17756 Unknown;
Localized in nucleolus
ne
US12 088 09792 IE protein (IE12; IE-5) ne
Table 1. Properties of HSV-1 encoded proteins
1. Mr : Molecular weight for unprocessed polypeptide chain.
2. Apparent molecular weight of ICP34.5 protein in HSV-1 strain F.
3. Molecular weight of ICP34.5 protein in HSV-1 strain 17+.
4. ef essential; ne, nonessential; * , necessity depends on culture 
conditions or temperature.
5. References not mentioned are cited in the original papers of 
McGeoch etal. (1988b) and McGeoch (1989).
1991). This gene was shown to be important for the
neurovirulence in mice (McLean et a l . . 1991)(See section
1.1.5.3). In latently infected cells, latency associated
transcripts are transcribed downstream of IE-1 (See section 
1.1.11.2) (Stevens et a l .. 1987; Rock et a l .. 1987; Spivack 
and Fraser, 1987). A novel HSV gene designated UL49A has 
been located between the coding region of UL49 and UL50. It 
encodes a putative membrane protein (Barnett et a l .. (1992).
HSV genes are densely arranged, show some gene overlap 
and only rarely have introns (e.g. Vmw 110) (McGeoch, 1987). 
Several genes (IE110, U L 2 , 23, 24, 39, 44, 50, 55, 56, US1-4 
and US7-12) seem to be dispensible for virus growth at least 
in actively dividing cells (Reviewed by McGeoch et a l .. 
1988a; McGeoch, 1989).
1.1.6. REPLICATION OF VIRAL DNA.
DNA replication is semi-conservative. At 37*C DNA 
replication starts in the nucleus of BHK cells at 3h post 
infection. It reaches a maximum at 9-11 hours p.i., and it 
is completed by 16h p.i. (Rixon, 1977). DNA in the nucleus, 
is thought to be quickly converted to a circular form, 
because there is a decrease in the number of terminal 
fragments detectable when compared with virion DNA (Jacob
et a l .. 1979; Poffemberger and Roizman, 1985; McGeoch,
1987). Studies with murine cytomegalovirus suggested that 
circularization may be the result of direct ligation of the 
ends (Marks and Spector, 1988).
Late in infection, DNA is in a very rapid sedimentable 
form. There is a decrease of terminal fragments. This is in 
favour of a circular molecule, and a rol^.ng circle f 
mechanism, yielding head to tail concatemeric DNA genomes 
(Jacob et a l ..1979). This theory has been supported by an in 
vitro experiment using a preformed replication fork and 
nuclear extracts of HSV-1 infected cells. The products of
the DNA synthesis were concatemeric molecules as
demonstrated by alkaline gel electrophoresis and electron 
microscopy (Rabkin and Hanlon, 1990).
1.1. 6.1, ORIGINS OF REPLICATION.
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There are three origins of replication in HSV.
There is one origin of replication in the middle of the 
UL,termed oriL,(Gray and Kaerner, 1984; Quinn and McGeoch, 
1985), and one in the middle of the short repeat region, 
termed oris (Stow, 1982). The location and the sequence of
r
the oris was detemined using plasmid and deletion analysis. 
The origin of replication oris is located between the 
divergently transcribed IE-3 and IE-4/5 genes. The cis- 
acting sequences are present within a 90 b.p. region. A 
prominent feature of the origin region is an almost perfect 
palindrome sequence 45 b.p. long containing 18 A or T 
residues at its center (Stow and McMonagle, 1983). The cis- 
acting sequence contains two binding sites for the origin 
binding protein, UL9, both sites are required for origin 
activity (Weir et a l .. 1989, Weir and Stow, 1990).
The DNA sequence of oris of HSV-2 HG52 is closely 
similar to HSV-1 oris (Whitton and Clements, 1984).
The oriL is located between the divergently transcribed 
genes for the major DNA binding protein and the DNA
polymerase (Gray and Kaerner, 1984; Quinn and McGeoch,
1985). It is constituted by a long perfect palondrome with 
144 b.p.. The arms are similar to oris (Weller et a l .. 
1985).
1 .1.6.2. CLEAVAGE AND PACKAGING SIGNALS.
Cleavage and packaging are tightly linked (Deiss and 
Fraenkel, 1986; Stow et a l .. 1986). The "a" sequence
contains signals for both cleavage and packaging (Stow et 
a l . . 1986; Varmuza and Smiley, 1985). Two cis-acting
sequences within the "a” sequence appear to be essential for 
both cleavage and packaging (Deiss et a l .. 1986; Deiss and 
Frenkel, 1986). The cleavage signal has been identified as a 
179 bp fragment across a "a-a" junction (Nasseri and 
Mocarski, 1988). The structure of the signals involved in 
processing and packaging have been partially conserved among 
herpes viruses. The mechanism is therefore likely to share 
common features (Davison, 1984; Albrecht, 1985; Spaete and 
Mocarski, .1985; Hammerschmidt et a l . . 1988; Marks and
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The gene UL26 encodes a protease. This protease 
processes the virion protein VP22a, the product of the gene 
UL26.5, truncating the carboxy terminus (Preston, V.G. et 
al.. 1992).
Spector, 1988).
The viral proteins required for processing and packaging 
DNA have been defined using mutants capable of replicating 
DNA but unable to process and package DNA. Insertion mutants 
in the alkaline exonuclease gene (UL12) produced wild type 
levels of DNA synthesis and late proteins. Electron 
microscopy studies showed that a large number of empty 
capsids accumulated in infected cells, This indicated that 
UL12 may play a role in DNA packaging (Weller et a l .. 1990). 
The other genes implicated are UL6, UL26, UL28, UL32 and
UL33 (Weller et a l .. 1983, 1987; Preston, V.G. et a l .. 1983; 
Matz et a l .. 1983; Sherman and Bachenheimer, 1987, 1988;
Rixon et a l .. 1988; Addison et a l .. 1990; Al Kobaisi et a l ..
1991). The role of the individual genes is not yet clear. 
The product of gene UL26 is required for the formation of 
viral capsid (Preston, V.G. et a l .. 1983), and is
transiently associated with it (Rixon et a l .. 1988). This 
suggests a link between formation of the capsid and DNA 
packaging
1.1.h HSV TRANSCRIPTION.
Upon infection of permissive cells, three sets of HSV 
genes are expressed sequentially. They are termed immediate 
early (IE) or alpha, early (E) or beta and late (L) or gamma
genes (Honess and Roizman, 1974; Clements, J.B. et a l ,
1977) .
1.1.7.1.IE GENES AND GENES PRODUCTS.
IE genes are expressed immediately after viral 
infection, and no de novo protein synthesis is required 
(Honess and Roizman, 1974; Kozak and Roizman, 1974; Clements 
J.B. et a l ., 1977, Jones and Roizman, 1979). All the IE 
genes with the exception of IE-2 are located near the repeat 
regions of the genome. IE genes 1 and 3 are situated within 
the long and short repeat regions respectively resulting in 
the presence of two copies of each (Watson et a l .. 1979; 
Anderson et a l .. 1980; Mackem and Roizman, 1980; Marsden et 
a l .. 1982; Rixon et a l .. 1982). All IE genes with the
exception of IE-5 encode phosphoproteins. IE genes products,
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except IE-5, are found in the nucleus of the infected cells 
(Pereira et a l .. 1977; Hay and Hay, 1980). IE genes products 
appear to be transcriptional modulators whose activity is 
essential for the expression of later classes of viral genes 
(O’Hare and Hayward, 1985a and b; Everett, 1986).
In addition to the five IE genes encoded by HSV, the 
gene encoding the large sub-unit of the ribonucleotide 
reductase (Vmw 136) of HSV-1 exhibits characteristics of an 
IE gene. It is expressed very early in infection, in the 
presence of cycloheximide and in the absence of IE 
transcription (Preston C.M. et a l .. 1979a; De Luca et a l ..
1985). Moreover a TAATGARAT element has been demonstrated in 
the promoter (Wymer et a l .. 1989).
1.1.7.1.1. Vmw 175, IE3, ICP4.
Vmw 175 is essential for virus growth in vitro: a 
deletion mutant in IE-3 failed to grow in normal cells (De
Luca et a l .. 1985). Temperature sensitive and deletion
mutants in the IE-3 gene fail to synthesize DNA or to 
express early and late genes at npt. Temperature sensitive 
mutants in Vmw 175 overexpress IE transcripts at npt
(Preston C.M. et a l .. 1979b; Dixon and Schaffer, 1980),
suggesting that Vmw 175 autoregulates IE genes. In 
transfection assays Vmw 175 can repress gene expression 
induced by its own promoter (O’Hare and Hayward, 1985b), 
and other IE promoter elements can be repressed by Vmw 175 
under certain conditions (De Luca and Schaffer, 1985; Gelman 
and Silvestein, 1987a).
At early time of infection Vnw 175 is distributed 
diffusely in the nucleus after viral DNA replication 
occurs, Vmw 175 is distributed in replication compartments 
within the nucleus (Reviewed by Knipe, 1989).
Vmw 175 binds to the consensus sequence 3 ’- 
ATCGTCnnnnYCGRC-5*(R=purine, Y=pyrimidine, which is present 
at the transcription start site of its own gene (Faber and 
Wilcox, 1986 ) .
Using insertion mutants the functional domains of the 
protein were defined. The domain between residues 275 and
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490 is important for both repression and transactivation, 
the domains between residues 840 and 1000 are more important 
for transactivation than repression and the nuclear signal 
is located between residues 682-774 (Paterson and Everett,
1988) .
Vmw 175 binds to the consensus sequence in promoter 
regions of IE-1, IE-3 and glycoprotein D (Faber and Wilcox, 
1986; Kristie and Roizman, 1986; Muller, 1987), but has also 
been reported to bind to several promoter regions lacking 
the consensus (Kristie and Roizman, 1986). The role of 
Vmwl75 binding to the consensus sequence is, however, not 
clear .
It was thought that this interaction mediated 
autoregulation (Gelman and Silverstein, 1987b; Muller,
1987), but experiments with HSV-1 infected cells did not 
support this hypothesis. Mutations in the Vmw 175 binding 
site on the Vmw 110 promoter element reduced the ability of 
Vmw 175 to repress IE-1 expression in transfection assays, 
but had no effect on the level of Vmw 110 expression during 
normal HSV-1 infection (Everett and Orr, 1990).
1.1.7.1.2.Vmw 110, IE-1, ICP0.
Vmw 110 is essential for viral growth in vitro. At early 
and late time during the viral replication cycle, Vmw 110 is 
localized diffusely in the nucleus (Knipe and Smith, 1986). 
Vmw 110 is a phosphorylated protein, it transactivates or 
increases the transcription of many genes both viral and 
cellular in vitro (Everett, 1984a; O ’Hare and Hayward, 1985a 
and b; Quinlan and Knipe, 1985; Gelman and Silverstein, 
1985; Mavromara-Nazos et a l .. 1986). The growth of Vmw 110
deletion mutants is impaired at low multiplicity of
infection (m.o.i.) but not at high m.o.i. (Stow and Stow,
1986, 1989).
Vmw 110 is a potent transactivator of gene expression in 
transfected cells, either by itself or in cooperation with
Vmw 175 (Everett, 1984b; O ’Hare and Hayward, 1985b; Quinlan
and Knipe, 1985; Gelman and Silverstein, 1985). There is, 
however, little evidence that Vmw 110 can promote gene
i
expression on its own in lyticaly infected cells, since as
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discussed in the previous section, in cells infected with ts 
mutants in the IE-3 gene, there is very low expression of
beta gene products. Vmw 110 increases the amount of
transcripts of the gene it transactivates, but the mechanism 
of action is unknown (Reviewed by Knipe 1989).
1.1. 7.1.3. Vmw 63, IE-2, ICP27.
Vmw 63 is a complex regulatory gene, with positive and
negative regulatory effects in infected and transfected
b
cells. In infected cells Vmw 63 coperates with Vmw 110 and
Vmw 175 (McCarthy et a l .. 1989). Vmw 63 is essential for
viral growth in vitro. Null mutants were replication 
incompetent, they induced the synthesis of greatly reduced 
level of DNA and were characterized by the overexpression 
of early proteins, reduced levels of leaky late and absence 
of detectable true late proteins (McCarthy et a l .. 1989).
In transfection assays Vmw 63 modulates the activity of 
Vmw 175 and Vmw 110 (Everett, 1986; Sekulovitch, 1988; Su 
and Knipe, 1989). However Vmw 63 seems to be capable of 
independent transactivation of the gB promoter (Rice and 
Knipe, 1988 ) .
1.1. 7. 1.4. Vmw 68, IE-4, ICP 22.
^  virus mutant with a deletion in the Vmw 68 genes grows 
normaly on certain human and monkey cells (Post and Roizman, 
1981). This virus does not grow well in rodent cells and 
the level of the transcription of the late genes is reduced 
in HEL cells (Sears et a l . . 1985a).
1.1.7.1.5.Vmw 12, IE5, ICP 47.
In contrast to all other IE gene products, Vmw 12 is not 
phosphorylated and localizes in the cytoplasm (Preston, C.M. 
et a l .. 1979b, Marsden et a l .. 1982). Vmw 12 is non
essential for growth in tissue culture (Umene, 1986, 
Longnecker and Roizman, 1987; Brown and Harland, 1987).
1.1.7.2.PROTEINS REQUIRED FOR DNA REPLICATION.
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The genes required for DNA replication were identified 
using virus mutants. The results were confirmed in 
transfection assays. Seven proteins encoded by the genes 
UL30, UL29, UL42, UL9, UL5, UL8 and UL52 are necessary and 
sufficient to support the replication of origin containing 
plasmids (Challberg, 1986). These genes were cloned in 
Baculovirus expression vectors using their predicted 
sequences and the proteins purified to homogeneity (McGeoch 
et a l .. 1988b; Olivo et a l .. 1989). Antibodies have been
raised against synthetic peptides deduced from the predicted 
DNA sequences (Quinn and McGeoch, 1985; Olivo et a l .. 1989). 
These developments allow the determination of the function 
of each protein separately, as well as their localization in 
the cell during the replication of the viral DNA (Olivo et 
al.. 1989).
1.1.7.2.1.UL30, viral DNA polymerase.
The virus DNA polymerase was distinguished from the
cellular DNA polymerase by its sensitivity to inhibitors, by
the salt concentration required for its maximum activity and .
Tfce^ v G o t x L  W t x X tU c O ,. ly c c )
by its immunologic reactivity (Purifoy et a l . 19>77). It has
been purified from infected cell extracts, migrates with an
apparent MW of. 140,000 on SDS gels (Powell and Purifoy,
1977; Knopf 1979). 'fWu> tUcju, lia
UL30 and UL42 are closely linked, and purify together. 
Calculation from the Stokes radius and the sedimentation 
coefficient yielded a MW of 190,000 which is in agrement 
with a predicted MW of 187,000 for UL30+UL42 (Crute and 
Lehman, 1989).
In addition to its DNA polymerase activity on single or
double stranded DNA, UL30 gene product has a 3*-5*
exonuclease (proof reading) activity (Knopf, 1979; O ’Donnel
et a l .. 1987; Marcy et a l .. 1989). UL30 has also a
ribonuclease H activity (Crute and Lehman,1989 ) .
Experiments with purified proteins showed that UL30 is 
the active enzyme and the addition of UL42 to UL30 enhances 
its activity (Gallo et a l .. 1989) by increasing its
processivity (Gottlieb et a l ., 1990).
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1.1.7.2.2. UL29, major single stranded DNA binding 
protein. (mDBP).
UL29 is the major ssDNA binding protein. UL29 binds ss 
and dsDNA although the binding is five times more effective 
to ssDNA . No specific binding sequence is known (Bayliss 
et a l .. 1975; Conley et a l .. 1981; Reviewed by Knipe, 1989). 
During the viral DNA replication the protein localizes in 
the replication compartments in association with viral DNA 
(Quinlan et a l ., 1984).
UL29 is essential for DNA synthesis in vitro, since ts 
mutants fail to synthetize DNA at npt (Weller et a l .. 1983).
The functional domains of UL29 were defined by mapping 
mutants. Four classes of mutants were defined showing that 
the domains required for localization to the nucleus and DNA 
binding as demonstrated with affinity columns were 
different. One of the protein mutants lacking the N-terminus 
bound to ssDNA and localized in the nucleus but the virus 
mutants failed to replicate showing that the role of UL29 in 
replication is more than just binding to DNA. The N-terminal 
one fifth of UL29 shares sequence homologies with rat 
proliferating cell nuclear antigen (PCNA) also termed cyclin 
(Matsumo et a l .« 1987). Synthesis of PCNA is tightly
associated with the cell cycle, occurring immediately before 
DNA synthesis. Therefore it is conceivable that the N- 
terminus of UL29 has some nuclear function (Gao and Knipe,
1989) .
UL29 may also have a role in transcriptional regulation 
of the IE-3 gene (Godowski and Knipe, 1986) and late gene 
expression (Gao and Knipe, 1991).
1.1.7.2.3.UL42, double stranded DNA binding protein.
UL42 is an HSV-1 DNA binding protein, it has a molecular 
weight of 65,000 Daltons and binds dsDNA in a sequence
U t u j  d rx X  j f ip p
independent manner. Its homologue in HSV-2 is a 55 KD 
protein. It is different from the 65 KD trans inducing 
factor (Marsden et a l .. 1987). It purifies in close
association with DNA POL (UL30) (Gallo et a l .. 1988). It 
stimulates but is not essential for DNA POL activity (Gallo
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UL8 may be required for the efficient entry of UL5 and 
UL52 in the nucleus (Calder and Stow, 1990).
(
et a l . , 1989)(See section 1.1.7.2.1.). It was thought that 
UL29 was required for the DNA POL activity of UL30 + UL42, 
but recent work using more highly purified proteins did not 
find such a requirement (Gottlieb et a l .. 1990)
1.1.7.2.4, U L 9 , origin binding protein.
UL9 is the origin binding protein. Protein-DNA complexes 
containing Oris and the origin binding activity were 
immunoprecipitated only by the anti-UL9 antiserum (Olivo 
et a l .. 1988); the binding of UL9 to the Oris sequence was 
confirmed by gel retardation assays (Weir et a l .. 1989). 
UL9 binds to a 11 bases sequence (site I) within Oris. UL9 
binds also to a second 11 base sequence in inverted 
orientation in the right arm of the palindrome (site II), 
but with a lower affinity. However conservation of site II 
is required for efficient initiation of HSV-DNA replication 
as shown by deletion analysis (Weir and Stow, 1990) and the 
inefficient replication of VZV Oris which lacks site II, in 
response to HSV helper functions (Stow and Davison, 1986)
1.1.7.2.5. UL5, UL8 and UL52.
The HSV-1 helicase-primase complex consists of the
TcwCn *A-oJL
products of the U L 5 , UL8 and TJL52T genes. These three
proteins exhibits ATPase, DNA dependent GTPase, DNA helicase
and DNA primase activities in HSV-1 infected cells (Crute et 
a l ., 1988, 1989; Dodson et a l .. 1989). These three proteins
were expressed in insect cells using baculovirus vectors.
DNA dependent ATPase and DNA helicase activities were
detected in cells triply infected with viruses expressing 
UL5, UL8 and UL52 but also in cells where only UL5 and UL52 
were expressed (Calder and Stow, 1990).
1.1.7.3. VIRAL GLYCOPROTEINS
HSV encodes at least eight glycoproteins, namely gB, gC, 
gD, gE, gG,gH, gl and the gene product of U S 5 , gJ (Spear, 
1976; Marsden et a l .. 1978, 1984; Baucke and Spear, 1979;
Buckmaster et a l .. 1984; Roizman et a l .. 1984; Gompels and 
Minson, 1986; Frame et a l .. 1986; Ackerman et a l .. 1986b;
Longnecker et a l .. 1987; Johnson and Feenstra, 1987;
McGeoch, 1987; Gao and Spear, 1990).
From experiments with mutants, the glycoprotein gC is
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gK : The product of the gene UL53 was known to be 
involved in the syncytial phenotype(Ruyechan et al,, 1979; 
Bond and Person, 1984; Pogue-Geile et al. , 1984) and was
recently shown to be glycosilated. The gene UL53 was 
translated in vitro using a rabbit reticulocyte lysate and 
the products analyzed on SDS gels. When canine pancreatic 
microsomal membranes were added, the UL53 gene product was 
glycosilated as showm by the increase in mmolecular weight 
and the sensitivity to glycosidases (Ramaswamy and Holland,
1992). Furthermore, the UL53 gene product was labelled with 
[3H ] glucosamine in vitro (Hutchinson et a l . , 1992a).
gL : The product of the gene UL1 was involved in the 
syncytial phenotype (Little and Schaffer, 1981) but its 
exact role has only recently be discovered. Peptide antisera 
to the predicted sequence of the UL1 gene immunoprecipitated 
two species of 30KD and 40KD from HSV-1 (K O S ) infected cells 
as well as two proteins of 100KD and 110 KD which were 
identified as g H . Immunoprecipitation followed by Western 
blotting experiment showed that gH and gL were forming a 
complex. The 30KD species is processed to the 40KD species 
as shown by pulse chase experiments. This processing does 
not occur in the absence of g H and require only gH. Report 
that the protein was glycosylated were confirmed by the 
sensitivity of the 30KD and 40KD species to endoglycosidase 
F. Formation of a complex between gH and gL is required for 
their localization to the cell surface (Hutchison et a l ..
1992).
not essential for infectivity (Heine et a l .. 1974; Holland 
et a l .. 1984; Draper et a l ■, 1984; Homa et a l .. 1986). gE,
gG, gl and the product of the gene US5 was shown to be 
dispensable for virus growth (Longnecker and Roizman, 1986, 
1987; Longnecker et a l .. 1987; Weber et al.. 1987; Harland 
and Brown, 1988). Only gB, gD and gH are required for 
infectivity in vitro (Sarmiento et a l .. 1979; Little et a l .. 
1981; Ligas and Johnson, 1988; Weller et a l .. 1983; Gompels 
and Minson 1986; Desia et a l .. 1988).
The properties of the individual glycoproteins are the 
following.
The glycoprotein gB, gD and gH are required for virus 
penetration of the cell in vitro.
The glycoprotein gC of HSV-1 (gCl) binds C3b (Friedman 
et a l .. 1984). The glycoproteins gCl and gC2 are involved in 
adsorption of the virus to the cell membranes (Langeland et 
a l .. 1990; Campadelli-Fiume et a l .. 1990; see section
1.1.4.1. ).
The glycoprotein gD prevents re-infection by HSV. gD is 
present on the plasma membrane of infected cells. 
Experiments show that HSV-1 and HSV-2 attach but fail to 
penetrate in cells expressing gD (Campadelli-Fiume et a l ..
1988).
The glycoprotein gE binds polymeric IgG (Dubin et a l ..
1990) but gl is required in conjunction with gE to bind 
monomeric IgG. This is probably a mechanism to protects the 
virus from the immune responses (Dubin et a l .. 1990).
The glycoprotein gG provides antigenic specificity of 
HSV and elicits an antibody response which allows for
the distinction between HSV-1 and HSV-2 (Whitley, 1990). The 
genes encoding gGl and gG2 have diverged more than any 
equivalent genes HSV-l/HSV-2 studied (McGeoch et a l .. 1985, 
1987; Reviewed by Marsden, 1987).
1.1.7.4. CAPSID PROTEINS
There are 7 major capsid proteins.
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Protein gene MW Functions
VP5 UL19 155 KD It is the major capsid protein,
being the constituent of both
pentons and hexons. (Schrag et
a l .. 1989; Newcomb et a l . . 1991).
VP19C UL38 53 KD It is a DNA binding protein
(Braun et a l . 1984). It is
probably an internal protein 
important for morphogenesis
(Pertuiset et a l .. 1989).
VP22a UL26.5 40 KD It is associated only with empty 
capsids. It is involved in DNA 
packaging (Preston, V.G. et a l .. 
1983; Rixon et a l .. 1988).
VP23 UL18 36 KD It may form the trimeric
structure that links adjacent
hexons (Schrag et a l .. 1989).
VP21 45 KD Not known.
VP24 UL26 24 KD Protease? (Preston V.G. et al . . 
1992 ) .
VP26 UL35 12 KD Not known
(Rixon, F.J., personal communication).
1 . 1 . 7. 5. ENZYMES.
1 . 1 . 7 . 5 .1. Ribonucleotide reductase ( RR ) .
Ribonucleotide reductase is an enzyme required for the
synthesis of ,deoxy-r ibonucleotides. The viral enzyme can be
distiTTguished from the cellular enzyme by its immunological 
(KweM tUeJ. M*)
(BaccheTti et a l ., 1984) and biochemical properties (Huszar 
et a l .. 1983). The enzyme consists of two subunits which
2 0
together give the RR activity namely RR1 + RR2 of MWs 136
Using mutants in the RR genes, it has been shown that 
the HSV-1 RR activity is dispensable for virus growth and 
DNA replication in exponentially growing cells in vitro at 
34°C, but it is required for optimal growth in resting cells 
or at high temperature (39.5‘C). (Goldstein and Weller, 
1988a and b; Preston V.G., et a l ., 1988). Therefore a
cellular factor is capable of complementing HSV RR but only 
in certain conditions.
A 9 AA peptide of the small subunit of the RR 
specifically inhibits the viral enzyme interfering with the 
interaction between the two subunits (Dutia et a l .. 1986; 
Darling et a l .. 1990) These findings can form the basis of 
the design of an antiviral drug, based on a synthetic 
peptide which abrogates replication. The potentiality of RR 
as an antiviral target is supported by the observation that 
the virulence of RR mutants in mice is highly attenuated 
(Cameron et a l .. 1988).
In vivo a deletion mutant in RR failed to grow in the 
mouse eye model and failed to establish reactivable latency 
(Jacobson et a l ., 1989). Mutant viruses in RR, however, 
inoculated into the skin of guinea pigs produced cutaneous 
lesions as severe as those produced by wild type strains and 
in vivo replication was demonstrated for one of the mutants 
suggesting that the virus encoded enzyme is non-essential 
for replication in the guinea pig (Turk et a l .. 1989).
1.1.7.5.2. Thymidine kinase.
The virus encoded thymidine kinase (T K ) activity (Kit 
and Dubs, 1963) was mapped in HSV-1 (Wiggler et a l ..1977; 
Halliburton et a l .. 1980; Reyes et a l .. 1982) gene UL 23 
(McGeoch et a l ., 1988a). HSV TK is dispensable for growth in 
growing cells in tissue culture (Dubbs and Kit, 1974) but 
not in resting cells (Jamieson et a l .. 1974). In vivo HSV TK 
mutants have a decreased neurovirulence (Marcialis et a l .. 
1975; Field and Wildy, 1978; reviewed by Tenser et a l .. 
1993 ). HSV TK is important for reactivation of latency in 
vivo (Reviewed by Tenser, 1991). The possible explanation is
and 38 KD and is
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discussed in the latency section 1.1.11.3.1.
The specificity of HSV TK is wider than cellular TK. 
Virus TK phosphorylates thymidine (Dubs and Kit, 1964), 
deoxycyttdine (Jamieson and Subak-Sharpe, 1974) and a
variety of nucleoside analogues (Elion et a l .. 1977). This 
property was used to specifically engineer antiviral drugs 
such as Acyclovir* effective in the infected cell (Elion et 
a l.. 1977; Fyfe et a l .. 1978).
1.1. 7. 5. 3. dUTPase.
HSV induced UTPase catalyses the hydrolysis ofdUTP to 
dUMP and pyrophosphate (Wohlr^ab and Franke, 1980; Caradonna 
and Cheng 1981; Williams 1984). The gene encoding thedUTPase 
activity has been mapped on the HSV-1 genome (Preston V.G. 
and Fisher, 1984) to a region corresponding to the UL50 gene 
(McGeoch et a l .. 1988a). Viral dUTPase is not essential for 
growth.
1 . 1 . 7 . 5 . 4. Urac j 1 DNA glycosylase.
Uracil DNA glycosylase is an enzyme involved in DNA 
repair. It removes uracil residues from DNA. This gene is 
not required for growth in tissue culture (Mullaney et a l ..
1989). This gene has been mapped on HSV-1 to a position
corresponding to the UL2 gene (Worrad and Caradonna, 1988;
Mullaney et a l ., 1989).
1.1.7.5.5. Alkaline exonuclease.
HSV-1 and HSV-2 induce an alkaline exonuclease activity 
in infected cells (Keir and Gold, 1963; Morrison and Keir, 
1968; Hay et a l ., 1971). The evidence that this activity is 
virally encoded is the following. An HSV-1 jts mutant in 
alkaline exonuclease activity has been isolated (Franke et 
a l .. 1978). Micro-injection of HSV DNA fragments in Xenopus 
Haevis oocytes resulted in the production of alkaline
Q
exonuclease activity (Preston, C.M. and Cordingly, 1982). 
The activity has been mapped on the HSV-1 genome (Preston 
and Cordingley, 1982; Costa et al . . 1983; Wathen and Hay
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1984; Banks et a l ., 1985) to a position corresponding to the 
gene UL12 (McGeoch et a l ♦. 1988).
Early experiments with a ts mutant suggested that the 
exonuclease activity was essential for virus replication 
(Moss et a l .. 1986). But an insertion mutant in UL12 has 
shown that the activity is dispensable for virus growth as a 
small amount of infectious virus is produced. UL12 is 
dispensable for viral DNA and late protein synthesis. The 
UL12 gene product may be involved in processing the viral 
DNA into capsids (Weller et a l .. 1990).
1.1.7.5.6. Protein kinase.
HSV induces a protein kinase activity following 
infection of cells (Blue and Stobbs, 1981; Purves et a l .. 
1986; McGeoch and Davison, 1986). Several genes can encode a 
protein kinase activity.
By comparison of eukaryotic protein kinases with the 
published sequences of HSV-1 (McGeoch et a l .. 1985), HSV-2 
(McGeoch et a l .. 1987) and VZV (Davison and Scott, 1986), a 
protein kinase activity was predicted for the gene US3 
(McGeoch and Davison, 1986; McGeoch et a l .. 1987). This was 
confirmed by immunological studies using an antiserum raised 
against a synthetic peptide from the predicted DNA sequence 
(Frame et a l .. 1987). This activity is dispensable for viral 
growth in tissue culture (Frame et a l ., 1987; Purves et a l ..
1987).
Other potential^protein kinases are the product of UL13 
(Smith and Smith, 1989) and the amino terminus of the large 
subunit of the ribonucleotide reductase of HSV-2 but not of 
HSV-1 (Chung et a l .. 1989; see section 1.2.10.2.).
1.1.8. REGULATION OF HSV TRANSCRIPTION.
1.1.8.1.IE GENE REGULATION.
Transcription of immediate early genes is induced by a 
viral protein Vmw 65/alpha TIF, which is also an essential 
structural protein (Ace et a l .. 1988). Each viral particle
contains 500-1000 copies of Vmw 65 packaged in the tegument.
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Vmw 65 translocates to the cell nucleus independently of the 
virus DNA (Batterson and Roizman, 1983). Vmw65 interacts 
with the consensus sequence 3 *-TAATGARAT-5* (R = purine) 
which is found in the far upstream region of all IE genes 
but not E and L genes (Mackertl and Roizman 1982; Preston, 
C.M. 1984)
Vmw 65 does not interact with the viral DNA directly but 
it induces the formation of a specific complex with one or 
more host proteins on TAATGARAT elements (Preston, C.M. et 
a l .. 1988). One of the cellular proteins appears to be the 
ubiquitous octamer binding protein Oct-1, also called NF 
III (Pruizn et a l .. 1986; OBP 100 (Baumruker et a l .. 1986); 
OTF 1 (Gerster and Roeder, 1988); TRF (O’Hare and Goding,
1988) and alpha 1 (Kristie and Roizman, 1988).
The activation domain of Vmw 65 has been located to the 
C terminus.It is not required for immediate early complex 
formation. The C terminus contains a high proportion of acid 
residues and has been shown to bind directly and 
specifically to TFIID in vitro. Mutations in this region 
which inactivate the polypeptide in vivo eliminate TFIID 
binding in vitro (Stringer et a l .. 1990).
In addition to the TAATGARAT sequence other cis-acting 
regulation signals have been identified. The promoter 
sequences regulating the IE-3 genes were found to contain a 
TATA homology located approximately -25bp from the RNA 
start site, there are also multiple GC rich region (Spl 
binding sites) (Whitton et a l ., 1983) similar to those of
the simian virus 40 (SV40)(Jones and Tijan, 1985), and a GA 
rich element which enhances the responsiveness of the 
TAATGARAT elements (Bzik and Preston, 1986).
It was long held that IE gene expression peaked in the 
early stage of infection. A gene was defined as IE if it was 
expressed without prior viral protein synthesis or 
functional Vmw 175. But in fact where studies were carried 
out IE genes expression persists during the course of 
infection (Reviewed by Everett and Orr, 1991). VmwllO was 
found to accumulate throughout the viral infection. A 
mutation preventing Vmw 175 binding to the promoter of Vmw 
110 resulted in an increased expression of Vmw 110 in a 
transient assay, but has no noticeable effect on Vmw 110
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expression in lytic infection (Everett and Orr, 1991).
1.1. 8. 2. E GENE REGULATION.
Prior synthesis of IE gene products is required for 
early gene expression (Honess and Roizman, 1974; Clements et 
a l.. 1977).
The kinetics of expression of early genes are variable. 
gD is expressed as an early gene but is maximally produced 
only at the onset of viral DNA replication (Gibson and 
Spear, 1983; Johnson et a l .. 1986). Such genes have been
described as beta-gamma or early-late genes (Wagner, 1985; 
Harris-Hamilton and Bachenheimer, 1985).
Promoters of the early genes show a considerable 
diversity. No specific viral sequences involved in 
transactivation have been detected in the promoters of the 
early gene already studied. All regions have an identifiable 
"TATAM box 28-30 bases upstream of the mRNAs end. Most have 
recognizable variants of j"CAAT” at about 60 and again 90 
bases and many have distinguishable GC rich elements between 
90 and 120 bases (Wagner, 1985).
The promoter regulatory region of the TK gene was found 
to contain a TATA box, two GC rich elements, and a CAAT box. 
(McKnight et a l .. 1981; McKnight and Kingsbury, 1982; Jones 
and Tijan, 1985). Analysis of the sequences sufficient for 
regulated expression of gD found a TATA box and two GC rich 
elements (Everett, 1983).
This diversity may explain the different rate of 
expression observed among early genes (Honess and Roizman, 
1974; O ’Hare and Hayward, 1985a; Harris-Hamilton and 
Bachenheimer, 1985). Increase of transcription of early/late 
genes may be the result of an increase in template copy 
number rather than a requirement for viral DNA synthesis 
(Johnson and Everett, 1986a).
1.1.8.3.L GENE REGULATION.
Late gene products appear 3 hours post-infecton but are 
greatly increased following initiation of DNA replication. 
Presence of a functional Vmw 175 (Watson and Clements, 1980)
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and DNA synthesis are required for late gene expression as 
shown by experiments with mutants ts in DNA synthesis in 
addition to experiments with inhibitors of DNA synthesis 
(Swaanstrom and Wagner, 1974; Honess and Roizman , 1974; 
Powell et a l .. 1975; Marsden et a l .. 1978; Jones and
Roizman, 1979; Holland et a l .. 1980; Conley et a l .. 1981;
Pederson et a l .. 1981).
Late genes are subdivided into "leaky late" and "true 
late" genes. "Leaky late" gene expression is detectable in 
the absence of DNA synthesis but requires DNA synthesis for 
maximum expression. An example of a "Leaky late" gene is the 
UL19 product, Vmw 155. True late genes have an absolute 
requirement for DNA synthesis for expression. An example of 
true late gene is the US 11 gene product (Wagner, 1985; 
Roizman and Batterson, 1985; Johnson et a l .. 1986).
Using plasmids which contains a functional origin of 
replication oris, it appears that a late gene promoter 
consists only of a proximal TATA box and a cap site region 
(Johnson and Everett, 1986b).
It is unclear how DNA synthesis increases late gene 
expression. An increase in the number of templates cannot be 
the only explanation because this would affect early gene 
expression also. Vmw 63 and Vmw 68 may be involved since ts 
mutants in these genes failed to synthesize some late genes 
(Sacks et a l .. 1985; Sears et a l .. 1985).
1.1.9a EFFECT OF HSV INFECTION ON CELL METABOLISM.
In order to provide a suitable environment for the 
efficient replication of its DNA, HSV causes a disruption of 
the metabolic processes of the host. Cellular DNA and RNA 
synthesis is largely inhibited, protein synthesis decreases 
rapidly, within 2-4 h postinfection (Reviewed by Fenwick,
1984). The shut off of host functions by HSV-1 occurs in 2 
stages.
Early shut off does not require protein synthesis. 
Infection in the presence of actinomycin D or with UV 
irradiated virus still induces a rapid shut off of host 
protein synthesis suggesting that it is controlled by a
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virion component (Sydiskis and Roizman, 1967; Fenwick and 
Walter, 1979; Fenwick et a l ♦, 1979; Scheck and Bachenheimer,
1985). HSV-2 is generally more efficient at host shut off 
mechanism than HSV-1 (Powell and Courtney, 1975; Peireira et 
a l .. 1977; Fenwick et a l .. 1979; Scheck and Bachenheimer
1985 ) .
The virion component involved has been identified as the 
product of gene UL 41 (Read and Frenkel, 1983; Kwong et a l ..
1988). Transfer of a competent gene into a virus deficient 
in early shut off creates the shut off function (Fenwick and 
Everett, 1990). Recently HSV strain HG 52 has been found to 
encode a truncated UL41 product which most likely accounts 
for its poor shut off (Everett and Fenwick, 1990).
Late shut off requires de novo virus protein synthesis 
after infection (Honess and Roizman, 1974; Nishioka and 
Silverstein, 1978; Silverstein and Engelhardt, 1979).
1.1.10L ACTIVATION OF CELLULAR GENES BY HSV.
Some cellular RNAs are induced upon infection by HSV-1. 
The mechanism involved may require IE genes expression 
(Patel et a l .. 1986), or parallel activation of IE genes by 
Vmw 65, or they may simply be activated by adsorption of the 
virus to the cell surface (Kemp et al.. 1986).
HSV IE gene products can activate certain cellular genes 
in transfection experiments. The rabbit beta globin gene 
promoter responds to virus activation when in a plasmid. 
This activation may be explained by the presence of G rich 
sequences in the promoter of the beta globin gene. These 
sequences are similar to constitutive elements in the 
promoters of HSV-1 genes (Everett, 1983). The beta globin 
gene promoter can be activated when integrated into the host 
chromosome of a biochemically transformed cell line. 
Transfection of the transformed cells with plasmids 
expressing Vmwl75 and/or VmwllO also activated the promoter 
(Everett, 1985). However virus infection fails to activate 
the endogenous beta globin gene of rabbit kidney cells. The 
promoter may be unavailable for viral trans-activation 
because of the densely packed chromatin configuration. Many
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TG7A is a Mab raised by Dr N . LaThangue against the DNA 
binding proteins of BHK cells infected with HSV-2 strain 333 
(Macnab et al.. 1985; LaThangue and Latchman, 1988).
other genes may not be activated for the same reason.
HSV-1 infection can activate proto-oncogenes. HSV-1 
inoculated by scarification in the eye of mouse was reported 
to activate the expression of c-fos, c-jun and Oct-1 (Valgiy 
Nagiy et a l .. 1991).
Induction of heat shock proteins follows infection of 
chick embryo fibroblast by HSV-1 tsk at non permissive 
temperature (Notorianni and Preston, C.M. 1982). This 
cellular response has been shown to be the result of the 
presence of an abnormal Vmw 175, rather than the 
overproduction of IE proteins (Russell et a l .. 1987a). This 
effect may be important in vivo. since natural isolates 
frequently show — mutation in the gene coding Vmw 175 (Knipe 
et a l .. 1981; Post et a l .. 1981).
Infection of human fibroblasts with HSV-2 induces the 
synthesis in a growth regulated manner of a minor cellular 
stress protein of 57 KD (LaThangue et a l .. 1984). Induction 
of this gene is at the level of transcription (Patel et a l ..
1986).
Polypeptides of MW 90KD, 40KD and 32KD were recognized 
in transformed cell lines by two types of sera. Sera to HSV- 
2 infected BHK cells and sera of rats bearing tumours
induced by injection of Bn5T cells. (Macnab et al.. 1985). 
These results suggest that the activation of cellular genes 
in HSV-2 infected cells and in several transformed cell 
lines shares a common mechanism.
 A monoclonal antibody (Mab) TG7A, was used to identify a
set of tumour specific proteins of MWs 200KD, 90KD (a 
doublet, U90 and L90) 40KD and 32KD (Macnab et a l ., 1985.
These peptides were also precipitated by TBS. Later studies
from LaThangue and Latchman (1988) showed that Mab TG7A
reacted with a protein of 90KD which increased with HSV-2 
infection and a protein of 40KD which increased with HSV-1 
infection. However, the results of J.C.M. Macnab (personal 
communication) do not confirm those of LaThangue and 
Latchman. Using TBS Macnab et a l .. (1992) and Grassie et
a l .. (in preparation) did not find this difference but 
showed that the U90 protein and the 40KD protein were both 
increased by HSV-1 and HSV-2. This suggests that Mab TG7A
28
The absence of viral termini can be due to 
circularization, concatemerization or integration via the Ul 
or Us regions of the genome.
i
and TBS recognize similar but not identical proteins.
1.1.11 .LATENT INFECTION WITH HSV.
1. 1 .11 . 1. NATURAL HISTORY.
HSV-1 and HSV-2 share with other herpesviruses the
ability to latently infect its host following a primary
infection. During the latent state there are no overt signS 
of viral replication, cell damage or disease and^ no
infectious virus can be detected. Sometimes the viral 
genome may be reactivated, viral replication occurs and a
clinical disease may result. The stimuli triggering
reactivation in humans include menstruation, psychological 
and physical stresses such as ultra-violet light, 
meningococcal and pneumococcal infections and nerve
sect ion.
The site of HSV latency is the neuron of the sensory 
ganglia (Cook et a l .. 1974; McLennan and Darby, 1980;
Kennedy et a l .. 1983; Reviewed by Stevens, 1989). Latency in 
other cells has been reported. Latent HSV genomes have alsn 
been detected I
in human brain tissues (Sequera et a l .. 1978; Fraser et a l .. 
1981) and from corneas arising from patients with herpes 
simplex keratitis but not from the normal human corneas 
(Cook et a l .. 1987).
^;— --------- The viral genome appears to be in an endless state
(Rock and Fraser, 1983, 1985). HSV DNA is associated with
nucleosomes in a structure similar to cellular chromatin 
(Deshmane and Fraser, 1989). HSV DNA is not methylated in
vivo (Dressier et a l .. 1987), but may be methylated in vitro 
(Youssoufian et a l .. 1982). Demethylating agents enhance
reactivation of latent infection established in vivo (Whitby 
et a l .. 1987; Stephanopoulos et a l .. 1988) or in vitro
(Kondo et a l ♦. 1990).
1 .1 . 11 . 2. VIRAL GENE EXPRESSION.
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1.1.11•2 .1. Latency associated transcripts.
The expression of the latent HSV genome is very limited. 
The detection of HSV RNA has been reported in the neurons of
latently infected mice, rabbits and humans. These
transcripts are termed latency associated transcripts (L A T ) 
and are located in the nuclei. They are transcribed from 
the long terminal repeat, from the complementary strand 
encoding Vmw 110, but 3' of its gene and partially
overlapping it (Stevens et a l .. 1987; Rock et a l .« 1987;
Spivack and Fraser, 1987; Croen et a l ♦. 1987, 1991; Krause 
et a l .. 1988; Wagner et a l .. 1988a; Steiner et al.. 1989).
These RNAs comprise a major 2 kilobases (kb) transcript with 
one or two minor transcripts of 1.5 and 1.4 kb spliced from 
within the major transcript. These minor transcripts are 
characteristic of neurons (Spivack and Fraser, 1987; Wagner 
et a l .. 1988b). Transcription has also been detected 5* and 
3 ’ of the major transcript in trigeminal ganglia of latently 
infected mice (Mitchell et a l .. 1990). There is evidence
that latency associated transcripts are processed from a 
larger 8 kbp transcript. It starts from a TATA box 700 bp 
upstream the 5 ’ end of the major LAT and terminates 
downstream of the LAT at a polyadenylation signal (Dobson et 
a l .. 1989).
The two major transcripts contain an open reading frame 
(O R F ) (Wechsler et a l .. 1988), but are not polyadenylated
and it is thought that no protein is expressed (Wagner et 
a l ., 1988a). Moreover these ORFs are not conserved in 
different HSV strains (McGeoch et a l .. 1991).
1.1.11.2.2.The role of the LATs
The role of the LATs is unclear. The latency associated 
transcripts are not required for the establishment of 
latency in vivo (Leib et a l .. 1989). They are not required 
for the reactivation of the latent HSV genome in vitro 
(Javier et_al., 1988; Block et a l .. 1990), but LATs may
facilitate reactivation in some models since reactivation is 
delayed (Steiner et a l .. 1988) or occurs at reduced
frequency (Leib et a l .. 1989). In one case LATs have been
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Latent HSV genomes have also been detected in tumour 
derived from rat cells (Park and Macnab, 1983),
found to facilitate reactivation in vivo but not in vitro 
(Hill et al.. 1990) .
There is strong evidence that LAT is a stable intron.
The arguments are the following. The 5* end of LAT is an 
excellent match for the vertebrate splice donnor sequence.
HSV DNA encompassing the LAT was inserted into the beta- 
galactosidase gene of an expression vector and another DNA 
fragment encompassing the LAT and Vmw 110 were inserted into 
an expression vector. In both cases LAT of the expected size 
(two kilobases) as well as beta galactosidase and Vmw 110 
mRNA were detected by Northern blotting experiments. 
Analysis by PCR of the spliced products revealed that the 
LAT was spliced from the beta galactosidase fusion 
transcript at the consensus splice donnor and acceptor site.
In a transient system cells were transfected with three 
plasmids expressing the LAT, VmwllO and luciferase driven by 
the HSV-1 TK gene. Expression of LAT prevented 
transactivation of the HSV-1 TK gene by VmwllO. The author 
concluded that LAT modulates reactivation events by 
inhibiting VmwllO gene expression possibly via an antisense 
message, although this is difficult to envisage given the 
phenotype of LAT- mutants (Farrell et a l . 1991).
1.1.11.3. VIRAL GENES INVOLVED IN LATENCY.
The viral genes required for the establishment, 
maintenance and the reactivation from latency have been 
studied in animal models and in in vitro models.
1.1.11.3.1.In vivo models.
Latent HSV infection can be established in the|dorsal root 
ganglia of the mouse, the rabbit and the guinea pig 
(Reviewed by Stevens, 1989). Outside the neural tissues, a 
latent HSV infection can be established in the mouse footpad 
(Al Saadi et a l .. 1983; G.B. Clements and Subak Sharpe,
1988; G.B. Clements and F. Jamieson 1989), in the mouse eye 
(Shimeld et a l 1990 a and b; Claoue et a l .. 1990), and in 
the rabbit cornea (Cook et a l .. 1987).
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The following genes were found dispensable for the 
establishment of latency in vivo : IE Vmw 68 (Sears et a l ..
1985 a and b), IE Vmw 12, glycoprotein G and E (Meignier et 
a l .. 1988), IE Vmw 110 (G.B. Clements and Stow, 1989).
Replication is not required for the establishment of latency 
(Katz et a l . 1990; Steiner et a l .. 1990).
The role of gene expression has been further studied 
with the HSV-1 mutant inl814. The HSV-1 mutant inl814 
contains an insertion inactivating alpha TIF destroying its 
transinducing properties and therefore the level of IE gene 
expression is reduced. (Ace et a l .. 1989), it does not
replicate in the mice trigeminal ganglia, but is capable of 
establishing latency in vivo (Steiner et a l . 1990).
Investigation of its gene expression suggests that the level 
of viral IE genes has a key role in determining the outcome 
of HSV infection in vivo (Valgiy-Nagy et a l . . 1991a).
Two enzymes ribonucleotide reductase and thymidine 
kinase were found necessary for reactivation from latency in 
vivo. A HSV-1 mutant lacking most of the large subunit of 
the ribonucleotide reductase failed to establish a 
reactivable latent infection (Jacobson et a l . . 1989). A
genetically engineered HSV-1 TK deletion mutant established 
latency in mice but failed to reactivate by explant culture 
(Efstathiou et a l . 1989). Ihis result is consistent with the 
hypothesis that HSV requires deoxypyr.lmydine kinase activity 
under conditions where the host cell de novo metabolism is 
low (Jamieson et a l .. 1974). However not all experiments
support the importance of the TK gene in latency in vivo 
(Reviewed by Tenser, 1991).
1.1.11.3.2. In vitro models.
Several methods have been devised to establish a latent 
HSV infection in cells cultured in vitro. They are described 
in more detail.
A latent infection can be established by treatment of 
HSV-1 infected cells by chemicals inhibitors such as (E)-5- 
(2-bromovinyl)-2 * - deoxyuridine, with or without human 
leukocyte interferon. After removal of the chemicals latency
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is maintained by incubation at 40.5"C the virus is 
reactivated by decreasing the temperature to 37 *C (Wigdahl 
et a l ., 1984)
A latent infection is established when a culture of 
primary sympathetic neurons is infected at a low 
multiplicity by HSV-1 (Wilcox and Johnson 1987). The viral 
genome is reactivated by deprivation of neural growth factor 
(Wilcox and Johnson, 1988).
Human foetal lung cells can be latently infected by 
transient incubation at 4 2 °C. The cells are inoculated with 
HSV-2 HG52 at 37°C for 1 hour. The infected cells are 
incubated 6 days at 42°C, then the temperature is decreased 
to 37°C and the virus remains latent. The virus is 
reactivated by superinfection with HCMV or with a HSV-1 ts 
mutant at npt (Russell and Preston, 1986).
The viral genes involved in the establishment of latency 
were defined in this model by using HSV-1 mutants. Virus 
mutants in Vmw 175 and Vmw 110 were able to establish a 
latent infection and were recovered by superinfection with 
complementary mutants, suggesting that very little gene 
expression is required for establishment of latency (Russell 
et a l .. 1987b). This point was confirmed by the
establishment of latency with the HSV-1 mutant inl814 whose 
alphaTIF/Vmw 65 is non functional. Mutant inl814 established 
a latent infection after incubation at 42*C but also at 
3 7 eC. The authors concluded that the absence of 
transactivation by Vmw 65 predisposes to latency and supports 
the concept that gene expression is not required for the 
establishment of latency (Harris and Preston, 1991).
The importance of VmwllO for reactivation was 
demonstrated by the following experiments. A HSV-1 mutant in 
Vmw 110 was unable to reactivate latent HSV-2 (Russell et 
a l . . 1987b). Latent HSV-2 could be reactivated by an
adenovirus recombinant expressing Vmw 110. The region of 
VmwllO required for reactivation was found to be the second 
exon (Harris et a l . 1989).
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1.2. ONCOGENES.
1.2.1. INTRODUCTION.
1.2.1.1, THE MULTISTAGE NATURE OF CANCER.
Several viruses are involved in the etiology of cancer 
(Klein 1985), but viruses would be only one of the factors, 
because naturally occuring cancer is viewed as a 
multi factorial disease (Reviewed by Weinberg, 1988). Other 
factors can be another virus, a chemical, ionizing 
radiation or a genetic event. (Reviewed by Weinberg,
1989). The development of cancer is also a stepwise 
process. The cells are altered stepwise, and with each 
step, the probability of evolving ultimately into a 
malignant neoplastic population is increased (Reviewed by 
Farber, 1984).
1.2. 1.2. EXAMPLES OF VIRUSES INVOLVED IN THE ETIOLOGY 
OF CANCER.
Retroviridae
Avian leukemia and sarcoma virus (ALV,ASV)
Feline leukemia virus (F L V )
Bovine leukemia virus (BLV)
Murine mammary tumour virus (MMTV)
Hepadnaviridae
Hepatitis B virus (HBV)
Ground squirrel hepatitis virus 
Woodchuck hepatitis virus
Papovaviridae
Human Papilloma virus (HPV)
Bovine papillomavirus (B P V )
Cotton tail rabbit papillomavirus (CRPV)
Herpesviridae
Marek Disease Herpesvirus (MDHV)
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Epstein-Barr virus (E B V )
Herpes simplex viruses 1 and 2 (HSV-1 and 2)
1.2.1.3. THE DISCOVERY OF THE TRANSFORMING GENES OF 
CHEMICALLY INDUCED AND NATURALLY OCCU^ING TUMORS.
It was first realized that the transformed phenotype of 
chemically induced tumours could be induced by transfection 
of the naked DNA of the tumour by Shih et a l . . (1979). The 
transforming DNA sequences were then isolated from a human 
bladder carcinoma (Shih and Weinberg, 1982). The genes 
responsible for transformation were called oncogenes. 
Oncogenes have been shown to be involved in the genesis of 
several tumours and they are also the transforming genes of 
RNA viruses. The properties of some oncogenes are 
summarized at the end of the introduction.
RNA and DNA viruses transform cells by different means. 
RNA viruses transduce and modify or deregulate cellular 
genes. The normal cellular counterpart of the oncogene is 
called a proto-oncogene, it is a gene involved in cell 
growth and proliferation. In contrast the genome of DNA 
viruses encodes virus coded oncogenes.
1.2.2. RETROVIRUSES.
1. 2.2.1.CLASSIFICATION.
Retroviruses are classified into three major 
subfamilies, the lentiviruses the spumaviruses and the 
oncoviruses which contain the oncogenic retroviruses.
Oncoviruses are subdivided into type B, C and D in 
accord with their particle morphology; the vast majority of 
oncoviruses have the type C morphology. Type C contains the 
animal and human leukemogenic viruses. Among them is the 
HTLV group, HTLV-1 is associated with adult T cell 
leukemia. An example of type B oncovirus is MMTV and of 
type D is Squirrel monkey virus.
1.2.2.2.REPLICATION.
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Figure 1.3. Retroviruses.
Integration of the retroviral genome in the cellular 
genome. (Hewitt, 1988).
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1.2.2.2.1, General features.
Retroviruses are enveloped RNA viruses. The core 
contains the viral genome and the virion associated enzyme 
the reverse transcriptase. The viral RNA genome is diploid. 
It consists in two identical positive-sense ssRNAs that 
possess a capped 5* structure and a polyadenylated 3 ’ end. 
The glycoproteins of the envelope serve as receptors for 
the virus to bind to target cells. After binding, the core 
is released into the cytoplasm. The reverse transcriptase 
transcribes the viral RNA genome into a double stranded DNA 
copy, called the provirus, which migrates to the nucleus 
and integrates covalently into the chromosomal DNA. 
Integration is a random process and is mediated by the 
reverse transcriptase which can function like an integrase. 
The retrovirus replication may be halted at this stage and 
the virus remains latent in the cells .
If transcription is activated, new genomic RNA and 
viral mRNA encoding proteins are transcribed from the 
provirus. Viral glycoproteins are inserted into the plasma 
membrane. The viral internal core is assembled, and the 
virus is released by budding from the cell wall . The 
release of RNA viruses is not usually cytopathic and the 
infected cells can divide. Furthermore, the viral infection 
can persist for all the life of the host (Reviewed by 
Cof f in, 1990 ) .
1.2.2.2.2.Genomic organisation.
The viral genome encodes three genes (gag, pol, env). 
The gene gag codes for internal antigens, pol codes for the 
reverse transcriptase and the IN protein needed for the 
integration of the viral DNA in the cellular DNA and env 
codes for envelope glycoproteins. At each end of the 
integrated pro-virus is a long terminal repeat which 
contains a strong promoter. It contains enhancers elements, 
a transcriptional control signal a "CAAT" box, an 
initiation site for RNA polymerase II, a "TATA" box and a
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polyadenylation signal (Reviewed by Coffin, 1990).
1.2.2.3. ONCOGENIC TRANSFORMATION.
The mode of transformation is described below.
1.2.2.3.1. Transformation by transduction and mutation.
Leukemia does not necessarily follow the infection of a 
chicken by avian leukemia virus. But if a tumour appears, 
acutely transforming viruses may be isolated from tumour 
tissues. These viruses are capable of reproducing rapidly 
the same type of tumour in its host.
Solid tumours are caused by RNA viruses such as Rous 
sarcoma virus (RSV) which was found to contain a gene, the 
v-src gene, responsible for the transforming properties of 
the virus. The origin of the v-src gene is the cellular 
counterpart c-src which is altered mutationally, 
incorporated in the virus genome by recombination and under 
the control of the strong viral LTR promotor.
The origin of viral oncogenes (v-onc) is the normal 
cellular genes (c-one) involved in replication and 
differentiation, i.e v-oncs are the equivalent of a 
cellular gene transduced into the viral genome. They lack 
introns and are derived by reverse transcription of 
processed mRNA. They contain mutations which activate their 
oncogenic potential by modifying their growth properties 
(v-src) or are expressed as a fusion protein with the gag 
gene product (gagErbA).
The transforming gene of Rous sarcoma virus, v-src, 
isolated from chicken sarcoma is a mutated form of the
normal c-src gene (Takeya and Hanafusa, 1982). The
oncogene v-ras of Harvey murine sarcoma virus has a human 
homologue. The oncogenic capacity is activated by a point 
mutation in bladder carcinoma resulting in the 
incorporation of valine instead of glycine as the twelfth 
amino acid (AA) of p21/ras (Reddy et a l .. 1982).
Several oncoviruses have been discovered which have
lost some viral sequences. They must be complemented by non
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mutant viruses for replication and spread into the host.
1. 2.2.3.2.Transformation by insertion.
These retroviruses are inserted adjacent to a target 
cellular gene. They disrupt the regulation of the 
expression of the cellular proto-oncogene. The oncogene c- 
myc is deregulated by the sequences contained in the LTR. 
In in vitro experiments they immortalize the cells.
Avian leukosis virus (ALV) integrates within or 
adjacent to c-myc genes in bursal lymphoma (Hayward et a l ..
1981). The level of c-myc transcription is increased 
(Linial and Groundine, 1985) and chimeric transcripts of 
c-myc can be detected.
1.2.2.3.3. Transformation by HTLV1.
It is now established that HTLV-1 is an etiologic agent 
of adult T cell leukemia particularly in Japan (Reviewed by 
Sarnagadhran et a l .. 1985).
The organisation of the HTLV1 genome is different from 
the other oncoviruses. It contains in addition to the gag, 
pol and env genes a Px region. The Px region encodes two 
genes tax and rex. The product of the tax gene, p40, is a 
transcriptional activator, it interacts with cellular 
proteins to upregulate the transcription of the provirus. 
p40 also stimulates the expression of interleukin 2 and 
receptors for interleukin 2. Rex is a nuclear oncoprotein 
which controls HTLV gene expression.
1.2.3. FUNCTIONS OF THE ONCOGENE PRODUCTS.
Oncogenes can be classified as cytoplasmic or nuclear. 
Cytoplasmic and nuclear oncogenes can cooperate to 
transform cells in culture.
The oncogene myc codes for a nuclear protein, which can 
immortalize primary cells in culture. Normal cells have a 
limited capability to divide in vitro. Transfection with a 
nuclear oncogene gives them the capability to divide
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perpetually. Immortalized cells are also able to grow in 
low concentrations of serum. Serum contains growth factors 
which promote cell growth and attachment and spreading of 
cells on a solid support.
Cytoplasmic oncogenes e.g. H-ras generally transform 
cells which have been immortalized. Cytoplasmic oncogenes 
have usually no effect on primary cells on their own 
unless they are overexpressed e.g. ras overexpressed by the 
control sequences of Moloney murine sarcoma virus or simian 
virus 40 (SV40) can transform passage three Chinese hamster 
lung cells, early passage rat cells from rat embryo and 
muscle and skin from 2-week-old Wistar rats (Spandidos and 
Wilkie, 1984).
Transformed cells differ from normal cells by several 
aspects.
Transformed cells fail to regulate their entry into and 
out of the cell cycle in response to factors such as 
population density and serum. Proliferation of transformed 
cells is not limited by contact inhibition. Cells can grow 
on top of each other and do not stop dividing at the 
monolayer stage in vitro. Proliferation is not limited by 
serum concentration, the cells deplete the nutrients and 
die rather than stop dividing.
Transformed cells grow in suspension thus in the 
absence of a solid support. The ability of transformed cell 
to grow in soft agar appears to be the parameter that 
correlates most consistently with the ability to form 
tumours in animals.
1.2.3.1. CYTOPLASMIC ONCOGENES.
The products of cellular proto-oncogenes are part of 
signalling pathways. Phosphorylation is critical for their 
functions. (Reviewed by Cantley et a l .. 1991).
1.2.3.1.1.Growth factors: sis.
The oncogene of simian sarcoma virus (v-sis) is a
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truncated form of the cellular gene encoding the beta 
chain of platelet derived growth factor (PDGF) (Waterfield 
et a l . « 1983 ). PDGF stimulates cell proliferation as part 
of the wound healing process. Therefore v-sis could 
stimulate cell proliferation by abnormaly activating PDGF 
receptors (Waterfield et a l .. 1983).
1.2.3.1.2. Tyrosine kinase growth factor receptors: 
ErbB.
ErbA and ErbB are the oncogenes of the avian 
erythroblastosis virus (AEV). ErbB encodes sequences 
similar to the epidermal growth factor (EGF) receptor. The 
v-erbB gene product lacks the external ligand binding 
domain for the EGF. It retains, however, the 
phosphorylation site and the protein kinase domain of the 
normal receptor which is presumed to be in a permanently 
active state (Downward et a l .. 1984). These defective
viruses induce rapid erythroblastosis (Graf and Stehlin,
1982) .
AEVs can also induce neoplasms with a long latency. Half 
of the tumours contain apparently intact proviruses. They 
are inserted upstream of c-ErbB, These proviruses disrupt 
the structure of the gene and may influence the level of 
its expression (Nilsen et a l .. 1985, Raines et a l , . 1988)
1.2.3.1.3. Non receptor membrane bound tyrosine kinase:
src.
The src gene of Rous sarcoma virus encodes a 
phosphoprotein pp60src which has a tyrosine specific kinase 
activity (Hunter and Sefton, 1980). The following 
experiments suggest that this activity is required for the 
transforming properties.
Transformation by RSV is accompanied, by an increase 
of phosphotyrosine (Sefton et a l .. 1980).
Mutations in the src gene that inactivate the protein 
kinase activity of pp60src abolish transformation activity 
(Kamps and Sefton, 1986).
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The protein sequence can be divided into four domains 
of activity.
Myristic acid is covalently attached to the N^-terminus.
V'
The 17 N-teminus AAs are required for myristilation. 
Myristilation enables the protein to bind to the 
cytoplasmic side of the plasma membrane (Krueger et a l ..
1983) and is required for the transforming activity (Wilson 
et a l , 1989).
The modulatory region contains two serine residues 
which can be phosphorylated by cAMP protein kinase or 
protein kinase C (PKC) Purchio et a l .. 1985; Patschinsky et 
a l . . 1986; Gould et a l .. 1985).
Mutations within the catalytic domain result in both 
temperature sensitive and transformation deficient 
phenotypes (Reviewed by Parson and Weber, 1989). Tyrosine 
416 is the site of autophosphorylation (Patschinsky et a l .. 
1986; Smart et a l .. 1981). Mutation of Tyr 416 suppresses 
the transformation induced by alteration of Tyr 527 
(Piwnicka-Worms et a l .. 1987).
The carboxy-terminus of c-src has regulatory functions, 
it contains 19 AAs missing from the viral oncogene
(reviewed by Parson and Weber, 1989). The major site of in
vivo phosphorylation of pp60arc is on tyrosine 527. 
Phosphorylation of this residue inhibits and down regulates 
the tyrosine kinase activity of pp60src in vivo 
(Courtneidge, 1987; Cooper and King, 1986). Binding to the 
polyoma middle T antigen prevents phosphorylation of 
Tyrosine 527 of pp60src thus activating the tyrosine kinase 
activity.
1.2.3.1.4. Cytoplasmic mediators: the ras family.
The ras oncogenes were discovered in two murine
retroviruses. Cellular homologs Ha-ras and Ki-ras are found
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at two separate chromosomal loci. They are part of a family 
containing 5 oncogenes. Mutant ras sequences are also 
detected in some human tumours (Reddy et a l .. 1982; Wigler 
et al . . 1984).
The ras gene product is a GTPase: GTPase activity is 
lower in p21c~r a s . The decrease in activity is the result 
of point mutations at AA residues 12, 59 and 61 (Reviewed 
by McCormick, 1989).
Clues for the activity of ras came from the study of 
the yeast ‘Saccharomyces cerevisiae which has two ras genes 
which stimulate adenylate cyclase, and also by analogy 
with the G proteins to which the ras p21 proteins have 
structural and biochemical homologies (Gilman, 1987).
G proteins have GTPase activity. They are converted to 
GTP bound active forms by membrane receptors and transmit 
signals to the inside of the cells, the GDP bound proteins 
are the inactive forms. They can interact with adenylate 
cyclase as a second message (Gilman, 1987).
Normally the GTPase activating protein (GAP) 
inactivates the normal p21/ras protein. If p21/ras is 
mutated this inactivation does not take place. Therefore 
once activated the mutated ras protein remains in an active 
state. (Trahey and Me Cormick, 1987; review by Me Cormick, 
1989 ) .
1.2. 3.2. NUCLEAR ONCOGENES.
Nuclear proto-oncogenes interact with specific DNA 
sequences to modulate transcription. Nuclear oncogenes 
usually immortalize primary cells in vitro.
1.2. 3.2.1. Intracelluar hormone receptors: p75gag/ErbA.
p75gag/erbA is a mutated form of the receptor for the 
thyroid hormone triiodothyronine (Sap et a l .. 1986). It is 
part of a family of hormone receptors which bind to 
specific DNA sequences and promote hormonal sythesis. 
Members of this family include the glucocorticoid receptor, 
the oestrogen receptor and the progesterone receptor. DNA
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binding is mediated by zinc finger elements. The motif of a 
zinc finger element comprises of four cysteine residues 
linked to a zinc atom. Specific binding to DNA sequences 
depends oJI the AA sequence within the motif (Umesomo and 
Evans, 1989 ) .
The oncogene v-ErbA was found fused with the viral gag 
gene and contained mutations which prevented its product 
binding to triiodothyronine. (Munoz et a l .« 1988) but not 
to DNA (Boucher et a l .. 1988). P75gag/ErbA prevents thyroid 
hormone induced transcriptional activation by c-ErbA in a 
competitive manner (Damm et a l .. 1989; Sap et a l .. 1989).
ErbA co-operates with ErbB to transform cells. ErbB 
alone can transform erythroid cells, but ErbA is required 
for stable transformation, ErbA can also cooperate with
other cytoplasmic oncogenes e.g. v-src and v-Ha-ras (Kahn 
et a l .. 1986)
1.2.3.2.2. The oncogenes fos/Jun.
The oncogene fos was first isolated from FBJ murine 
sarcoma virus (Curran and Teich, 1982). The fos gene 
product is a nuclear phosphoprotein of 55-62 KD. Its 
expression by agents inducing cell differentiation or 
proliferation is usually transient.
Molecular studies showed that the oncogenic conversion 
of c-fos is the result of increased abundance of fos mRNA, 
either by increased transcription or by stabilisation 
(Revewed by Verma, 1986). Mutants in 1 Fos sequences C
terminal to AA 338 fail to shut-off c-fos transcription 
after serum induced activation (Wilson and Treisman, 1988)
The oncogene Jun was defined originally as the oncogene 
of avian sarcomavirus ASV 17. It is part of a multi-gene 
family including J u n B  and JunT). The product of its cellular 
homolog p 3 9 - J u n  is similar to the mammalian transcription 
factor AP-1 (Angel et a l .. 1988) AP-1 has a transactivating 
activity and is stimulated by phorbol esters such as 12-0- 
tetradecanoyl-phorbol-14 acetate (TPA) (Chiu et a l .. 1987) 
and Ha-ras which stimulates the phosphorylation of the
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activation domain of c-jun (Binetruy et a l .. 1991).
Fos and p39/jun form a complex which binds to the DNA 
sequence TGACTA to modulate transcription (Schontal et a l . 
1988; Wilson and Treisman, 1988). Both belong to a class of 
DNA binding protein which shares a conserved structural 
motif the "Leucine zipper". A "Leucine zippers" is a 
periodic array of leucine residues on two proteins which 
interact with each other. This interaction enables the two 
proteins to bind to specific DNA sequences (Landschutz et 
a l . 1988) .
1.2.3.2.3.The oncogene c-myc.
The c-myc gene is part of a multigene family. It is 
expressed in normal cells in which it responds to growth 
control and is an immediate early gene. It can be activated 
by a retrovirus inserted upstream of c-myc coding 
sequences. In Burkitt’s lymphoma it is activated by a 
translocation. It can also be activated by amplification as 
in murine T-cell lymphoma (Reviewed by Alitalo and Schwab, 
1986) .
The human c-myc gene gives rise to two proteins which 
have DNA binding properties in vitro (Persson et al.. 
1984). Their transactivating activity is inhibited by TGF 
beta (Pietenpol et a l .. 1990).
1.2.4. DNA VIRUSES: INTRODUCTION.
There are three main groups of oncogenic DNA viruses, 
the adenoviruses, the papova-papillomaviruses and the 
herpesviruses. The genome of DNA viruses encode the 
oncogenes which are viral genes transcribed early in 
infection. However, in contrast to some other herpesviruses 
no oncogenes have been discovered for HSV.
1.2.5. ADENOVIRUSES.
Adenoviruses are small non enveloped DNA viruses. The 
MW of the DNA is 20x10® and the diameter is 70 to 90nm.
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Adenoviruses are ubiquitous in the animal kingdom, 
infecting birds and mammals. Human adenoviruses are not 
tumourigenic in the natural host. Neither adenovirus DNA 
nor adenovirus proteins have ever been found in human 
tumour.
Human adenoviruses can transform non permissive rodent 
cells, in vitro. They can be divided according their 
tumourigenic and transforming properties.
Acutely oncogenic e.g. Ad 12, 18, 31.
Transforming e.g. Ad 2, 5.
Not associated with tumours, all other types except 
above (1-44 ) .
Adenovirus DNA is integrated randomly into the 
chromosomal DNA of the transformed cell. The 8-12% left 
hand end of the adenovirus genome is conserved in all 
transformed cells. This region contains the sequences 
sufficient for the transformation of primary cells in 
culture (Gallimore et a l .. 1974; Sambrook et a l .. 1974).
This region of the DNA corresponds to the early region 
El which consists of two transcriptional units E1A and E1B.
E1A encodes two different mRNA, 12s and 13s. Their main 
products are two structurally related phosphoproteins MW 
23,000 and 26,000, which are transcriptional activators 
(Winberg and Schenk, 1984). E1A can transactivate certain 
cellular genes like heat shock protein (HSP)70 (Kao and 
Nevins, 1983) and beta tubulin (Stein and Ziff, 1984). E1A 
does not activate trancription directly but does so 
associated with cofactors ATF, E2F, TF3D and API and may 
also be associated with some TATA box binding factors. E1A 
immortalizes primary cells in vitro. The expressioj^ of 
major histocompatibility complex (MHC) is decreased'vrat 
cells transformed by Adl2 E1A, giving them a mean to escape 
lysis by cytotoxic lymphocytes (Bernards et a l .. 1983; 
Schrier et a l .. 1983).
E1B encodes two major RNA species of 22s and 13s which 
encode two unrelated polypeptides of MW 17,000 and 55,000. 
The 55 KD protein is nuclear and cytoplasmic, it forms a
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complex with the anti-oncogene p53 (Sarnow et a l .. 1982). 
The 17KD protein is localized in the nucleus and the 
nuclear envelope. E1B activates the expression of E1A. E1A 
immortalized cells express E1A mRNA at substantially 
reduced levels as compared to transformants that contain 
both E1A and E1B (Jochemsen et a l .. 1987). E1B is required 
for complete transformation of rodent cells but cannot 
transform the cells in the | absence of E1A. (Gallimore et 
a l .. 1974; Van den Elsen et a l .. 1984).
1.2.6. HEPATITIS B VIRUS.
HBV is an enveloped virus, its diameter is 42 nm. The 
DNA is circular and is r partially stranded
with a deletion in the internal strand, its
molecular weight is 2xl06 KD. It codes for a reverse
transcriptase. This virus cannot be cultured in vitro, 
studies have been carried out using cloned genomes.
e
The arguments supporting the involvment of HBV in the 
etiology of hepatocellular carcinoma (HCC) are the
following.
Members of the family hepadnaviridae, mainly woodchuck 
hepatitis virus (Popper et a l .. 1987) but also ground
squirrel hepatitis virus, produce tumours in their natural 
host.
An epidemiological study of 22707 patients in Taiwan 
showed that the 10% of the individuals who were of HBV 
carrier status had a 223 fpU higher risk of developing
carcinoma than the HBV negative controls (Beasley et a l .. 
1981).
The results of the molecular biology studies did not 
give a clear explanation of the oncogenicity but recently 
several mechanisms have been suggested.
HBV DNA has been found integrated to the cellular DNA 
(Koshy et a l .. 1983; Ziemer et a l .. 1985) or as an episome 
in HCC tissues but but integration is also found in tissues 
surrounding the neoplasm. HBV DNA has been found in a
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position where it disrupts the cyclin gene, and it was 
speculated that the HBV enhancer element could have been 
responsible of the increased steady state level of cyclin A
r
mRNA obseved in this tumour (Wang, E. et a l .. 1989).
A possible explanation is also the transcription of
host genes by HBV promoter sequences, but HBV is integrated 
randomly in the chromosomal DNA. The integrated HBV DNA 
always contains the S gene. Transcription initiated by
viral sequences can continue in the host DNA (Freytag von 
Loringhoven et a l . 1985).
The X gene may be involved in transformation. It
encodes a protein which is a transactivator (Koshy and
Hofschneider, 1989). Recently, transgenic mice were derived 
by microinjection of a HBV DNA fragment encoding the HBx 
gene. Male mice died earlier than female, on autopsy all 
males had liver tumours, many of which were diagnosed as 
HCC. This suggest strongly that the X gene of HBV is a 
virus encoded oncogene (Chang-Min Kim et a l .. 1991).
If mass immunization were practical, a reduction of the 
incidence of HCC in the populations with a high carrier rate 
of HBV, would be a strong argument in favour of the 
involvment of HBV in the etiology of HCC.
1.2.7.PAPOVA-PAPILLOMAVIRUS.
The family Papovaviridae is divided in 2 genera,
Polyomaviruses and Papillomaviruses. They are small non
enveloped viruses, containing double stranded DNA. The
diameter of- polyomavi ruses is 45 n m , and the MW of its DNA 
is 3.5xl06 . Papillomaviruses are slightly larger, the 
values are 55 nm and 8xl06 respectively. SV40 and 
polyomavirus are not tumourigenic in their natural host in 
the wild, but they are oncogenic in hamsters and mice 
respectively in the laboratory
1.2. 7.1. SV40.
The early region of SV40 codes for two proteins, known
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as the large T and the small T antigens.
The large T antigen is a complex multidomain 
phosphoprotein. It plays a direct role in viral DNA
replication. It binds to viral DNA at the origin of
replication, DNA binding is mediated by zinc finger domains
which recognize the sequence GAGGC and it has an ATP
dependent helicase activity. It interacts with DNA 
polymerase alpha and triggers the initiation of DNA 
replication. The SV40 large T antigen regulates its own 
synthesis and its activity is regulated by phosphorylation.
The SV40 large T antigen can both immortalize and 
transform rat embryo cells (Livingston and Bradley, 1987). 
SV40 large T can activate certain cellular genes, and has a 
mutagenic activity. The SV40 large T binds to the central 
region of the anti-oncogene p53. The affinity of the 
binding is lower in permissive than in non permissive cells 
(Lane et a l .. 1982). Both p53 and DNA polymerase alpha bind 
competitively with the large T antigen and the relative 
affinity of the two proteins may be a determinant of the 
host cell permissiveness (Murakami et a l .. 1986). The
large T antigen also binds to another antioncogene, Rb/pl05 
in the underphosphorylated form. The large T interfers 
with the function of p53 and Rb/pl05 which are both 
involved in the control of cell proliferation.
A small proportion of the large T antigen is associated 
with the cell membrane. Purified large T antigen has a 
tyrosine kinase activity, and can catalyze the 
phosphorylation of multiple proteins (Livingston and 
Bradley, 1987).
The SV40 large T antigen seems to combine the 
properties of a nuclear oncogene (immortalizing) and a 
cytoplasmic (transforming) oncogene.
The small T antigen co-operates with the large T to 
transform cells and is involved in the dissolution of actin 
cables.
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1.2.7. 2. POLYOMAVIRUS.
Transformation by polyomaviruses requires the 
cooperation of three distinct oncogenes, which are encoded 
by the early region of polyomavirus. In virus transformed 
and tumour cells, they are integrated into the cell DNA and 
are continually expressed (Cuzin et a l .. 1984).
The large T antigen is a nuclear phosphoprotein, It 
immortalizes primary cells and gives serum independence. 
Cells immortalized by the large T antigen can be 
transformed by an oncogene such as activated ras or the 
middle T antigen. The Large T antigen is a multidomain 
protein. One domain has DNA binding activity and is 
required for virus DNA replication and is different from 
the immortalizing domain (Strauss et a l .. 1989).
The middle T antigen is a membrane protein. It is 
sufficient to transform established cells (Treisman et a l ., 
1981). The protein is associated with the cell membranes. 
The N-terminus of the middle T binds to the carboxy teminus 
of c-src, and activatesc-src by phosphorylation of Tyr 416. 
Binding of c-src is indispensable for the transformation 
activity of middle T (Markland and Smith, 1987).
The small t antigen affects the cytoskeleton and 
cooperates with the large and the middle T antigen for full 
transformation (Rassoulzadegan et a l . 1982).
1 . 2 . 7 . 3. PAPILLOMA VIRUSES .
1.2.7.3.1. Animal papillomaviruses.
Papillomavirus are ubiquitous in the animal kingdom and 
are associated with cell proliferation (Warts).
In the rabbit, the cotton tail rabbit papillomavirus 
(C R P V ) causes warts which within 6-9 months progress to 
carcinoma in which the CRPV is integrated into the cellular 
DNA. (Mac Vay et a l ., 1982).
In cattle, bovine papillomavirus type 4 (BPV-4) causes 
alimentary tract warts which progress to carcinomas. The 
DNA in this case is not retained after the initial
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Figure 1.4. Genetic organization of BPV-1,
(Broker and Botcham, 1986).
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proliferating event. A co-carcinogen in the west of 
Scotland may be bracken which is indigenous and may act by 
depressing the immune response or by action of the co­
carcinogen quercitin (Campo and Jarret, 1987).
The role of the early genes have been studied in BPV-1 
which is the agent of benign skin papillomas in cattle 
(Reviewed by Horwitz et a l ., 1989). There are 8 early and 2 
late ORFs (Figure 1.4).
El is essential for replication.
E2 codes a DNA binding protein. It regulates E5 from 
BPV1 (Horwitz et a l ., 1989).
E5 codes for a protein of 44 AA residues. It is the 
transforming protein of BPV-1 (Iftner et a l .. 1989). The 
protein probably transforms by induction of DNA synthesis. 
The carboxy terminus expresses mutagenic activity (Horwitz 
et a l ., 1989).
E6 codes for a 15.5 kD protein found both in nuclear 
and membrane fractions of the transformed cell.
1.2.7.3.2. Human papillomaviruses.
Epidemiology
In the human, papillomaviruses are associated with 
benign and malignant diseases. The most persuasive study is 
that of epidermo dysplasia verruciformis in which many 
papilloma subtypes but principally type 5 and 8 are 
present. The disease which also has a genetic component 
progresses from premalignant lesion to malignant skin 
lesions (carcinoma) following exposure to the cofactor U.V. 
in sunlight.
HPV subtypes are associated with both premalignant and 
malignant lesions in the female genital tract. Carcinoma of 
the cervix is a progressive disease known as cervical 
intra epithelial neoplasia (CIN) and graded CIN I CIN III 
according the severity of the lesions. When the basal 
membrane is breached, then invasive cancer develops.
Original and limited studies showed HPV type 6 and 11 
(Gissmann, et a l .. 1982) to be characteristic of CIN
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Figure 1.5. Genetic organization of HPV-1
(Broker and Botcham, 1986).
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whereas HPV 16 (Durst et a l .. 1983) and 18 (Boshart et a l ..
1984) were associated with cervical cancer. However 
carefully controled studies from Scotland (Macnab et a l .. 
1986) with both internal et external controls showed that 
HPV-16 DNA was present in 84% of the tumour tissues but 
was also detected in 73% of internal histologically normal 
tissues, and in 11% in the healthy control women. Moreover 
Murdoch et a l .. (1988) in the same geographical region
showed that 63 % CIN and 48 % of internal histologically
normal control tissues contained HPV-16 DNA.
These studies support in vitro molecular evidence which 
shows that the E6 and E7 ORFs of HPV 16 can immortalize 
cells in vitro. These immortalized cells are not oncogenic 
But the presence of HPV 16 E6 and E7 in cervical tissues is 
not associated with the progression of the oncogenic 
phenotype (Parry et a l .. 1990).
Early genes
The HPV 16 genome (shown in figure 1.5) codes for seven 
early ORFs which can be expressed in non-permissive cells 
plus two late proteins associated with virus assembly and 
expressed only in differentiated cells. No in vitro system 
of virus propagation exists because the virion requires 
differentiating cells to synthesize late proteins and 
assemble virions. HPV-16 DNA is maintained in monomeric 
episomal form in a human cervical keratinocyte cell line 
(Stanley et a l .. 1989). This cell line can be induced to 
form a stratified differentiated epithelium by grafting 
onto nude mice. This experimental system appears to permit 
the completion of the HPV-16 cell cycle in virus containing 
keratinocytes (Sterling et a l .. 1990). In vitro the
following evidence exists for the function of El-7 ORF 
except E3 and E5 for which little is known.
The 3 ’part of El is essential for DNA replication and 
has homology with the polyoma and SV40 large T, the 5* part 
of the El controls the copy number of extrachromosomal 
viral DNA at least in C127 cells (Berg et a l .. 1986).
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E2 encodes a DNA binding protein, it is a 
transcriptional activator which regulates E6 and E7 of HPV 
16 (Cripe et a l .. 1987).
The E4 product is abundant in virus producing cells 
(Doorben et a l .. 1986), and is involved in control of late 
virus functions.
E6 encodes the main transforming protein of HPV-8.
E6 and E7 of HPV 16 are both transforming proteins. 
Schiller et a l . (1990) showed that E6 and E7 are both
necessary and sufficient to immortalize primary human 
keratinocytes. E7 alone, transiently extends the lifespan 
of the keratinocytes, but E6 is necessary to completely 
immortalize them. Other workers e.g. Di Paolo et a l ♦ (1990)
can immortalize a human epithelial cell line with E7 alone. 
The gene product of E6 binds to p53, and the gene product 
of E7 binds to pl05. The importance of these interactions 
are demonstrated by the following experiments.
Using proteins expressed in a rabbit reticulocyte 
lysate, the E6 proteins of different HPVs which bind (HPV- 
16 and HPV-18) or do not bind to p53 were incubated with 
p53. P53 remained stable in the presence of increasing 
amounts of the E6 proteins of HPV-6 and HPV-11. In the 
presence of E6 proteins of HPV-16 and HPV-18, p53 was
degraded in a manner dependent on the concentration of E6 
protein. The protein p53 was found to be bound to ubiquitin 
suggesting that E6 binding enhance the degradation by the 
ubiquitin-dependent protease system (Scheffner et a l ..
1990). The association of E6 with p53 is mediated by a 
100KD cellular protein (Huibregtse et a l . 1991).
Crook et a l .. (1991a), generated a series of mutations
within the E6 ORF. These experiments showed that E6 binding 
of p53 is not sufficient for E6 enhancement of p53 
degradation. This enhancement of p53 degradation is 
mediated by E6 sequences different from the binding 
sequence.
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Both p53 and RB/pl05 proteins are anti-oncogenes (See 
section 1.2.8).
Role of HPV in cervical cancer
The experiments presented show the importance of E6 and 
E7 gene products in the origin of cervical cancer, by 
inactivation of pl05/RB and p53.
In premalignant lesions the viral DNA is predominantly 
extra-chromosomal, in plasmid state. In cancer containing 
HPV-16 and HPV-18, the DNA has been detected as either an 
oligomeric episome, a monomeric episome or as an integrated 
sequence (Durst et a l .. 1985, Boshart et a l .. 1984). It has 
also been isolated from a cancer of the vulva as a head to 
tail dimeric episome with a deletion in the non-coding 
region (Kennedy et a l .. 1986).
When HPV DNA is integrated in the genome of the tumour 
cell, there is no particular site of integration. But the 
circular HPV DNA is disrupted within the 3*end of the El 
ORF and the 5 ’end of the E2 ORF (Schwarz et a l .. 1985; 
Pater and Pater ,1985; Baker et a l .. 1987). The E6 and E7
ORF are not deleted and are transcriptionally functional 
(Bedell et a l .. 1987). The loss of the E2 gene product, a 
DNA binding protein, which can repress the transcription of 
E6 and E7 (Cripe et a l .. 1987; Thierry and Yaniv, 1987)
deregulates E6 and E7 expression.
Microinjection of E6/E7 antisense RNA interferes with 
the survival of cells expressing E6 and E7 (Kleinheinz et 
al. . 1989).
The the RB and p53 genes in HPV positive and negative 
cervical carcinoma cell lines were sequenced (Scheffner et 
a l .. 1991; Crook et a l .. 1991b). Those cell lines
containing HPV DNA were found to express wild type p53 and 
RB while lines lacking HPV DNA contained mutations at both 
the RB and the p53 genes. This suggests that inactivation 
of RB/pl05 and p53 is important in cervical carcinogenesis 
and that inactivation can occur through the action of the 
E6 and E7 proteins.
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The data supporting the involvment of HPV in cervical 
cancer are strong, but other co-factors are required. One 
of the possible cofactors IS herpes simplex virusc .
encoding mutated or altered cell genes. DNA viruses code 
for an oncogene, their mode of action could involve in some 
instances the inactivation of normal cell genes termed 
"anti-oncogenes” .
1.2.8.1. pi 05/RB.
The retinoblastoma gene (R B ) controls the normal 
regulation of cell growth. Manifestation of the disease 
retinoblastoma involves an inherited genetic defect 
involving a chromosomal deletion and expression of a 
mutated abnormal autosomal recessive allele. Reintroduction 
of the normal Rb gene decreases the growth rate of cultured 
retinoblastoma cells and inhibits their growth in soft agar 
(Huang et a l .. 1988). The Rb gene was found also to be
inactivated in breast cancer cell lines (Lee, E.Y. et a l .. 
1988 ) .
The product of the retinoblastoma gene Rb/pl05 is a 
nuclear protein which is reversibly phosphorylated during 
the cell cycle (Lee, W.H. et a l ♦, 1987a and b). It can form 
complexes with several DNA virus oncogenes.
SV40 large T antigen and adenovirus E1A can both 
complex to Rb/pl05 (Whyte et a l ., 1988; De Capricio et a l .. 
1989). This interaction with RB/pl05 is essential for 
transformation by adenovirus (Whyte et a l .. 1989). It
occurs through a site on E1A which shows sequence 
conservation with a region in the transforming proteins of 
SV40, polyomavirus, and human papillomavirus (HPV-16) 
(Reviewed by Green, 1989).
The phosphorylation state of Rb/pl05 is maximal close
to the start of the S phase and low after mitosis and and 
entry into G1 (De Capricio et a l .. 1989; Chen, P.L. et a l ..
1.2.8. TUMOUR SUPRESSOR GENES.
some of them
Studies of RNA viruses show that transform by
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1989; Ludlow et a l .. 1990). This suggests that only the
hypophosphorylated form of RB/pl05 suppresses cell 
proliferation.
The protein Rb/pl05 which co-immunoprecipitates with
the large T antigen of SV40 is dephosphorylated (Ludlow et
a l .. 1989). The transforming proteins of DNA tumour viruses
With
may act at least in part by complexing and inactivating the 
hypophosphorylated protein. E7 proteins of the non 
oncogenic HPV type 6b and 11 bind RB/pl05 with a lower
affinity than proteins of oncogenic types HPV 16 and 18
(Gage et a l .. 1990).
The protein Rb/pl05 suppresses cell proliferation not 
directly, but through interaction with c-fos (Robbins et 
a l .. 1990) and c-myc (Pietenpol et a l .. 1990 a and b).
Recent evidence shows that E1A prevents the binding of Rb 
with the cellular transcription factor DRTF1 (Bandara and 
La Thangue, 1991).
1.2. 8. 2. p53_.
The product of the gene p53 is a nuclear phosphoprotein 
which was discovered as a complex with SV40 large T antigen 
(Lane and Crawford, 1979). It can also form a complex with 
E1B of adenovirus (Sarnow et a l . 1982) and E6 of HPV 16 and 
18 (Werness et a l .. 1990). Complex formation with SV40 LT
stabilizes p53. Increased stability is also
characteristic of mutants in p53 which are oncogenic. The 
transforming activity of SV40 large T antigen is linked to
the binding of p53 because mutants unable to bind p53 are
not oncogenic.
The activity of p53 seems to be regulated both by
abundance and by phosphorylation. The level of p53 is very 
low after mitosis but increases in G1 and p53 is
phosphorylated during the S phase of the cell cycle 
(Bischoff et a l . 1990).
The protein p53 seems to be necessary for the 
proliferation of normal cells (Shohat et a l . . 1987).
Tumours however have either a very low, perhaps 
undetectable, level of p53 (Mulligan et a l . 1990), or have
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mutant proteins which can be expressed at very high level 
(Finlay et a l . 1989; Halevy et a l . 1990). These p53 mutants 
can immortalize primary cells, which can in turn be 
transformed by an oncogene such as ras (Parada et a l .. 
1984 ) .
Introduction of the normal p53 gene into tumor cell lines 
with either low level of p53 or a mutant protein 
suppresses growth (Baker et a l . 1990; Diller et a l .. 1990).
The mechanisms of action of p53 may be the following 
(Reviewed by Marshal, 1991).
p53 may inhibit the expression or function of c-myc.
p53 may activate genes that suppress cell 
proliferation.
p53 may control the initiation of the DNA synthesis by 
interaction with DNA polymerase alpha and other components 
of the DNA replication complex (reviewed by Marshal, 1991). 
This is supported by the following facts. Normal p53 blocks 
the binding of SV40 large T antigen to DNA polymerase alpha 
(Gannon and Lane, 1987). p53 mutants which do not bind SV40 
large T fail to block SV40 DNA replication (Braithwaite et 
al., 1987; Wang, E.H. et a l .. 1989).
1.2.9. HERPESVIRUSES.
1.2.9.1. EPSTEIN-BARR VIRUS.
EBV readily infects human B cells in culture 
transforming them into permanent cell lines in which every 
cell carries multiple episomal copies of the viral genome 
(Reviewed by Dambaugh et a l .. 1986). The EBV genome in
naturally infected cells expresses 8 EBV encoded proteins, 
6 nuclear antigens (EBNAs) and 2 latent membranes proteins 
(LMPs). EBV is involved in the etiology of two human
tumours, Burkitt’s lymphoma and nasopharyngial carcinoma.
Burkitt’s lymphoma is a B cell lymphoma found 
predominantly in Central Africa. It is a childhood disease 
in which every tumour cell contains episomal copies of the
EBV genome. An early age of infection and malaria which
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depresses the immune system are probably the co-factors
required for the development of the tumour.
The functions of some of the early genes expressed in 
transformed cells are the following.
EBNA-1 is involved in maintenance of copy number of
episomal viral genomes (Yates et a l .. 1984; Lupton and
Levine, 1985).
EBNA-2 plays a role in the expression of the 
transformed phenotype. It is required for immortalization 
of B cells in culture and growth in low levels of serum 
(Dambaugh et a l .. 1986).
LMP-1 is detected in latently infected proliferating 
lymphocytes. LMP is a transmembrane protein, analysis of 
its AA sequence shows 6 possible transmembrane domains 
(Bankier et a l .. 1983). It is a phosphorylated protein but 
does not seem to have a protein kinase activity . It is 
associated with a component of the cytoskeletal framework : 
vimentin (Liebowitz et a l . , 1987). It has a considerably
more rapid turnover than cellular proteins. It converts 
Rat-1 cells (immortalized cells) to a tumourigenic 
phenotype (Wang et a l .. 1985).
Cells from Burkitts1 lymphoma contain translocations
involving the long arm of chromosome 8 and chromosomes 14, 
or chromosome 2 and 22. They show translocation of the 
oncogene c-myc normally on chromosome 8 with the 
immunoglobulin heavy chain gene in chromosome 14 or the 
immunoglobin light chain genes in chromosome 2 or 22 
putting c-myc expression under the control of the strong 
promoter of the immunoglobulin chains.
Nasopharyngeal carcinoma occurs predominantly in 
southern China. The cells of the carcinoma all contain 
episomal copies of the EBV DNA genome.
Studies of EBV gene expression was possible once NPC 
transplanted in nude mice became available. Passage in nude 
mice eliminates most of the contaminating lymphocytes which 
may be infected by EBV.
One of the tumours designated C15 contained multiple
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episomal copies of EBV. The episomal DNA is not grossly 
mutated, but the transcription pattern differs from that- 
observed in B lymphocytes. Transcription is strictly 
regulated, EBNA2-6 are switched off, and therefore EBNA-1 
and LMP are the only antigens detected. A family of 
cytoplasmic mRNA ^  _ transcribed in an anti-sense direction 
to the known ORFs in this region of the genome (Hitt et 
al . . 1989).
1.2.9.2. HERPES SIMPLEX VIRUSES.
There has been a great interest in HSV as a possible 
agent of cervical carcinoma. However molecular biology 
studies have not revealed an oncogene or a clear mechanism 
of oncogenesis.
The role of HSV in the etiology of cervical carcinoma 
was supported by epidemiological data, which found an 
increased frequency of HSV-2 positive sera among women with 
cervical cancer (Rawls, 1983; Melnick et a l ., 1991) with a 
seven fold increase of sera positive for HSV-2 and HPV 
(Rawls, 1983). But the results of two prospective studies 
do not support a role for HSV-2 in the development of 
cervical cancer (Vonka et a l . 1984, Melnick et a l .. 1991).
But these resuts may be biased because CIN is treated 
before progression occurs.
Cevical carcinoma was reproduced in mice, by vaginal 
application of swabs impregnated with HSV-1 (Wentz et a l .. 
1981), HSV-2 or its DNA (Anthony et a l .. 1989), and it is 
inhibited by prior immunization (Wentz et a l ., 1983; Chen 
et al . , 1986; Skinner et a l . 1987).
The transforming properties of HSV have been confirmed 
by in vitro experiments. Hamster embryo cells can be 
transformed after exposure to UV inactivated HSV-2 (Duff 
and Rapp, 1971), and to HSV-1 (Duff and Rapp, 1973). The 
oncogenic regions of HSV have been defined.
Three "regions of the HSV genomes are associated with 
morphological transformation of cultured cells. One of
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Figure 1.6. Genomic organization of HSV-2.
Localization of Bgl Iln and Bgl Ilg fragments and sub
fragments, (adapted from Macnab, 1987 and Chung et al_^
1988).
Map units y/
I-------------1-------------1-------------1-------------1------------ 1
0 0.2 0.4 0.6 0.8 1
Bgl IIC Bgl UN
Bam HI
0.54 0.584 0.61
Sail Pst1 Pst1/Sal1 fragment Jones etal., 1986.
0.559 3.6 kb Sal1/Pvu1 0.583
PK domain RR domain.
PK domain of RR1 Chung et al., 1989.
these (Camacho and Spear, 1978) present in HSV-1 and known 
as MTRI (morphological transformation region of HSV-1) maps 
in Xbalf (0.29 to 0.45 m . u . ) and Bgllli (Reyes et a l .. 
1979). The sequences coding for glycoprotein B (g B ) can be 
at least transiently expressed (Camacho and Spear, 1978). 
In HSV-2 there are two regions of the genome associated 
with the induction of morphological transformation (Figure 
1.6) : these are MTRII (morphological transformation region
of HSV-2) mapping (Reyes et a l . 1979, Macnab and
McDougall, 1980; Galloway and McDougall, 1981; Cameron et 
a l ., 1985) in Bgllln (0.58to 0.62 m.u.) and another region
referred to as MTR III (the third morphological region of
HSV); maps (Jariwalla et a l .. 1982) in Bglllc (0.54 to 0.58 
m.u. ). The 64% left hand of Bglllc can immortalize hamster 
embryo cells, while the 36% right hand is required for 
tumourigenicity (Jariwalla et a l . 1983). A smaller 480 bp
sub-fragment of Bglllc was found to be sufficient to
transform Rat-2 cells in a focus assay system (Jones et 
a h ,  1986).
1.2.10. MECHANISMS OF TRANSFORMATION BY HSV.
1.2.10.1. INTRODUCTION.
HSV-2 DNA sequences are detected in 10% of tumour cells 
(Park et a l ., 1983). The Bgllln fragment is the most 
frequently retained (reviewed by Macnab, 1987). To further 
identify this region, the insert in one tumour was multiply 
digested, by restriction enzymes, and restriction sites 
characteristic of the HSV-2 genome were demonstrated (Park 
et a l ., 1983).
Retention of HSV-2 DNA sequences is not necessary for
the maintenance of the transformed phenotype in HSV-2
transformed cells (Cameron et a l ., 1985).
These data suggested that HSV-2 DNA could induce
transformation, but would then be eliminated from the
transformed cells in a ’’hit and run mechanism" as suggested 
originally by Skinner (1976).
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The suggested mechanisms by which transformation could 
occur were reviewed by Macnab, (1987) and summarized to be:
4Involvment of the ribonucleotide reductase activity.
Mutagenesis and gene amplification.
Increased or altered expression of cell coded genes.
Activation of endogenous viruses.
Coding capacity of HSV for a protein kinase.
Homologies of HSV-2 and HSV-1 with cellular DNA 
sequences.
Recent studies strengthen these hypotheses, or suggest 
new ones, they will be- shortly described.
1.2.10.2.MUTAGENESIS.
The mutagenic activity of HSV was tested by 
inactivation of a gene cloned in the shuttle vector plasmid 
pZ 189 (Seidmann et a l ., 1985).
Infection of Cos cells by HSV-1 UV irradiated or not, 
increases the rate of mutation by two to sevenfold. The 
mutations are also different (Hwang and Shillitoe, 1990):
1/ The frequency of deletions and complex mutations is 
higher.
2/ Insertions of cellular genes opjl observed.
3/ Thirty per cent of the mutations occur at a hot 
spot with general sequence PPPYYYYPPP (where P = purine and 
Y = pyrimidine).
Using the same vector, the expression of the viral 
ribonucleotide reductase does not appear to be the cause of 
incresed mutagenesis in infected cells. UV inactivated DNA 
is mutagenic in cells which suggests that either a virion 
component or the HSV DNA itself could be the mutagenic 
agent (Clarke and Clements, 1991).
1.2.10.3.THE ROLE OF THE RIBONUCLEOTIDE REDUCTASE OF 
HSV-2.
RR is an enzyme required for the synthesis of deoxy-
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ribonucleotides. The viral genes are contained in the MTR 
II and III regions of HSV-2. The large sub-unit, Vraw 136, 
is encoded by the Bgl lie fragment, but the carboxy 
terminus sequence lies in Bgl Iln (McLauchlan and Clements,
1983). The small subunit, Vmw 38, is encoded by the Bgl Iln 
fragment. The enzyme is only active if the two sub-units 
are associated and act as a dimer.
The large subunit of HSV-2 R R , Vmw 136, can be detected 
in transformed cells by immunoprecipitation with a specific 
monoclonal antibody (Hayashi et a l . 1985). Vmw 136 is also
immunoprecipitated in 48% of CIN III, and 57% of genital 
invasive carcinoma. The protein is expressed even when its 
gene cannot be detected by Southern blot analysis in which 
only 5% of CIN III and 16% of genital invasive carcinoma
are positive (Di Luca et a l .. 1990).
Immortalized non tumourigriic Syrian hamster embryo 
cells transfected by a HSV-2 DNA fragment (0.554 - 0.572 
m.u. ) encoding the protein kinase activity of Vmw 136
acquire anchorage independent growth potential and
neoplastic potential. The importance of Vmw 136 expression 
was investigated using DNA constructs expressing full
length Vmw 136, the protein kinase domain, the non protein 
kinase domain and a non expressing frameshift mutant. The 
anchorage independent phenotype was acquired only by the 
cells transfected by the constructs encoding either full 
length Vmw 136 or the protein kinase domain. Vmw 136
expression was detected by immunofluorescence in cells
transfected by the DNA construct expressing full length Vmw 
136 (Smith et a l ., 1990)*
Enzymatic activity of Vmw 136.
Protein kinase activity had been predicted by computer 
analysis in the amino terminus of the HSV-2, but not of the 
HSV-1, large subunit of the RR . This protein kinase 
activity has been immunoprecipitated by specific monoclonal 
antibodies from either HSV-2 infected cells or from cells
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transformed by the cloned fragment of Vmw 136(m.u. 0.559- 
0583), but not from uninfected Hep2 cells (Chung et a l ..
1989). Computer analysis indicated the presence of a 
transmembrane segment, and the protein is myristilated by a 
cellular enzyme (Chung et a l .. 1990). This suggests that
Vmw 136 encodes an oncogene similar to v-src which is a 
tyrosine kinase and is bound to the cell membrane by 
myristic acid.
1.2.10.4. GENE AMPLIFICATION.
Gene amplification is induced by a subset of the genes 
necessary for HSV replication.
Plasmids expressing the viral genes UL30 DNA 
polymerase, UL29 major DNA binding protein, UL5 DNA 
helicase, UL8, UL42 DNA binding protein and UL52, but not 
UL9 origin binding protein were required for SV40 DNA 
amplification in SV40 transformed Syrian hamster (Elona) 
cells (Heilbronn and Zur Hausen, 1989). Amplification was 
also obtained by infection with a deletion mutant of HSV-1 
KOS for UL9 (Heilbronn et a l ., 1990).
Amplification by subclones of MTR III.
The minimal transforming fragment of MTR II was mapped 
to a 486 bp Pst 1-Sal 1 fragment (0.567-0.570 m.u. ) 
utilizing an established rat cell line (Jones et a l .. 
1986). This fragment cloned into a plasmid can induce the 
replication of the plasmid (Zhu and Jones, 1990). This 
suggests that this fragment integrated into a cellular 
chromosome may also trigger replication.
1.2.10.5. COOPERATION WITH OTHER VIRUSES.
DNA of another herpes virus HCMV is found in 5% of 
cervical cancer biopsies (Fletcher et a l .. 1986). The IE
gene product was expressed in the HCMV insert cloned from 
this DNA (Fletcher and Macnab, 1989).
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Cooperation between HSV and HPV was suggested by Zur 
Hausen (1982). Both viruses are sexually transmitted and 
they can be found associated in cervical cancer (Di Luca 
et a l .. 1990; reviewed by Macnab, 1987). A model of
cooperation was suggested in an in vitro experiment. Cloned 
HSV-2 Bgllln fragments were unable to transform primary 
human keratinocytes, but transformed keratinocytes already 
immortalized by HPV (Di Paolo et a l .. 1990). The
papillomavirus transactivator E2 protein activates 
expression from the promoter for the large subunit of RR of 
HSV-2 (Wymer and Aurelian, 1990).
1.2.10.6. TRANSFORMATION BY ALTERATION OF THE ACTIVITY 
OF CELLULAR PROTEINS.
The following experiment suggests that HSV infection 
may alter the functions of different cellular proteins 
involved in the control of cellular division. This could 
facilitate transformation by analogy with the mechanism of 
action of other tumourigenic viruses.
The major DNA binding protein, mDBP, is associated with 
the viral DNA in the replication |compartments (Quinlan et 
a l .. 1984). Using immunofluorescence techniques, it co- 
localizes with the following proteins: single stranded
DNA binding protein (Waseen and Lane, 1990), proliferating cell 
nuclear antigen (PCN A ) (Kenny et a l ., 1990), pl05/RB and
p53. It is however not known if the mDBP binds to p53 or to 
pl05/RB (Wilcox and Lane, 1991) but it cannot be 
immunoprecipitated (i.p.) (Lane, personal communication).
1.2.10.7. TRANSFORMATION BY ACTIVATION OF CELLULAR 
GENES.
HSV-1 does not need to enter the cell to activate the 
expression of cellular genes. The ts 1204 mutant of HSV-1 
17 fails to penetrate the cell at npt, (Addison et a l ..
1984). The mutant ts 1204 c induces the expression of a 
protein of apparent molecular weight 56 KD in human
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fibroblast cells but not BHK cells or CV1 cells at n p t . 
Synthesis of p56 is induced by the specific interaction of 
ts 1204 with the cell surface (Preston, V.G. 1990).
Our studies centre on HSV induced cellular genes 
(Macnab et a l . 1992) in which patients with cervical
cancers develop antibodies to a polypeptide of MW 40,000 
which can be induced by HSV infection. The relevance of 
this polypeptide to transformation will be the subject of 
this thesis. The identification of this (these) 
polypeptide(s) is the first step in understanding its role.
The sera of rats bearing tumours to HSV-2 transformed
cells (TBS) i.p. a set of polypeptides of MW 200KD, 90KD (a
doublet), 40KD and 32KD which are expressed in HSV-2
transformed (Bn5 T ) cells but not in rat embryo cells.
Studies with a monoclonal antibody raised against HSV-2 
cedi
infected^polypeptide purified by DNA binding affinity 
chromatography^TG7A;(Macnab et a l .. 1985; LaThangue and
Latchman, 1988) showed that the 90KD polypeptide could be
i.p. in cells transformed by RSV and Ad-12 (Macnab et a l ..
1985). These polypeptides are cellular and induced by 
viruses.
The pattern of the Staph. aureus V8 digestion of the 
90KD polypeptides i.p. by TBS and by the Mab TG7A (TBS:90 
and TG7A:90) is undistinguishable. It is not proved but it 
is reasonable to assume that they are two highly similar 
polypeptides. The analysis of the same experiment with 
TBS:40 and TG7A:40 showed that the two polypeptides give 
different bands but have some in common. The two 
polypeptides can be similar but different or TBS:40 can 
consist of several polypeptides one of them identical to 
TG7A:40 and sharing epitopes with TBS:90.
The aim of this thesis will be to purify and sequence 
the TBS:40. From the data generated it should then be 
possible to identify the function of the protein and the 
relationship to U90 if any.
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PART 2 
MATERIALS AND METHODS.
2.1. MATERIALS.
2.1.1. ANIMALS
Hooded Lister rats from a closed colony maintained in 
the Institute of Virology by inbreeding, brother/sister 
mating for over 20 years were used to prepare Tumour
Bearing Sera (TBS) and Rat Embryo (RE) cells .
Female Balb C mice, 3 weeks old were purchased from
Bantin and Kingman, Hull, U.K..
2.1.2. CELLS.
RE fibroblast cultures are prepared from embryos of 16 
to 17 days gestation. Primary or secondary cultures were 
used as negative control in the i.p. experiments.
Bn5 is a clone of rat embryo fibroblast transformed by 
the Bgl Iln fragment of HSV-2 strain HG 52. This fragment 
codes for the small sub-unit of the ribonucleotide
reductase, and the carboxy terminal of the large sub-unit 
of the ribonucleotide reductase and the host virion shutoff 
gene, UL41.
BN5T is cell line cultured from tumour induced by 
injection of Bn5 cells In Hooded Lister rats (Cameron et 
al . . 1985).
The myeloma cell line P3-X67 Ag8, was kindly supplied
by Dr Ann Cross of this Institute. It secretes IgG. 
(Kohler and Milstein, 1975).
Baby hamster kidney (BHK) cells, establised by 
Macpherson and Stoker (1962) and maintained in this
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institute, were used in preparation and titration of virus 
stocks.
2.1.3. VIRUS.
HSV-2 strain HG52 (Timbury 1971) stock was supplied by 
Mrs M. Murphy working in this Institute.
2.1.4. TISSUE CULTURE MEDIA AND SOLUTIONS
The Dulbecco’s modified Eagle’s medium (DMEM), BHK21 
medium 10X stock (Glasgow modified ETagle’s medium) and the 
supplements, sodium bicarbonate 7.5%,
penicillin/streptomycin, glutamine, gentamycin, foetal calf 
serum, newborn calf serum and horse serum were purchased 
from Gibco Ltd., Paisley, Scotland, mycostatin, lOU/ml, 
Squibb and Sons, Hounslow, M i d d l e s ^  , England and 
ciprofloxacine from Bayer, Newbury, Berkshire, U.K..
EF2-met , Eagle’s minus methionine prepared at the
Institute of Virology, Glasgow, was used to label cells 
with [35S] L-methionine.
Versene: 0,6mM disodium ethylenediaminetetraacetate
(EDTA) dissolved in phosphate buffer saline (PBS) 
containing 0.002% phenol red.
Trypsin: Trypsin (Difco Laboratories, West Molesley, 
England) was used as a 0,25% (w/v) solution in tris-saline.
Selection medium for hybridomas: 100X HAT stock
solution contains 20ml of 10~2 M hypoxanthine, 3.2ml 10-2 M 
thymidine, 1.6ml 10-3 M aminopterin and 0.6ml of 10’2 M 
glycine. To disolve the aminopterin, 0.5ml of 1M NaOH is 
added for each 100ml of solution and the solution is 
titrated back to neutrality with 1M H C 1 .
2.1.5. CHEMICALS
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Analytical or HPLC grade reagents were purchased from 
the following companies.
Aldrich Chemical Company, Gillingham, Dorset, England: 
3-[cyclohexylamino]-l-propane-sulfonic acid (CAPS), N , N ’- 
diallyltartardiamide (DATD), pyridine, vinylpyridine, 
tributylphosphine, N-heptane, ethylacetate.
Amersham International pic., Amersham, Buckinghamshire, 
England: [35S]L- methionine >800 Ci/mmol, [14C] labelled 
molecular weight markers, rainbow marker 3KD-46KD or 14KD- 
200KD range, with or without [14C] label.
Applied Biosystems Inc.,Foster City, California,
U.S.A.: trifluoroacetic acid, acetonitrile.
BDH Chemicals Ltd, England: acetone, ammonium
bicarbonate, ammonium sulphate, bromophenol blue, disodium 
ethylenediamine tetraacetate (EDTA), disodium hydrogen 
phosphate(Na^HPO^), hydrogen peroxide, glycine, 2-
mercaptoethanol, potassium chloride (KC1), sodium chloride 
(NaCl), sodium deoxycholate, sodium dodecyl sulphate (SDS), 
sodium dihydrogen phosphate (NaH^PO^), sodium hydroxide 
(NaOH), trichloracetic acid
tris(hydroxymethyl)aminomethane (tris)
Biorad Laboratories, Richmond, California, USA.:
acrylamide, ammonium persulphate, Coomassie brillant blue 
R-250, horseradish peroxidase (HRP) color development 
reagent (4-chloro-l-naphtol), N ,N-methylene diacrylamide 
(BIS), protein assay kit (Bradford method), N,N,N*,N*- 
tetramethylenediamine (TEMED)
Boehringer Mannheim, Lewes, East Sussex, U.K.: aldolase 
A (rabbit).
James Burroughs Ltd., London, England: ethanol.
Koch-Light Laboratories, Haverhill, Suffolk, England:
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acrylamide.
May and Baker Ltd., Dagenham Essex. England: acetic 
acid (glacial), glycerol, hydrochloric acid, methanol.
Pharmacia LKB, Uppsala, Sweden: Pharmalyte pH range 
3,5-9,5.
Sigma Chemical Company Ltd., Poole, Dorset, England: 2- 
aminoethanol, aminopterin, benzamidine, chymotrypsin,
glutathione, hypoxanthine, N-chlorosuccinimide,
phenanthroline, phenylmethylsulphonyl fluoride (PMSF), 
thioglycolic acid, thymidine, triton X-100, Staph, aureus 
V8 protease.
2.1.6. STANDARD BUFFER SOLUTIONS
2.1.6.1. GENERAL USE.
Phosphate buffered saline (PBS): 0.17M Nacl, 3.4mM K C 1 , 
ImM Na2 HPCU , 2mM KH2 PO4 , pH 7.2
2.1.6.2. CELL LYSIS.
WF buffer: tris acetate pH 7.5 20mM, NaCl 20mM, EDTA
O.lmM, 2-mercaptoethanol 15mM.
2.1.6.3. DOT BLOTS AND WESTERN BLOTS.
Tris buffered saline(TBuS): 20mM tris, 500mM NaCl,
adjust to pH. 7.5 with H C 1 .
TTBuS: Tris buffered saline with 0,1% Tween 20.
Blocking buffer: Tris buffered saline with 1% gelatin 
for the dot blots experiment or 3% gelatin for the Western 
blots experiments.
Antibody dilution buffer: TTBuS + 1% gelatin and 0.1%
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N a a z i d e .
Electrophoretic transfer of polypeptides to "Problott" 
or nitrocellulose: CAPS 10 mM is prepared as a 10 times 
solution, the pH. is adjusted to 11 with 2M NaOH and used 
with 10% methanol.
2.1.6.4 IMMUNOPRECIPITATION ASSAYS.
RIPA: 0.1%(w/v) SDS, l%(w/v) sodium deoxycholate,
l%(v/v) triton X-100, 150mM NaCl, 1OmM tris-Cl pH7.4.
Tris-saline (T S ): 140mM NaCl, 30mM KCl, 280mM Na2HP04, 
lmg/ml glucose, 25mM tris-Cl pH7.4.
2.1.6.5. PEPTIDE MAPPING.
Rehydratation buffer: 0.1% (w/v) SDS, ImM EDTA, 0.125M 
tris-HCl pH 6.8 or pH. 8.
Enzyme and fill-in buffer have the same composition as 
the rehydratation buffer but contain 10% and 20% glycerol 
respectively.
2.1.6.6. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS ( SDS- 
PAGE ) .
Electrophoresis tank buffer: 0.1% (w/v) SDS, 53mM
glycine, 53mM tris.
Stacking gel buffer: 0.1%(w/v) SDS, 0.125M tris-Cl pH
6.7
Separating gel buffer: 0.1%(w/v) SDS, 0,375M tris-Cl pH
8.9
Electrophoresis sample buffer: 2%(w/v) SDS, 10% (v/v)
glycerol, 700mM 2-mercaptoethanol, 50mM tris-Cl pH 6.7, 
0.001% (w/v) bromophenol blue.
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2.1.7, IMMUNOLOGICAL REAGENTS.
Formalin fixed Staph, aureus type A cells (Pansorbin*) 
was purchased from Calbiochem, La Jolla, California, USA.
Rabbit anti-goat and sheep anti-mouse IgG, linked to 
horseradish peroxidase from Sigma Chemical Company ltd, 
Poole, Dorset, England.
Sheep anti-mouse gamma-globulin from Scottish Antibody 
Production Unit (SAPU) Law Hospital, Carluke, Scotland.
2.1.8. MISCELLANEOUS MATERIALS.
1.5 ml reaction vials and pipette tips: Starsted Ltd., 
Leicester, England.
Falcon plastic centrifuge tubes, 15ml and 50ml; Falcon 
rotating plastic 850 cm2 culture bottles: Becton Dickinson 
Labware, New Jersey, USA.
Plastic tissue culture flasks, 96 and 24 wells 
microtiter plates: Nunclon Ltd., Roskilde, Denmark.
Plastic petri dishes, 50mm, 90mm, 140mm: Sterilin Ltd., 
Feltham, Middlesex , England.
PD-10 columns containing Sephadex G-25 M: Pharmacia 
Fine Chemicals, Uppsala, Sweden.
Centricon microconcentrating tubes: Amicon Corp.,
Danvers Massachusetts, USA.
Problott transfer membranes: Applied Biosystems Inc.:
Foster City, California, USA.
Ecoscint scintillation fluid: National Diagnostics,
Manville, New Jersey, USA.
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EN3HANCE: New England Nuclear, Boston, Massachusetts,
USA.
XS1 autoradiographic film: Kodak Ltd., London, England.
RPN 213 mouse antibody screening kit. (Single vacuum 
manifold, membrane bottomed plates), Enhanced
chemiluminescence Western blotting detection reagents: 
Amersham International, Amersham, England.
Nitrocellulose and micro sample filtration manifold 
(slot blott apparatus): Schleicher & Schuell, Dassel,
Germany.
2.1.9. SEPARATION SYSTEMS.
Mini-Protean II electrophoresis cell (Mini-gel Kit) and 
Mini Trans-Blot Cell: Biorad Laboratories, Richmond,
California, USA.
FPLC system, Mono Q HR 5/5 prepacked column (1ml anion 
exchange Mono Q column), Mono P HR 5/20 prepacked column 
(chromatofocusing Mono P column), Mono S HR 5/5 prepacked 
column (1ml cation exchange Mono S column) : Pharmacia LKB, 
Uppsala, Sweden.
HPLC system AB 130A, 1mm microbore column filled with 
Brownlee Aquapore RP 300 C8 substituted resin: Applied 
Biosystem Inc., Foster city, California, USA.
Centrifuges Sorvall RT6000B, RC5B and OTD50: DuPont 
U.K., Hitchin, Herts, U.K.
Electrophoresis of large gels were carried out using 
"Institute made" kits using glass plates of the following 
size$ 160mm x 190 mm, 220mm x 190mm and 265mm x 165mm. 
Spacers were either 1.5 or 0.75mm thick.
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2.2. METHODS
2.2.1. CELL CULTURES
2 . 2 . 1.1. RAT EMBRYO CELLS
Rat embryos, 16-19 days old, were separated from the 
foetal annexes, eviscerated, minced finely and incubated 
with 150 ml of 0.05% trypsin at 37*C, 30 minutes (min.), 
with gentle stirring. The supernatant was removed, and 5ml 
of foetal calf serum was added. The embryos were incubated 
a second time with trypsin, and the supernatants pooled. 
The cells were centrifuged at 500G for 5 min., and 
resuspended in Dulbecco’s modified Eagle’s medium 
supplemented with 0.1lg of sodium pyruvate supplemented 
with 5% foetal calf serum, 4mM/l glutamin, lOOU/ml of 
penicillin, lOOug/ml of streptomycin, lOU/ml of mycostatin. 
Cells were counted in an haemocytometer, and 1x10® cells 
were seeded in each roller bottle. Cells were incubated at 
37°C, with 5% CO2 , until a confluent monolayer was 
obtained. Cells were passaged by washing the monolayer 
twice with 20ml of Versene, then 10ml of versene and 10ml 
of trypsin. When the cells are detached from the surface of 
the flask, the cells are resuspended in a small volume of 
media, centrifuged at 500G for 5 min., resuspended in fresh 
medium, and seeded as required e.g. 2xl06 cells per 50mm 
plate.
2. 2.1.2. Bn5T CELLS
Bn5T cells were cultured using the same medium and 
passaged using the same procedure as for RE cells. Bn5T 
cells were incubated with 5% CO2 . To obtain the mass of 
cells required by the project, the cells were grown in 850 
cm2 roller bottle. On confluence the monolayer was washed
three times with PBS and the cells scraped into 10ml of
|*\
PBS, and transfered to 50ml Falcon tubes. A protease 
inhibitor mixture containing 300mg benzamidine, 999mg
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phenanthroline and 340mg phenylmethylsulfonyl fluoride in 
10 ml of ethanol was added at a ratio of 1%, and the cells 
were sedimented for 10 minutes at 3,000g at 4'C. Cells were 
stored as dry pellet at -70* C.
2.2.1.3. MYELOMA CELLS
Myeloma cells, were thawn from frozen stocks, and grown 
for at least a week before using for fusion at 37*C and 
with 5% CO2 . The day before the fusion the cells were 
counted and seeded at a density of 4xl07 in a fresh large 
flask, with 100ml of fresh media. The medium used was 
Dulbecco’s modified Eagle’s medium supplemented with 0.11 g 
Na pyruvate/1, 4mM/l glutamine, 10% foetal calf serum, 10% 
horse serum, 100 u/ml of penicillin, lOOug/ml of 
streptomycin and O.lmg/ml gentamycin.
2. 2.1.4. BHK CELLS.
BHK cells were grown in ETC10: Glasgow modified Eagle’s 
medium supplemented wifrh 10% newborn calf serum, 4mM/l 
glutamine, lOOU/ml of penicillin, lOOug/ml of streptomycin, 
10% tryptose phosphate broth and 24uM/ml sodium 
bicarbonate.
BHK cells were incubated at 37*C in an atmosphere 
containing 5% CO2
2.2.2. PRODUCTION OF VIRUS STOCKS.
Stocks of HSV-2 strain HG52 were prepared by infecting 
subconfluent BHK cells in roller bottles at a m.o.i. of
0.003 plaque forming unit (p.f.u.) per cell. Cells were 
incubated in 20 ml ETC10 at 31*C until extensive cytopathic 
effect (c.p.e.) had developed. Infected cells were 
harvested into medium by shaking and were pelleted by 
centrifugation at 1000 r.p.m. in a Sorvall RT6000B 
centrifuge 15 min. at 4*C. Sterility checks were performed 
by streaking virus stocks on blood agar plates. Cell 
associated virus was released by sonicating the cell pellet
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in 5ml of ETC10 and the cell debris pelleted by 
centrifugation at 2000 r.p.m. in a Sorvall RT6000B 
centifuge 10 min. 4*0. The cells debris were sonicated 
again, the supernatants pooled and stored in 1ml aliquots 
at -70 ° C .
2.2.2.1 TITRATION OF VIRUS STOCKS.
Virus was titrated on subconfluent monolayers of BHK 
cells in 50mm petri dishes. Serial ten-fold dilutions of 
virus were made in PBSA containing 5% newborn calf serum. 
Inocula of 0.2ml were added to BHK monolayers from which 
grwth medium had been removed, After adsorption of virus 
for lh. at 37‘C cells were overlaid with ETC10 containing 
1% methylcellulose. One set of plates were incubated at 
37°C for 2 days and another set at 31 “C for 3 days. 
Monolayers were then overlaid with Giemsa stain for 10 
min., the stain wased off with water and virus plates 
counted under a dissecting microscope.
2.2.3. PREPARATION OF ANTISERA.
2.2.3.1. TUMOUR BEARING SERUM (TBS)
Bn5T cells (5xl07 ) were injected into the back of eight 
weeks old anesthetised Hooded Lister rats. Up to three 
months could be required for a tumour to appear. The rats, 
anesthetised with chloroform, were bled by cardiac 
puncture. The serum was stored at -20*C.
2. 2.3.2. MOUSE ANTISERA.
To immunise mice three preparations of the antigen were 
used.
Bn5T cells (2xl07 ) were injected in the mouse 
peritoneal cavity, in 0.5 ml of PBS. 2 mice were injected 
with cells sonicated for 10 seconds, and 2 mice with living 
cells.
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Proteins immunoprecipitated by mouse antisera to Bn5T 
cells were injected in the mouse peritoneum as
immunecomplexes containing mouse antisera, sheep anti-mouse 
serum, and Pansorbin*. The method used for the preparation 
of this complex is described in section 2.2.5.
In all cases the mice were injected three times at one
month intervals. The mice were bled from the eye to test
their immune status. This was kindly performed by Dr Ann
Cross of this Institute (The author is not licensed for 
this I procedure). If the titre of the antibody was
satisfactory, the animal was selected for a spleen cells 
fusion experiment and the animal was boosted 5 to 7 days 
before the fusion by another injection.
2.2.4. IN VIVO RADIOLABELLING.
Bn5T and RE cells were grown to subconfluence, the
culture media was removed and EF-2met medium was added. The 
cells were incubated at 37°C for 4 hours. The medium was 
removed, and EF-2met medium containing 50 uCi/ml of [35S] 
L-methionine was added.
The following volumes of EF-2met medium with 50 uCi/ml 
of [35S] L-methionine were used: 50 mm plates 2ml,
90mmplates 5ml, 140mm plates 12ml and 850 cm2 roller 
bottles 20ml.
After 17 hours incubation at 37*C the cells were washed 
three times with PBS and scraped in the buffer used for the
i.p. experiment. Cells from 140mm, 90mm and 50mm plates 
were harvested with lml, 0.5ml and 0.2ml of buffer 
respectively. Cells to be used for protein purification, 
were harvested in PBS sedimented in 1.5ml tubes and stored 
dry at -70° C.
Cells were lysed by sonication, left on ice 30 
minutes, and and the resulting mixture clarified by 
centrifugation, 15 minutes at 13,000 r.p.m. in a MSE 
Microcentaur microfuge. A protease inhibitor mixture 
containing 300mg benzamidine, 999mg phenanthroline and
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340mg phenylmethylsulfonyl fluoride in 10ml of ethanol was 
added at a ratio of 1% before storing the supernatant at - 
70° C.
2.2.5. SCINTILLATION COUNTING.
An aliquot of lul was spotted on a filter paper disk. 
The protein was precipitated by two washes of three minutes 
in 5% trichloroacetic acid, one wash in acetone, and dried 
under a heat lamp. The filter paper disk was placed into a 
scintillation vial with four millilitres of scintillation 
fluid, and counted for one minutes on an Intertechnique 
scintillation counter.
For a protein profile, 5xl05 counts per minute (c.p.m.) 
were required, the amounts used in i.p. experiment are 
shown in the following section.
2.2.6. IMMUNOPRECIPITATIONS OF THE POLYPEPTIDES.
For a standard i.p. 4xl06 c.p.m were used and to obtain 
bands intense enough for peptide mapping 4xl07 c.p.m. were 
used. The experiments were set up as follow.
Counts
TBS
Mouse
antiserum
hybridoma
culture
supernatant
4xl06 4xl07
10 ul 50 ul
4xl06
10 ul
4x107
20 ul
4x106
50 ul
Sheep anti­
mouse
Pansorbin*
Incubate 1 h. 4*C
5 ul 10 ul 10 ul
Incubate 1 h. 4*C
60ul lOOul 60 ul 100 ul 60 ul
Incubate 1 h. 4 ’C 
Spin 10 min. at 13,000 r.p.m. in a microfuge. 
Wash twice with RIPA buffer.
Wash once with tris saline buffer.
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Add 50ul of sample buffer
Heat 10 minutes at 70*C
Load on SDS-PAGE
The immune complexes which were injected into the mice 
used 2xl07 Bn5T cells, which were incubated 1 h. with 20ul 
of mouse antiserum, 1 hour with lOul of sheep anti-mouse 
serum and and 1 hour with lOOul of pansorbin*. The immune 
complexes were resuspended in 0.5ml PBS and injected intra- 
peritoneally into the mouse.
2.2.7. ELECTROPHORESIS ANALYSIS OF POLYPEPTIDES.
2.2.7.1. SDS POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS- 
PAGE ) .
The Laemmli system was used (Laemmli, 1970). Gel slabs 
of the following concentration were used: 7.5%, 9%, 10%, 15% 
and 16.5%. Acrylamide was cross-linked with N-N*- 
methylenebisacrylamide, 1 part in 40 (w/w). Gels were
polymerized by addition of 0.04% (w/w) of ammonium
persulphate and 0.04% (w/v) of TEMED. Gels were overlaid
with butanol to obtain a flat surface. Butanol was removed 
by washing with deionized water, the stacking gel was poured 
immediately afterwards or the gel was overlaid with 1 X 
stacking gel buffer and stored at 4°C.
The stacking gel which contained 5% acrylamide in 
stacking gel buffer, was crosslinked with 1 part in 40 (w/w) 
N - N ’-diallyl-tartar-diamide and polymerized as above. Wells 
were formed with teflon combs.
Tank buffer was prepared from a 10 X stock.
Samples were disolved in sample buffer, heated 10 
minutes at 70°C before loading.
To minimize heating, gels were run at 4 #C, except gels 
for enzymatic digestions. Large gels were run at fixed 
intensity, the maximal intensity used were according the 
size of the gels:
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160 mm X 190 mm X 1.5 mm : 40 mA.
220 mm X 190 mm X 1.5 mm : 60 mA.
160 mm X 190 mm X 0.75 mm : 30 m A .
Mini-gels were run at fixed voltage : 200 V.
Proteins were fixed by 50% methanol, 7% acetic acid in 
water (v/v)(l h.), the gel were then washed with 5%
methanol, 7% acetic acid in water (1 h . ) and water (1 h . )
and dried. Later the gels were simply dried without fixing. 
Alternatively the gels were fixed (1 h.), soaked in EN3HANCE 
(1 h.), washed 20 min. maximum in several changes of water 
and dried at 8 0 #C under vacuum onto a sheet of 3MM filter 
paper.
Gels were autoradiographed with flashed Kodak X-Omat XS- 
1 films which were exposed at -70°C
2.2.7.2. COOMASSIE BLUE STAINING.
Gels were stained in a solution of 0.1% Coomassie Blue 
R-250 in methanol and acetic acid in water (50/7/43, 
v/v/v), 1 h maximum; destained by several washes in methanol 
and acetic acid in water (5/7/88, v/v/v), at 37#C to speed
up the process.
When proteins were prepared for digestion with Staph. 
aureus V8 protease and sequencing of the fragments, the gels 
were stained with a 0.1% solution of Coomassie Blue R-250 
but the acetic acid and the methanol concentration was 
modified to 1% and 10% respectively, and stained for a 
maximum of 15 min. Gels were destained with the same 
solution minus dye, until the bands were visible. The 40KD 
band is then excised and equilibrated with the rehydratation 
buffer used for peptide mapping for 30 min. before storage 
at -700C .
2.2.7.3. PEPTIDE MAPPING.
Enzymatic cleavage was carried out by the method
published by Cleveland et a l . (1977) and used for Staph.
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aureus V8 protease and chymotrypsin digestions. The 
polypeptides are separated on a first acrylamide gel. The 
gel may be stained with Coomassie blue R-250, but Enhance* 
cannot be used (the resolution of the generated peptides is 
poor). The gel was exposed overnight, and the bands that 
were visible on the film contain enough radio-activity to 
produce detectable peptides. Marks with radio-active dye 
allowed a perfect alignment to cut out the bands. Bands were 
rehydrated in rehydration buffer pH. 6.8 for an analytical 
peptide map or pH. 8 to generate larger peptides for N- 
terminus sequencing, and inserted into the wells of a second 
gel, taking care to avoid trapping any air bubble. The pH 
was raised to 8 because at pH.6.8 the enzyme cleaves at 
aspartate and glutamate residues. At pH 8.1 the specificity 
may be restricted to the glutamate residues (Aitken et a l . 
1988). This modification was used in the department for the 
digestion of the U90. Larger peptides were generated and 
were successfully sequenced (M. Grassie, personal 
communication). The stacker of this gel was 5 - 7cm long 
from the bottom of the well, and the concentration of the 
resolving gel is 15% or 16.5%. Analytical gels were 1.5mm 
thick, to facilitate electroblotting, 0.75mm thick gels were 
used. The gel slice was overlaid with lOul of rehydratiOA/ 
buffer containing 20% glycerol (v/v), and the gel kit was 
filled with tank buffer. The stock solution of enzyme is 
prepared by dilution in rehydratio/v . buffer containing 10% 
glycerol, 20ul of the enzyme solution is added to each well.
The electrophoresis was performed as usual, but at room 
temperature, and the current never exceeding 30 mA. The 
current was turned off for 1 h. when the dye front was 
approximatively at 5mm from the bottom of the stacker gel to 
allow the digestipn of the polypeptide by the enzyme.
Chemical cleavage by N-chlorosuccinimide (NCS) was 
performed as published by Lischwe and Ochs (1982). A 
solution is made the day of the experiment with 10ml of 
acetic acid, 10 g of urea and 10ml of water (AUW). The band 
cut out of the gel was rehydrated for lOmin. in AUW at room 
temperature, the AUW solution was changed once, with
occasional agitation. The gel slice was equilibrated with 
3ml of AUW solution containing N-succinimide (2mg/ml), on a 
rotating wheel, for 20 min. at room temperature. To 
neutralize acidity the gel slice was equilibrated with 10ml 
of trisHCl pH. 8, on a rotating wheel. The gel slice was 
loaded into the well of a 15% gel and overlaid with 20 ul of 
sample buffer and the gel was run as usual without 
interruption.
The gels were fixed, enhanced and exposed for three 
weeks in the first instance.
2.2.8. PROTEIN ASSAY.
The Bio-Rad Protein Assay kit uses the shift of the 
maximum absorbance of Coomassie Brillant Blue G-250 from 465 
nm to 595 nm when protein binding occurs. The usefulness of 
the method was first pointed out by Bradford (1976). The 
stock solution is diluted 1 in 5 with deionized water and 
filtered through Whatman n #l paper. Five millilitres of the 
reagent were dispensed in assay tubes. Standards solutions 
containing 0.14, 0.28, 0.42, 0.56, 0.70 0.98 and 1.4 mg/ml
of proteins were prepared. lOOul of standards, sample buffer 
and unknown are added to 5 ml of reagent. The optical 
density at 595 nm is read after 5 minutes. A standard curve 
is drawn and the unknowns are plotted against the standards.
For the micromethod the reagent is used undiluted. The 
concentration of the protein standards are 1 to 25 ug. 0.8 
ml sample is added to 0.2 ml of concentrated reagent.
2.2.9. CELL FRACTIONATION.
Bn5T cells were fractionated, using a method suggested 
by Dr M. Finbow (Beatson Institute for Cancer Research, 
Glasgow).
After washing 3 times with PBS, cells were scrapped in 
5mM tris-HCl pH 7.4, (One millilitre per 140 mm petri dish).
The cells were broken down in a Dounce| homogeniser , until
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no more than 90% of the cells were lysed as viewed by phase 
contrast microscopy and taking care to keep the nuclei
r.intact. The lysate was centrifuged at 1500G (centifuge 
Sorval RT6000D 3000 r.p.m.), for 5 min. at 4°C to sediment 
the membrane fragments and the nuclei: the supernatant is
referred to as the cytosolic fraction. The pellet containing 
the membrane fragments and the nuclei were resuspended in
30% sucrose. The membrane fragments and the nuclei were
further separated by centrifugation at 150,000G (centrifuge 
Sorval OTD50, rotor AH650, 35.000 r.p.m.), for 30min, at 4*C 
on a 60% sucrose cushion. The membrane fragments floated on 
top of the 60% sucrose cushion and were collected with a 
syringe. The pellet was termed the nuclear fraction. Both
fraction were washed with 5mM NaHCO^, to remove the sucrose 
and resuspended in RIPA buffer. The cells are thus 
fractionated in cytosolic, membrane and nuclear fractions.
2.2.10. PURIFICATION EXPERIMENTS.
2.2.10.1.CELL LYSIS.
Cells were frozen, thawed and lysed with a Dounce 
homogeniser (40 strokes) in the buffer used by Welsh and 
Feramisco (1987), to purify the heat shock protein 70 
(HSP70): 20mM tris acetate, 20mM NaCl, 0.5 mM EDTA, and 10 
mM mercaptoethanol (WF buffer). Cells were sonicated in a 
sonibath for 5 minutes. The crude extract was centrifuged at
13,000 r.p.m. for 10 min. at 4°C in a MSE Microcentaur 
microfuge for the pilot experiments or at 10,000 r.p.m., 10 
min in a Sorvall SS34 rotor for the preparative experiments. 
The supernatant was used for the ammonium sulphate 
f ractionation.
2.2.10.2. AMMONIUM SULPHATE FRACTIONATION.
Ammonium sulphate was first ground with a pestle and a 
mortar. It was added to the cell lysate with continuous 
stirring at room temperature. After complete solubilisation, 
the solution was left on ice with stirring for at least half
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an hour. Proteins were precipitated by the following 
percentage of saturation: 30%, 50 %, 70 % for the pilot
experiments, 30 %, 60 %, and 80 % for the preparative 
experiments. After each cut the solutions were cleared by 
centrifugation at 13,000 r.p.m. for 10 min. at 4*C in a MSE 
Microcentaur microfuge for the pilot experiments or at
10,000 r.p.m., 10 min in a Sorvall SS34 rotor (10,000G) for 
the preparative experiments. The proteins soluble in a 70% 
saturated solution were desalted by dialysis against several 
washes of lOmM NH4 CO3 . The pellet of the 60-80 % pellet was 
desalted using a PD 10 column equilibrated with 50mM tris 
HC1 buffer.
2.2.10.3. DESALTING AND CONCENTRATION OF PROTEINS.
The following methods were used to desalt and or 
concentrate proteins:
2.2.10.3.1. Dialysis.
The protein solution was loaded in dialysis tubing and 
proteins were dialysed against at least 5 changes of 2.5 
litres of lOmM NH4 CO3 . The proteins were concentrated with 
polyethylene glycol (PEG) 6000 and/or by freeze drying.
2.2.10.3.2. Microdialysis unit.
This system allow desalting of 28 samples which are 
separated from the lOmM NH4 CO3 buffer by a dialysis
membrane. A peristaltic pump was used to pump the buffer 
through the microdialysing unit. Samples were dialysed
against 2.5 litres of NH4 CO3 buffer. This method was used to
analyse the fractions from the FPLC experiments.
2.2.10.3.3. Gel filtration.
A PD10 column contains 10ml of sephadex G25. The column 
is first equilibrated with 15ml of the chosen buffer. The 
volume of the sample was made up to 2.5ml and loaded onto
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the column. The polypeptides were eluted free of salt by 
3.5ml of the chosen buffer.
2.2.10.3.4. Ultrafiltration.
The centricon 30 tube was used for ultrafiltration. This 
tube is closed by an ultrafiltration membrane retaining 
protein having a molecular weight over 30,000 Dalton. The 
sample (up to 2ml) is put in the top chamber and the small 
molecules are forced into the lower chamber by 
centrifugation. The acceleration force used is limited to 
7500G, as obtained by a speed of 7500r.p.m. in a Sorval SS34 
rotor, a 2ml sample was concentrated with this fixed angle 
rotor to a volume of 30ul in 20 minutes. The tube was 
inverted and the concentrated sample was recovered by a 1 
minute centrifugation in a cup. This system allowed 
concentration and desalting at the same time.
2.2.10.3.5. TCA precipitation.
Protein were precipitated by adding trichloroacetic acid 
to a proportion of 5%. Fifty microlitres of sample buffer 
made of two millilitres 1M trisbase, 1.5ml glycerol, 0.5ml of 
10% SDS and 0.5ml of water was added to each sample followed 
by 5ul of IN HC1. The sample were heated as described in 
section 2.2.6.1 before loading on a gel.
2.2.10.4. ANION EXCHANGE CHROMATOGRAPHY AT p H .8.
Dr A. Darling, of this Institute suggested the 
following method to separate the 40KD protein using the Mono 
Q prepacked HR 5/5 column (1ml Mono Q). The polypeptides 
were resuspended in 0.5ml of buffer A (50mM trisHCl pH.8), 
and insoluble material pelleted by centrifugation in a MSE 
Microcentaur microfuge 5 min, 13,000 r.p.m. at room 
temperature, before loading on the Mono Q column. The void 
volume of the column was set at three millilitres, the 
polypeptides were eluted by a 13ml gradient of 50% buffer B 
(buffer A + 1M NaC l ) and the 1ml Mono Q column was washed by
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three milliltres of 100% buffer B. In scaled up experiments 
the void volume was increased to 6ml, but the volume of the 
gradient remained the same.
As in all chromatography experiments described in this 
thesis 1ml fraction were collected which were desalted and 
concentrated with the microdialysis unit or by TCA 
precipitation before loading onto a SDS-PAGE. The column 
flow rate used was 1.5ml/min..
2.2.10.5. CATION EXCHANGE CHROMATOGRAPHY.
The Mono S prepacked HR5/5 column was used (1ml Mono S 
column). The void volume of the anion exchange 
chromatography at pH.8 step was desalted by dialysis and 
concentrated by freeze drying. The proteins were resuspended 
in 500 ul of buffer G (50mM sodium phosphate buffer, Na2HP04 
- NaH2P04 pH 7.2). The protein was loaded on the 1ml Mono S 
column. The void volume was set at 3ml, the proteins were 
then eluted with a 13ml gradient of buffer H (Buffer G + 1M 
Na C l ) . Any remaining proteins were finally eluted by 3ml of 
buffer H.
2.2.10.6. PREPARATIVE ELECTROFOCUSING.
Electrofocusing is a method of separating proteins 
according their pi. The machine Rotofor* is sold for 
preparative electrofocusing. This machine consists of a 
rotating horizontal column divided by several porous nylon 
filters with an electrode at each end.
A 5.5ml sample (polypeptides eluting in the void volume 
of the anion exchange experiment at pH.8), in buffer A, 
together with 1.5ml of ampholines (Amphoteric molecules used 
as buffer), 6ml of glycerol and 45ml of H 2 O was loaded in 
the column. When an electric field is applied to the column, 
a pH. gradient forms, and the proteins migrate toward the 
part of the column whose pH. equals their pi.. The nylon 
diaphrams limit the diffusion of the proteins and define 
chambers which can be harvested separately.
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2.2.10.7 ANION EXCHANGE CHROMATOGRAPHY AT pH.9.5.
The buffer containing the polypeptides from the void
volume of the anion exchange chromatography at pH.8. was
changed to buffer C (20 mM Ethanolamine pH 9.5) using a PD10 
column. The polypeptides were loaded on the 1ml Mono Q
column in 3,5ml buffer C. The void volume was set at 6ml,
the polypeptides were eluted with a 13ml linear gradient of 
50% buffer D (buffer C + 1 M NaCl). The column was then
washed with 3ml of 100% buffer D.
The gradient was linear for the first experiment. To 
obtain a better separation of the polypeptides, step 
gradients of 3ml of 2.5%, 5% and 7.5% of buffer D were
introduced between the void volume and the linear gradient 
of buffer D. After four preliminary experiments the 
gradients were fixed as follow; 0-5ml void volume, 6-9ml 
2.5% buffer B, 10-13ml 5%, 14-17ml 7.5%, 17-32ml linear
gradient of 50% buffer D and 32-35ml 100% buffer D.
2.2.10.8. CHROMATOFOCUSING.
The Mono P HR5/20 prepacked column was used (Mono P 
column). The sample was loaded onto the Mono P column in 7ml 
of 25 mM diethanolamine pH.9 and eluted by a linear pH. 
gradient created between pH. 9 and pH. 7 with 34ml of 
buffer. This buffer consisted of 1ml of Pharmalyte 8-10.5 
and 5.2 ml of "polybuffer 96 H C 1 , pH. 7.0", in 100ml of
water, and was titrated to pH.7 with H C 1 .
2.2.11. PREPARATION FOR SEQUENCING.
2.2.11.1. REVERSE PHASE HIGH PERFORMANCE LIQUID
CHROMATOGRAPHY (RP-HPLC).
The Aquapore RP-300 column which is a silica based 
column, and therefore unstable at a pH. above 8. The
ethanolamine buffer pH. 9.5, was changed to buffer E (0.1% 
TFA in water), and each fraction of the void volume were 
concentrated using a Centricon 30 device. A 50ul loop was
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used, and larger volume were loaded in 50ul aliquots. The 
polypeptides were loaded on the column in buffer E and were 
eluted by a gradient of buffer F (60% acetonitrile in buffer 
E). First a linear gradient of 0 to 100% buffer F in 45 
minutes was used then to improve the separation the gradient 
was modified as follow.
t %B
(in minutes)
0 0
3 0
8 45
45 75
48 100
53 100
55 0
2.2.11.2. STAPH. AUREUS V8 PROTEASE DIGESTION OF THE 
4OKD POLYPEPTIDE TO OBTAIN INTERNAL AA SEQUENCE DATA.
Coomassie blue staining and Staph. aureus V8 protease 
digestion were described in sections 2.2.6.2. and 2.2.6.3..
2.2.11.3. ELECTROBLOTTING.
Proteins separated by SDS-PAGE were electro-eluted onto 
Problott* membrane using lOmM CAPS buffer pH 11 in 10 % 
methanol, according the instruction of the manufacturer Bio- 
Rad: The membrane was soaked for a few seconds in methanol, 
and then transfered into a dish containing the CAPS buffer. 
The transfert was performed at 50 Volts for half an hour 
with a 0.75mm thick gel or one hour for a 1.5mm thick gel, 
using a Bio-Rad mini-gel transfert kit. Rainbow markers are 
used to check the transfer efficiency. For the initial 
experiments, the gels were also stained with Coomassie blue 
to make sure that no protein was remaining in the gel. The 
membrane was then rinsed in distilled water, soaked for a 
few seconds in methanol, stained 1 min. in 0.1 % Coomassie 
blue in 40 % methanol and 1% acetic acid in water. The 
membrane was destained in 50 % methanol in water, the
membrane was extensively washed with distilled water before 
cutting the bands of interest.
8 6
Dr Ailsa Campbell from the Department of Biochemistry 
was also consulted.
2.2.11.4. S-PYRIDYLETHYLATION OF THE PROTEIN.
The method published by Amons, R. (1987) was used. 
Pyridylethylation was performed in a vial with a
constriction. At the bottom of the vial a freshly prepared 
mixture of lOOul of water, lOOul of pyridine, 20ul of 4- 
vinylpyridine and 20ul of tributylphosphine was introduced. 
The sample blotted on Problott, as described in the previous 
section was suspended over the mixture, taking care that the 
membrane did not touch the liquid reagent. Oxygen was 
removed by injecting some helium and the vial was closed. 
The vial was incubated two hours at 60°C. The membrane was 
then washed in the following solvents: n-heptane, n-
heptane/ethyl acaetate (2:1, v/v), ethyl acetate and dried.
2.2.12. METHODS USED IN THE ATTEMPT OF RAISING 
MONOCLONAL ANTIBODIES.
2.2.12.1. FUSION.
Splenocytes from the immunized mice were fused with 
myeloma cells according a protocol devised by Dr A. CROSS of 
this Institute7/ The mice were immunized and boosted by 
intra-peritoneal injection of 4xl07 cells, five to seven 
days before the fusion. Mice were anesthetized, 
exsanguinated and the serum stored.
The spleen was dissected out of the mice and the capsule is 
teased apart with 18 gauge needles in a few millilitres of 
medium (The medium referred to in this section is the medium 
used to grow myeloma cells: Dulbecco’s modified Eagle’s
medium supplemented with 0.11 g Na pyruvate/1, 10% foetal 
calf serum, 10% horse serum, 100 ug/ml of penicillin, 
lOOug/ml of streptomycin and O.lmg/ml gentamycin). The
r
suspension was transfered into a 15ml Falcon tube and left 
to rest for two to three min. so that clumps and others 
debris settle. The supernatant was saved and the cells 
sedimented (500 r.p.m., 10 min). The splenocytes were
resuspended in serum free medium and counted. The myeloma
87
cells were harvested, centrifuged resuspended in serum free 
medium and counted.
The proportion used for the fusion was 10 spleen cells 
for 1 myeloma cell. Cells were mixed in a 50ml Falcon tube, 
and 1 ml of 50 % PEG 1500 in serum free medium was added and 
mixed gently. After 1 min., 1 ml of serum free medium was 
added, then at 1 min. intervals, 2, 4, 8, 16ml of serum free 
medium was added.
The cells were sedimented, and resuspended in medium. 
Hybridoma were selected by adding 1ml of HAT stock solution 
per 100ml of medium. They were diluted to a concentration 
of 3.5xl06 cells per ml. One hundred microlitres were 
dispensed in each well of a 96 well flat bottomed plate.
2.2.12.2. CULTURE OF THE HYBRIDOMA CELLS.
Hybridoma cells were incubated at 3 7 ’C with 4% C 0 2 . 
After 5 to 7 days, the plates were examined for colonies of 
large cells. After 7 to 10 days 0.1ml of medium was added to 
each well, after 14 days the medium was changed, aminopterin 
was removed and medium with HT was provided, after a month 
hypoxanthine and thymidine was removed from the medium. 
Growing colonies were first transfered to 24 wells plates 
and then to small flasks. Supernatant was saved from wells 
in which the colony occupied l/3rd of the well for testing.
2.2.12.3. SCREENING OF THE HYBRIDOMA.
2.2.12.3.1. Immunoprecipitation experiments.
I.p. experiments were set up as described in section 
2.2.5., 4xl06 c.p.m. of Bn5T cell extracts labelled with 
f3 5 S J L-methionine with 50ul of the hybridoma culture 
supernatant.
2.2.12.3.2. Dot blots.
The hybridoma culture supernatants were screened using 
the mouse antibody screening kit RPN 213 (Amersham
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International). This kit provides membrane bottomed plates 
which can be emptied by pulling solutions through membrane 
under vacuum. The protocol derived from the manufacturer 
instructions was the following:
Step 1: Add 50ul of cell extract to the wells in PBS +
0.05% SDS. Incubate for 15 min, and pull through membrame 
under vacuum.
Step 2: Wash membrane once with tris buffered saline 
with 0.05% Tween-20 (TTBuS).
Step 3: Block membrane with 1% gelatin in TBuS, for 10 
minutes. Wash membrane 3 times with TTBuS. Dry off the 
bottom of the membrane bottomed plate.
Step 4: Incubate with mouse antibody or 50 ul of
hybridoma supernatants for 15 minutes. Wash membrane 3 times 
with TTBuS and dry off the bottom of the membrane bottomed 
plate.
Step 5: Incubate with horseradish peroxidase (HRP)
labelled anti-mouse antibody diluted in TTBuS, Wash membrane 
three times with TBuS and dry off the bottom of the 
membrane bottomed plate.
Step 6: Incubate membrane in substrate solution. Wash 
membrane bottomed plate.
Step 7: Interpret results, a dark purple colour develop 
in the positive wells.
The peroxidase labelled anti-mouse antibody used was 
diluted 1/2000 following the instruction of the manufacturer 
and after testing the validity of this dilution against 
negative and positive controls.
The substrate solution was prepared by dissolving 60mg 
of HRP colour reagent (Bio-Rad) in 20ml ice cold (high 
grade) methanol (solution A). Immediately prior to use, add 
60ul of ice cold 30% H2O2 to 100ml of room temperature TBuS 
(solution B). Mix A and B, uses immediately.
The optimal experimental conditions were determined by a 
checker-board titration carried out using the method 
recommended by the manufacturer.
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The growth of four roller bottles (8xl08 cells) was 
used to make the antigen solution. The cells were lysed in 
PBS buffer with 0.05% SDS. This buffer was used because PBS 
had previously been used before to extract the TBS:40 (see 
section 3.4.1), it extracts also the U90 albeit poorly. SDS 
at the concentration of 0.05% was added to improve the 
extraction of the U90, and this concentration does not 
prevent binding of the protein to the blotting membrane 
according the information supplied by the manufacturer 
(Amersham). The capability of this buffer to extract the U90 
and the 40KD was tested by i.p. with both TBS and mouse 
antiserum.
The concentration of the U90 and the 40KD could not be 
measured. Instead, the protein concentration of the antigen 
solution was measured to determine the optimum condition of 
the experiments and to reproduce them. The Bradford method 
of protein determination was used, the result was 2.88 
mg/ml.
Doubling dilutions of the antigen solution were prepared 
from 1/2 to 1/64. One hundred microlitres of the neat 
solution loaded in row A and double dilutions were loaded in 
rows B to G. Row H was used as the negative antigen control 
and PBS + 0.05% SDS was loaded in it.
A mouse antiserum was used as antibody, because no 
positive supernatant was available. Double dilutions of mice 
antiserum were made in tris buffer saline, from 1/4 to 
1/2000, These dilutions were loaded in row 1 to 10. Row 11 
was used as negative antibody control and received tris 
buffer saline.
A 1/2000 dilution of peroxidase labelled anti-mouse 
antibody was prepared and 100 ul were loaded in each well. 
After 15 min. incubation, the antibody was removed and the 
presence of antibodies against Bn5T polypeptides was
revealed by adding 100 ul of substrate solution containing 
4-chloro-l-naphtol.
The results of the experiments are presented in figure
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Figure 2.1a and b. Checker-board titration.
figure 2.1a: plan of the experiment.
Rows 1-10 : antibody dilutions.
11 : PBS + 0.05% SDS.
Rows A-G : antigen dilutions
H : Tris buffered saline.
figure 2.1b: photograph of the microtitreplate, positive 
results are visualized by addition of alpha chloro-4-
naphthol.
FIGURE 2.1a.
1 2 3 4 5 6 7 8 9 10 11 12
1/4 1/8 1/16 1/32 1/64 1/128 1 1 1 1 C
256 512 1024 2048
A  1 
B 1/2
C 1/4 
D  1/8 
E 1/16
F 1/32 
G  1/64 
H  C
FIGURE2.1b.
2 . 1 .
After processing the PVDF membranes, a positive reaction 
was detected in most wells. The row H was the negative 
antigen control, the row 11 was the negative antibody 
control: Both are negative as expected.
In row 10 (1/2000 dilution of the antibody), the result 
is negative irrespective of the concentration of antigen.
In row 9 the reaction is weak in well 9 (1/64 dilution 
of the antigen).
From these results it was decided to use a 1/32 dilution 
for the cells. As far as the antibody was concerned, the 
supernatant of the hybridoma would first be used neat and 
later a dilution would be made to test for positivity.
2.2.13. WESTERN BLOTTING EXPERIMENTS.
Bio-Rad mini gel kits were used for these experiments.
Samples were run on a 9% SDS-polyacrylamide gel. 
Proteins were then transferred to nitrocellulose using CAPS 
buffer pH.11, with 10% methanol, the voltage was set at 50 
Volts for 1 h. 45 min.
The gel was blocked with 3% gelatin in TBuS for two 
hours or overnight at 37°C. The gel was washed 3 times with 
TTBuS.
The mAspAT antibody was diluted 1/1000 in TTBuS with 1% 
gelatin and 0.01% sodium azide. The blot was incubated 1 
hour at 37°C and then washed 10 times with TBuS
The HRP conjugated rabbit anti-goat antibody was diluted 
in TBuS (1/1000) and incubated for 1 hour at RT, after which 
the blot was washed 3 times with TBuS (no Tween was added 
to the washing buffer).
The colour reagent (see section 2.2.11.3.) was then 
added. Once the colour reagent has developed the blot was 
washed in distilled water, and the results recorded.
To increase the sensitivity a enhanced chemiluminescence 
kit marketed by Amersham was used. Horseradish peroxidase 
catalyzes the oxidation of luminol in the presence of
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hydrogen peroxide.
An equal volume of the two detection solutions of the 
kit are mixed. The excess buffer is washed off the blots 
and the blots are transferred to petri dishes. The detection 
reagent is directly added to the blot on the surface 
carrying the protein.
Incubate exactly 1 min. at RT.
Drain off excess detection reagent and wrap blots in 
cling film.
Place the blots protein side up, in the film cassette, 
add an autoradiographic film, and expose for 15 sec..
The autoradiographic film is developed and the exposure 
time can be modified if necessary according the results.
2.2.14. SLOT BLOT EXPERIMENTS.
The micro-sample filtration manifold (Schleicher & 
Schuell) was used for these experiments. Protein samples 
were blotted through slots in a perspex plate onto 
nitrocellulose by aspiration.
The growth of one roller bottle was harvested, lysed as 
described in section 2.2.9.1.. The protein concentration was 
measured by the Bradford method. The protein concentration 
in the HSV-2 infected and uninfected Bn5T extracts were 
equalized. Double dilutions of the extracts were loaded in 
the slots by aspiration. Immunoblotting was carried out as 
for Western blotting (section 2.2.11)
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PART 3
RESULTS.
3.1. BACKGROUND OF THE PROJECT.
The basis from which the proposed tumour specific 
polypeptides were studied is the original experiment of 
Macnab, et a l . (1985). This experiment showed that the sera 
of animals bearing a tumour (TBS) to HSV transformed cells 
(Bn5T) immuno-precipitated (i.p.) a set of polypeptides
from these same Bn5T cells but not from rat embryo 
control cells (RE) . These polypeptides have molecular 
weights of 200,000, (200KD), 90,000 (a doublet: U90 and
L 9 0 ), 40,000 (40KD), and 32,000 (32KD), the 32KD peptide
was later resized as 34KD and was often not i.p. (Hewitt, 
1988). Antisera prepared in rats and in mice to HSV-2 
infected cells i.p. a similar set of polypeptides (Hewitt 
et a l . , 1991 ) .
The monoclonal antibody (M a b ) TG7A was raised by Dr 
N.B. LaThangue against DNA binding proteins from HSV-2 
infected BHK clone C13 cells (Macnab et a l .. 1985; La
Thangue and Latchman, 1988) . The Mab TG7A i.p.
polypeptides from Bn5T cell lysates which comigrate at the 
same MW as those i.p. by TBS, and which give very similar 
peptide maps (Macnab et a l .. 1985; Hewitt et a l .. 1991).
However, the Mab TG7A i.p. a 35KD polypeptide instead of 
the 34KD polypeptide i.p. by TBS (Hewitt, 1988). Moreover 
the Mab TG7A did not immunoprecipitate the polypeptides 
from RE control cells, but, similar to TBS, only from 
transformed cells (Macnab et a l .. 1985; Hewitt et a l ..
1991). These transformation specific polypeptides could 
also be i.p. from rat or mouse cells transformed by Rous 
sarcoma virus or adenovirus 12 as well as from immortalized 
rat cells, and are therefore clearly cell encoded and not 
HSV encoded. (Macnab et a l .. 1985).
These findings suggested that certain cellular 
polypeptides induced by HSV-2 infection were related to 
polypeptides expressed at raised levels in cells
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transformed by HSV-2 or by other viruses or carcinogens, 
and thus may play a role in the induction of transformation 
by HSV-2 (Macnab et a l .. 1985).
3.2. PRELIMINARY EXPERIMENTS.
3.2.1. IMMUNOPRECIPITATION EXPERIMENTS.
To verify the original findings of Macnab et al.. 
1985, i.p. and peptide mapping studies were carried out. 
Bn5T cell lysates in RIPA buffer were i.p. by TBS (figure 
3.1). Two 90KD polypeptides (U90 and L 9 0 ) were consistently 
i.p., but TBS did not always i.p. the 40KD polypeptide 
which is the subject of this thesis. At the beginning of 
the study, sixty six percent (16/24) of the TBS tested by 
the author were found to be positive. The 40KD polypeptide 
i.p. by TBS from Bn5T cells extracted in RIPA buffer will 
be referred to as TBS:40 in this thesis.
This ability to precipitate the 40KD polypeptide was 
tested in a standard i.p. experiment. Bn5T cells in vivo 
labelled with [35S] L-methionine were lysed by sonication 
in a sonibath, in RIPA buffer. The protease inhibitor 
mixture (300mg benzamidine, 999mg phenanthroline and 340mg 
phenylmethylsulfonyl fluoride in 10ml ethanol) was added at 
a concentration of 1% to all preparations.
The radio-activity of a one microlitre aliquot was 
counted. A volume of lysate containing 4xl06 counts per 
minute (c.p.m.). was incubated for 1 hour with 10 ul of TBS
at 4 0C then 60 ul of a suspension of Staph, aureus protein
A containing cells (Pansorbin*) was added for another hour 
at 4°C.
The samples were analysed on SDS-PAGE. Only SDS-PAGE
and the buffer system described by Laemmli (1970) were used
in this thesis.
An example of the ability of TBS to i.p. the 40KD.
polypeptide is given in figure 3.1. In this figure three 
different TBS were used to immunoprecipitate Bn5T cell 
extracts. All three TBS precipitate a 200 KD polypeptide 
and the 90 KD polypeptide doublet (U90 and L 9 0 ) but the 40
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Figure 3.1 : Immunoprecipitation experiments with TBS.
Autoradiograph of a 7.5%^polyacrylamide gel which shows 
i.p. experiments performed on [35S] L-methionine labelled 
polypeptides extracted in RIPA buffer from RE control and 
Bn5T tumour cells with the antiserum TBS. Although these 
samples were all run on the same gel only the relevant tracks 
were cut from the autoradiograph for photography.
These experiments detect a set of tumour specific 
polypeptides and show that the affinity of TBS for the 40KD 
protein is variable.
Track 1 shows the MW markers.
Track 2 shows the Bn5T cell polypeptides profile 
(labelled Bn5T ) .
Tracks 3-5 show the RE control cells polypeptides i.p. by 
3 different TBS (labelled RE ip).
Tracks 6-8 show the Bn5T cell polypeptides i.p. by the 
same three different TBS (labelled Bn5T ip).
Track 9 shows the RE cell polypeptides profile (labelled
RE) .
The U90 and L90 are indicated by arrows.
The position of the TBS:40 is indicated by triangles.
The MW of the markers is at the left of the gel
The U90 and L90 are i.p. by the three TBS in the Bn5T 
extract, but the TBS:40 is i.p. strongly in track 7 faintly 
in track 8 and not at all in track 6.
Two different TBS i.p. a 56 KD protein. This proteins 
was not further studied due to lack of resources.
RE
U&O
L90
|T8s40
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KD polypeptide was precipitated very well by only one 
antiserum, faintly by a second and not at all by a third.
3.2.2. STAPH. AUREUS V8 PROTEASE DIGESTION.
The immunoprecipitated polypeptides were further 
characterized by enzymatic digestion. The enzyme used was 
Staph, aureus V8 protease because the results obtained 
could be compared to previously published work (Macnab et 
al . , 1985; Hewitt, 1988; Hewitt et a l . ,1991 ) and was a well 
characterized proteolytic enzyme for peptide analysis in 
the laboratory where this work was carried out.
The ability to detect peptide bands after overnignt 
exposure was essential. So the i.p. experiment was expanded 
(4xl07 c.p.m. ) to obtain a polypeptide band on an 
unenhanced gel. The bands were excised from the gel and 
digested by the method of Cleveland et a l ., (1977)
previously described by Macnab et a l ♦, (1985) and Hewitt et
al . , (1991 ) . The amount of Staph. aureus V8 protease used 
was always 5 ug unless otherwise stated, as it was 
previously shown that this gives reproducible identifiable 
results after digestion (Macnab et a l ., 1985; Hewitt et
a l .,1991; J.C.M. Macnab, personal communication). The 
products of the digestion were analyzed on a 15% SDS-PAGE. 
The gel was enhanced, dried and exposed for three weeks in 
first instance, and then for longer periods of time.
The figure 3.2 shows the result of digestion of the 
TBS:40 by Staph. aureus V8 protease compared with the 
digests of the U90 and L90. The peptide map of the TBS:40 
was quite dissimilar to that of the 90KD polypeptides 
showing that they were most likely different proteins 
although they might share an epitope in common. This 
epitope similarity could account for their i.p. by the Mab 
TG7A.
The TBS:40 peptide map is characterized by two groups
of peptides one group greater that 14KD and composed of 4
bands and a second group of bands of about 4-8 K D . Between
those groups a faint band can be distinguished. This 
Upc.lX 0^ 9 C*~ Coi^U^C,
experiment^was repeated 37 times. The relative intensity of
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Figure 3.2.Staph, aureus V8 digests of the U90, the L90 and 
the 40KD proteins.
The U90, L90 and 40KD f3 5 S ] L-methionine labelled
polypeptides i.p. by TBS (figure 3.1) were digested by 5ug 
of Staph, aureus V8 protease. The result was analysed on a 
15% polyacrylamide gel and visualized by autoradiography. 
Although these samples were all run on the same gel only the 
relevant tracks were cut from the autoradiograph for 
photography.
Track 1 shows the MW markers.
Track 2 shows the digest of the U90
Track 3 shows the digest of the L90.
Track 4 shows the digest of the 40.
The MW of the markers is at the left of the gel
This experiment shows that the three proteins all have 
different peptide maps.
U90 L 9 0  4 0
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radio-label of the two groups of bands can vary 
considerably and the faint band described here can be much 
more apparent, but the general pattern always remains the 
same.
Only TBS was used in this thesis because the original 
ascitic fluid from Mab TG7A used for the i.ps. was 
exhausted by the time I started this project. Dr J.C.M. 
Macnab obtained some more material and the original 
hybridoma from Dr N.B. LaThangue. However, unfortunately Dr 
J.C.M. Macnab was unable to detect antibodies to any of the 
tumour specific polypeptides set in the hybridoma fluid, 
nor was it possible to detect the polypeptides in ascitic 
fluid or after purification of IgG from either the 
hybridoma or the ascitic fluid. These results were 
confirmed by me (data not presented) and we were forced to 
conclude that the hybridoma TG7A had ceased to produce 
antibodies. No further source of hybridoma was located.
3.2.3. METHODS USED FOR IDENTIFICATION OF THE 40 KD 
POLYPEPTIDE.
The subject of the study presented in this thesis was 
the purification and sequencing of the TBS:40. The 
polypeptide of interest during the purification will be 
identified in all the experiments described by a 
combination of the following:
1/ Comparison of the apparent molecular weight of the 
protein in question with the 40KD polypeptide as i.p. by 
TBS from Bn5T cells extracted in RIPA buffer and referred 
to as TBS:40.
2/Immunoprecipitation i.e. recognition of the polypeptide 
in question by TBS.
3/Comparison of the enzymatic digest of the protein in 
question with the digest of the TBS:40.
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For these experiments cells were radioactively labelled 
in vivo with [35S] L-methionine. All the experiments
described in this thesis used radioactively labelled cells 
except the samples prepared for the determination of the 
primary structure of the proteins (amino-acid sequence) and 
the Bn5T cell extract prepared for the dot blot 
experiments.
3.2.4. METHODS USED TO PURIFY THE TBS:40.
The first method was to try to raise monoclonal
antibodies against the tumour specific polypeptides. For 
this, pure antigen was not required. Living cells have been 
used to raise monoclonal antibodies. (Harlow and Lane,
1987). If a monoclonal antibody is produced, an affinity 
column could be constructed for the purification of the 
polypeptide.
Affinity columns can successfully be made with
polyclonal antibodies, but have severe drawbacks. Elution 
conditions are usually harsh. The affinity of the 
antibodies for the protein is variable therefore the 
protein is eluted with different strength of eluent, which 
result in a considerable tailing (Reviewed by Goding,
1986). An affinity column was made with TBS. It was
possible to bind the protein to it, but no method was 
devised which succeeded in eluting the tumour specific 
polypeptide from the column made with TBS (J.C.M. Macnab, 
personal communication).
The second method was to purify the 40KD polypeptide 
using biochemical techniques. Techniques available in the 
Institute included ion exchange chromatography available on 
a computer controlled system allowing fast and reproducible 
chromatographic separations, the Fast Protein Liquid 
Chromatography (FPLC) system (Pharmacia). Ion exchange 
chromatography had also the advantage of preserving the 
native conformation of the proteins and therefore was the
method of choice. Several prepacked columns are available
covering anionic and cationic exchange chromatography as
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well as electrofocusing.
Although infection with both HSV-1 and HSV-2 increases 
the amount of radiolabel in the 40KD protein recognized by 
TBS this result could reflect an increase in stability 
rather than a large increase in absolute quantity of 
protein (J.C.M. Macnab, personal communication). This was 
not known at the commencement of this work. Therefore the 
extra work required in generating virus stocks and in 
infecting Bn5T cells was not considered justified by the 
author for the work presented in this thesis.
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3.3. MONOCLONAL ANTIBODIES.
3.3.1. IMMUNIZATION OF THE MICE.
Female Balb C mice were used. Before immunization a 
test bleed was taken from the eye by Dr A.Cross (the author 
is not licenced for this technique) and lack of antibodies 
to the 40KD and the 90KD doublet was confirmed in i.p. 
experiments (Results not presented). Three methods were 
used to immunize the mice.
3.3.1.1. IMMUNIZATION WITH LIVING CELLS.
Initially no purified 40KD protein was available. Mice 
were immunized by injecting living cells. The cells were 
resuspended in the same buffer used to immunize rats: PBS.
3.3.1.2. IMMUNIZATION WITH SONICATED CELLS.
Fractionation studies had shown that the TBS:40 was a 
cytoplasmic protein, (see section 3.4.1). It was thought 
that limited lysis of the cells might improve the 
immunogenicity of the TBS:40. PBS was suitable for 
extracting the TBS:40 and has been used extensively in cell 
fractionation experiments (See section 3.4.1.). I.p. of the 
TBS:40 from the cytoplasmic fraction of cells extracted in 
PBS is shown in figure 3.3 ,(Section 3.4.1).
3.3.1.3.IMMUNIZATION BY IMMUNE COMPLEXES.
The mice were immunized with proteins i.p. by the moose 
antisera raised against Bn5T cells. Although the 40KD 
protein precipitated by immune mouse antiserum appeared 
different from the TBS:40, there was a strong possibility 
that the TBS:40 composed of more than one precipitated 
polypeptide (See sections 3.4-3.5). Therefore i.ps. might 
have increased the possibility or producing an antibody to 
a component of the TBS:40 and would definitely enhance the
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possibility of producing an immune response to the U90 
(Harlow and Lane, 1987).
Using data from the antibody screening experiment it 
was estimated that the extract from 2xl07 Bn5T cells could 
be i.p. by 20ul of mouse antisera followed by a further 
incubation with 10 ul of sheep anti-mouse serum; the immune 
complexes were trapped with lOOul of Pansorbin*. Four mice 
were immunized with these immune complexes and four other 
mice with sonicated cells. The mouse antisera were tested 
as previously described.
3.3.1.4. THE IMMUNIZATION PROTOCOL
A total of four mice were immunized; two with 2xl07 
Bn5T cells injected as live cells and two with 2xl07 Bn5T 
cells which had been sonicated for 30 seconds in a 
sonibath. The cells, sonicated or live, were injected into 
the peritoneum four times at one month intervals. A week 
after the last injection the mice were bled to test the 
antibody response.
In a separate experiment, the interval between the 
injections was also reduced to two weeks but the antibody 
response was less, and two further injections were 
necessary before a titre similar to the first method was 
reached.
3.3.2. TESTING THE ANTIBODY RESPONSE.
3.3.2.1. IMMUNOPRECIPITATION EXPERIMENTS.
The antibody response of the mouse was tested in i.p. 
experiments by reaction with the Bn5T cell lysate, followed 
by incubation with 5ul of sheep anti-mouse serum. Most 
mouse immunoglobulin classes bind poorly to protein A, and 
a second antibody is included which binds to the mouse IgG 
and binds strongly to protein A.
Figure 3.3 shows the results of these i.p. experiments. 
Mice injected with live cells developed antibodies against
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Figure 3.3. Test of an antiserum from a mouse immunized by 
Bn5T.
Autoradiograph of a 9% SDS polyacrylamide gel which shows
i.p. experiments performed on [35S] L-methionine labelled 
polypeptides extracted in RIPA buffer from RE control and 
Bn5T tumour cells with TBS and one mouse antiserum. Although 
these samples were all run on the same gel only the relevant 
tracks were cut from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows the Bn5T cell polypeptides profile 
(labelled B ).
Track 3 shows Bn5T cells polypeptides i.p. with TBS
(labelled B.TBS).
Track 4 shows the RE cell polypeptides profile (labelled
RE ) .
Track 5 shows RE control cells i.p. with TBS (labelled 
RE.TBS).
Track 6 shows Bn5T cells polypeptides i.p. with mouse
antiserum (labelled B.m).
Track 7 shows RE control cells i.p. with mouse antiserum 
(labelled R E .m ).
Track 8 shows Bn5T cells i.p. with sheep anti-mouse 
antiserum (labelled B.C).
Track 9 shows RE control cells i.p. with sheep anti-mouse 
antiserum (labelled RE.C).
The positions of the 90KD doublet is showed by arrows and 
the 40KD proteins are indicated by triangles.
The MW of the markers is at the left of the gel
A mouse can be immunized against Bn5T cells and its 
antiserum can i.p. a 90KD doublet and a 40KD protein from 
Bn5T cells extract and not from RE cells extract similar to 
those i.p. by TBS.

a few polypeptides expressed in Bn5T cells and not in RE 
cells.
A 90KD doublet (U90 and L 9 0 ) and a 40KD polypeptide are 
prominent, these bands co-migrate with the 90KD doublet and 
the 40KD bands observed in the TBS i.p. track. In addition 
mouse antisera immunoprecipitate three proteins of 120-150 
KD. These bands are fuzzy suggesting they are 
glycoproteins. Four other bands one of MW between 56KD and 
46KD and one each of 42KD, 38KD and 36KD are seen in figure 
3.3.
Only the actin band is i.p. in the RE cell track. One 
control track shows that sheep anti-mouse serum i.p. actin 
and a 56KD band (figure 3.3).
3.3.2.2. STAPH. AUREUS V8 PROTEASE DIGESTION.
The experiment was repeated using 200ul of cell 
extract containing 4xl07 c.p.m. and i.p. to use the 40KD 
and the U90 digest with Staph, aureus V8 protease.
The results are shown in figure 3.4.
The proteolytic digests of the U90 polypeptides 
precipitated by either TBS or mice antisera are 
indistingui shable.
The digests of the 40KD polypeptides precipitated by 
mice antisera (Tracks 3 and 4) and TBS (track 2) are 
different. However, in track 2, fainter bands of higher 
molecular weight shown by arrows, comigrate with bands in 
the TBS:40 digest (track 2); this suggests that mice may 
recognize two proteins, but these proteins have different 
immunogenicity which when run on a gel produce the result 
presented in figure 3.4.
3.3.2.3.TITRATION OF THE MOUSE ANTISERA.
Before starting to fuse the spleen cells with myeloma 
cells the antisera were titrated. Immunoprecipitation was 
used as the mean^of assay, because the difference between 
Bn5T cells and RE control cells was demonstrated by i.p. 
and because i.p. is a means of testing the suitability of an
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Figures 3.4a and b. Comparison of Staph, aureus V8 digests of 
the U90 and the 40KD proteins i.p. by TBS and mice antisera.
The U90 and 40KD [35S] L-methionine labelled polypeptides 
extracted from Bn5T cells and i.p. by TBS and mice antisera 
were digested by 5ug of Staph. aureus V8 protease. The 
results were analysed on a 15% polyacrylamide gel and 
visualized by autoradiography. Although these samples were 
all run on the same gel only the relevant tracks were cut 
from the autoradiograph for photography.
Figure 3.4a.
Track 1 shows the MW markers.
Track 2 shows the digests of the U90 i.p. by a mouse 
antiserum raised against Bn5T cells injected as live cells.
Track 3 shows the control digest of the U90 i.p. by TBS.
Figure 3.4b.
Track 1 shows the MW markers.
Track 2 shows the control digest of a TBS:40,
Track 3 shows the 40KD i.p. by a mouse antiserum raised 
against an immune complex made from Bn5T cells polypeptides 
i.p. by a mouse antiserum.
Track 4 shows the digests of the 40KD i.p. by a mouse 
antiserum against Bn5T cells injected as live cells. Arrows 
show the faint bands co-migrating with the high MW bands of 
the TBS:40 control track (track 2).
The MW of the markers is at the left of the gels
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T A B L E  3.1. S E Q U E N T IA L  I  P.
TITRATION OF T HE M O U S E  ANTISERUM 
F O L L O W E D  B Y  I.P. WITH TBS.
Bn5T cells extract 4.10^ c.p. m. in each tubes 
incubate 1 h with the following volumes of mouse antiserum
20 ul 2 ul 0.2 ul 0.02 ul
add 60 ul of 
pan sorbin* 
incubate 1 h
spin, wash, load 
on gel.
(figure 3.5)
save supernatant
add 60 ul of 
pansorbin* 
incubate 1 h
spin, wash, load 
on gel 
(figure 3.5)
add 60 ul of 
pan sorbin* 
incubate lh
add 60 ul of 
pansorbin* 
incubate 1 h
spin, wash, load spin, wash, load
on gel 
(figure 3.5)
on gel 
(figure 3.5)
save supernatant
add 20 ul of 
TBS
add 20 ul of 
TBS
incubate 1 h incubate 1 h
add 60 ul of 
pansorbin*
add 60 ul of 
pansorbin*
incubate lh incubate 1 h
spin, wash and 
load on gel 
(figure 3.6)
spin, wash and 
load on gel 
(figure 3.6)
In the first tube only the antigens not immunoprecipitated by mice antisera will 
ndappear in the 2 gel (figure 3.6).
antibody for affinity chromatography. Tenfold dilutions of 
antisera were used, with a fixed amount of cell extract 
(4xl06 c .p . m . ).
An experiment used to show the relatedness of the 
proteins recognized by TBS and mouse antisera was carried 
out. It consisted of preadsorbing the protein of interest. 
In this experiment the proteins were first i.p. with a 
mouse antiserum and then the resulting supernatant i.p. 
with TBS. The protocol is described as a flow diagram in 
table 3.1.
The results of the titration experiments are shown in 
figure 3.5.
A mouse antiserum i.p. a 40KD band in tracks 3, 4 and
5, and a U90 band in tracks 3 and 4 . The dilution is
1/100 in track 5, and 1/10 in track 4. The titres were
sufficient to undertake fusion experiments. Titres of 1/5 
or 1/10 are satisfactory accordingtflthe antisera used by 
Harlow and Lane (1987). A band can be seen under the U90 
band in tracks 3 and 4 but it is also present in the 
control track 7, therefore it is unlikely to be the L90.
The result of the second i.p. experiment is shown in 
figure 3.6.
Twenty microlitres of a mouse antiserum 
immunoprecipitated all the U90 polypeptide. The U90 band 
was absent in the analysis of the proteins subsequently 
precipitated from the supernatant by TBS. A 1/1000 dilution 
(0.02 ul of a mouse antiserum) was insufficient to 
precipitate the U90 completely and in this case TBS i.p.
the remainder from the supernatant.
The L90 polypeptide and the 40KD polypeptide bands have 
the same intensity in both i.p. experiments, therefore the 
intensity of the bands is not altered by the dilution of the 
mouse antiserum used in the titration experiment. Twenty 
microlitres of mouse antiserum may not have been sufficient 
to bind to all the 40KD band which can be i.p. by TBS
The proteolytic digestion data showed that the Staph. 
aureus V8 protease digests of the 40KD polypeptide i.p. by 
mouse antisera (mice:40) was different from TBS:40. TBS
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Figure 3.5. Titration of an immune mouse antiserum.
Autoradiograph of a 9% SDS polyacrylamide gel which shows 
i.p. experiments performed on [3 5 S ] L-methionine labelled 
polypeptides extracted in RIPA buffer from Bn5T tumour cells 
with ten fold dilutions of a mouse antiserum. Although these 
samples were all run on the same gel only the relevant tracks 
were cut from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows Bn5T cells polypeptides i.p. with TBS .
Tracks 3-6 show Bn5T cells polypeptides i.p. with 20, 2,
0.2 and 0.02ul of a mouse antiserum to Bn5T cells.
Track 7 is a control track for the second antibody. It 
shows Bn5T cells i.p. with lOul of the sheep antiserum used 
as second antiserum.
The position of the U90 and L90 are indicated at the left
of track 2 by two arrows and the TBS:40 is indicated by a
triangle at the left of track 2. The 90KD polypeptide i.p. by 
the mouse antiserum is indicated by an arrow at the left of 
track 3. The 40KD polypeptide i.p. by the mouse antiserum is 
situated between the two empty triangles.
The MW of the markers is at the left of the gel
A 1/10 dilution of the mouse antiserum i.p. an U90 and a 
1/100 dilution i.p. a 40KD protein

Figure 3.6. Identification of the polypeptides i.p. by mice 
antisera.
Autoradiograph of a 9% SDS polyacrylamide gel which shows 
i.p. experiments with TBS performed on supernatant of i.p. 
experiments with mice antisera (figure 3.5). The
polypeptides extracted in RIPA buffer from Bn5T tumour cells 
were labelled with[35S] L-methionine. Although these samples 
were all run on the same gel only the relevant tracks were 
cut from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows a control Bn5T cells i.p. with TBS
(label1ed c ) .
Track 3 shows Bn5T cells polypeptides i.p. with TBS from 
an extract preadsorbed with 20ul of mouse antiserum (labelled 
20 ) .
Track 4 shows Bn5T cells polypeptides i.p. with TBS from 
an extract preadsorbed with 0.02ul of mouse antiserum
(labelled 0.2) .
The MW of the markers is at the left of the gel
The U90 and L90 are shown by arrows, the TBS:40 by a 
filled triangle, and the 40KD polypeptides by empty 
triangles.
This figure shows that twenty microlitres but not 0.02ul 
of mouse antiserum i.p. the U90. The dilution of mouse
antiserum has no effect on the i.p. of the 40KD by TBS.
.11 'KD
and mouse antisera, therefore, precipitate two different 
40KD polypeptides. The U90 polypeptides digests are, 
however, indistinguishable.
It would be impossible to produce a monoclonal antibody 
to the TBS:40 using spleen cells from these mice. 
Monoclonal antibodies could be raised, however, against 
the U90 polypeptide and a 40KD polypeptide. For the reason 
now to be explained, it was nevertheless decided to proceed 
with the fusions.
The Mab TG7A used in previous studies i.p. both the U90 
and a 40.000 MW protein showing they are either related or 
share an epitope. Thus it was possible that Mabs prepared 
to the 90KD protein could also recognize the 40KD protein. 
The work presented in the sections 3.4-3.6 relates to the 
purification of the 40KD protein which TBS i.ps. from Bn5T 
lysate. This work was carried out at the same time and it
became clear that the TBS:40 was a polypeptide band which
consisted of several different proteins precipitated as a 
complex (see section 3.4.5.3. figure 3.21). Moreover the
proteolytic digestion pattern of one of the 40KD protein
(referred as the "VOID VOLUME 40", see section 3.4.5.3.) 
was similar to the pattern of digestion of the 40KD i.p. 
by mice antisera (figure 3.21 tracks 5, 6 and 7). This
result suggested that the TBS:40 was a composite protein 
produced by several polypeptides one of which was of major 
immunogenic dominance to the mouse. Furthermore 
similarities between U90 and the TBS:40 where investigated 
by experiments to determine the mechanisms of induction of 
both proteins. Originally these proteins were recognized by 
Mab TG7A (generated by N. LaThangue) . Mab TG7A was raised 
against the DNA binding proteins of HSV-2 infected BHK C13 
cells and not Bn5T implying that both proteins could bind 
to DNA. Experiments to determine if alterations in the DNA 
topology could alter the expression of the 40KD and the 
90KD led to the use of ciprofloxacin (Ciproxin*), an 
antibiotic with activity against DNA topoisomerase type II 
(information obtained from the manufacturer: Bayer).
Addition of this drug to the culture medium abolished the
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ability of all the transformation specific polypeptides 
U90, L90 and 40KD to be i.p. by TBS fom Bn5T cells.
3.3.3. EFFECT OF CIPROXIN*.
Bn5T cells were passaged and an equal number of cells 
were seeded in medium with or without Ciproxin*, (lul/ml). 
After 24h incubation the medium was removed and the cells 
labelled with [35S] L-methionine for 17h as described in 
materials and methods, using medium without Ciproxin*. The 
cellular incorporation of radiolabel into cell coded 
proteins was similar as shown in this 3 separate 
experiments (c.p.m./ul) (Table 3.2).
TABLE 3.2. INCORPORATION OF [3 5 S ] L-METHIONINE IN CELLS 
GROWN IN MEDIUM WITH OR WITHOUT CIPROXIN*.
Cells grown in medium
Experiment with Ciproxin without Ciproxin
(c.p.m./ul) (c.p.m./ul)
3 x 1 05 
0.6x105 
2 x 1 05
2 . 5x105 
1 xl 05 
1 . 7 x 105
An aliquot containing 4xl07 c.p.m. was i.p. by 50ul of 
TBS and the immune compl exes t. rapped with lOOul of 
Pansorbin*. The results are shown in figure 3.7. Addition 
of Ciproxin* to the culture medium resulted in a 
considerable reduction in the intensity in the bands i.p. 
by TBS, i.e. TBS:40 and 90KD doublet i.p. by TBS. This 
result shows that inhibition of the DNA topoisomerase type 
II prevents either directly or indirectly the expression of 
the U90 and the TBS:40 as detected by i.p..
3.3.4. FUSION OF THE SPLEEN CELLS.
The method developed by Dr A. Cross in this Institute
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Figure 3.7. Effect of Ciproxin*.
Autoradiograph of a 9% SDS polyacrylamide gel which shows 
i.p. experiments performed on [35S] L-methionine labelled 
polypeptides extracted in RIPA buffer. Bn5T cells were grown 
without or with Ciproxin* lug/ml. Although these samples were 
all run on the same gel only the relevant tracks were cut 
from the autoradiograph for photography.
Track 1 shows the MW markers.
Tracks 2 and 3 show the polypeptide profile of Bn5T cells 
grown without and with Ciproxin*.
Track 4 and 5 show the polypeptides i.p. with TBS from 
Bn5T cells grown without or with ciproxin.
The U90 and the L90 are shown by two arrows, and the 
TBS:40 by an empty triangle.
The MW of the markers is at the left of the gel
TBS 40
was used. The four mice immunized with Bn5T cells 
developed antibodies against the U90, the L90 and the 40KD 
polypeptide, they were all used for fusion experiments and 
were boosted 5 to 7 days before the fusion by an intra- 
peritoneal injection.
The myeloma cells line used was the P3-X67 A g 8 , which 
secretes IgG (Kohler and Milstein, 1975).
On the day of the fusion, a mouse was killed and the 
spleen dissected out of the animal. Myeloma cells and 
spleen cells were counted and mixed in the ratio of 10 
spleen cells to one myeloma cell. The cells were fused 
using 1ml of 50% polyethylene glycol (PEG) 1500. The PEG
was progressively diluted and then removed by
centrifugation (5 min at 500 r.p.m.). The cells were then
resuspended at 3.5xl06 cells/ml in selective HAT medium 
(Stock HAT contains 20ml 10~2M hypoxanthine, 3.2ml 10"2
thymidine and 1.6ml 10~3M aminopterin. 1ml of this stock 
solution was added to every 100ml of complete medium). 
Cells were plated out O.lml/well in 96 well plates.
After the experiments/ cultures were observed each week 
for growing fused cells, but only 15 wells showed growth. 
The supernatants were tested by immunoprecipitation, but 
none was positive. I decided to repeat the experiment, and 
immunized four mice with sonicated cells and four mice with 
the Bn5T cell polypeptides i.p. by mice antisera as 
described in section 3.1.3.
3.3.5. TESTING THE SUPERNATANTS OF THE HYBRIDOMA
FUSIONS.
3. 3.5.1. IMMUNOPRECIPITATION EXPERIMENTS.
Three mice were used for fusion experiments according 
to the protocol described in the previous section. Mice N°1 
and 2 were immunized with sonicated cells, N #3 was 
immunized with immune complexes. The results are shown in 
table 3.3
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TABLE 3.3. RESULTS OF THE I.P. OF BN5T POLYPEPTIDES BY 
THE CULTURE MEDIUM OF HYBRIDOMA.
Mouse Spleen Wells Wells Positive
N° cells filled screened wells
10
1 2 280 37 2
2 2.2 540 19 0
3 2.2 480 236 0
The supernatant of the two positive wells i.p. a 40KD 
protein as shown in figure 3.8. The clones were subcultured 
when well grown into 24 well plates as is the routine 
method of clonal expansion used in this Institute. 
Unfortunately both positive clone ceased to grow at this 
stage.
3.3.5.2. DOT BLOTS.
As an alternative to immunoprecipitat ion, supernatants 
were tested by dot blot analysis. A system marketed by 
Amersham was used. This system consists of a 96 well 
microtitre plate sealed at the bottom by a 
polyvinyldifluoride (PVD F ) membrane. The microtitre plate 
fits a manifold which is linked to a vacuum pump so that 
the contents of all the wells can be sucked out at the same 
time. With this system 96 samples can be tested 
simultaneously.
One hundred microlitres of the antigens were added to
s
the wells and incubated for 15 min. at R T . The membrane was 
blocked with 1% gelatin in tris buffer saline (TbuS ) for 15 
min. and washed three times with TBuS containing 0.05% 
Tween 20. Fifty microlitres of hybridoma supernatants were 
added and incubated 15 min. at R T . The membrane was washed 
three times with TTBuS and incubated with 100 ul of a 1/200 
dilution of horse radish peroxidase labelled anti-mouse
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Figure 3.8. Immunoprecipitation with the culture medium of 
the hybridoma to test for hybridoma clones positive for 
antibodies to the U90, the L90 or the 40KD.
Polypeptides labelled with f 3 5 S 3 L-methionine, extracted 
in RIPA buffer from Bn5T tumour cells were i.p. with the
culture medium of hybridomas to test for clones positive for
antibodies to the U90, the L90 or the 40KD. The polypeptides 
were analysed on a 9% SDS-PAGE and visualized by
autoradiography. Although these samples were all run on the
same gel only the relevant tracks were cut from the
autoradiograph for photography.
Track 1-3 show Bn5T cells i.p. with the culture medium of 
three different hybridoma clones.
Track 4 shows a control Bn5T cells i.p. with TBS.
The position of the U90 is indicated by an arrow and the
TBS:40 by a triangle at the right of track 4.
A 40 KD polypeptide is i.p. by the culture media tested
in track 1 and 2. Their position is indicated by triangles at
the left of the tracks.
The MW of the markers is at the left of the gel.
U 90
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antibody. After washing three times with TBuS, the colour 
developer containing alpha chloro naphthol was prepared and 
50 ul were added to each well. A purple colour developed in 
the positive wells.
A total of 196 supernatants were screened by this 
method, but no positives were found.
3.3.6. THE ATTEMPT TO RAISE MONOCLONAL ANTIBODIES; 
CONCLUSIONS.
Figure 3.4&showed that the Staph. aureus V8 digest of 
the TBS:40 differs from the digest of the mice:40. Figure 
3.7 showed that the i.p. of a 40KD polypeptide by- a mouse 
antiserum does not affect the i.p. of the TBS:40.
Therefore the antibody response of rats to the tumour 
and mice to the injection of Bn5T cells is different. The 
mice were expected to develop antibody to all the proteins 
antigenic for the rats since they are xeno-antigens for the 
mice. Instead the mice failed to react to a 40KD protein of 
identical peptide map to the TBS:40. This could be partly 
explained by the results of the purification experiments; to 
be presented in section 3.4 onwards.
The purification experiments described in the following 
chapters appeared to show that the TBS: 40 consists o f  & 
complex of at least three proteins. However not ell three 
could have been immunogenic in the mouse, a fact vhich may 
explains the difference between the peptide map of the 
TBS:40 and the mouse:40 .
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T A B L E  3.4.
CELL FRACTIONATION.
LYSE 90% OF THE CELLS WITH A 
D O U N C E  HOMOGNEISER. 
Control by phase contrast microscopy.
Spin 1500G, 10 min., 4 *C.
Save pellet. Supernatant.
Cytosolic fraction.
Spin 150,000G 4°C, 30min., 
on a 60% sucrose cushion.
Pellet.
Nuclei.
Supernatant at the 
interface. 
Membrane fragments.
^-The experiment used 4xl07 cells labelled with EF2-met 
and 50uCi/ml of [3 5 S ] L-methionine.
3.4. PURIFICATION PROCEDURES.
3.4.1. THE 40 000 MW POLYPEPTIDE IS A CYTOPLASMIC
POLYPEPTIDE.
The TBS:40 was i.p. from a whole cell extract, however
the exact intracellular location was not known. Knowledge
of the intracellular location of a polypeptide could assist 
in devising a purification procedure.
Bn5T cells were fractionated, using a method suggested
by Dr M. Finbow (Beatson Institute for Cancer Research,
Glasgow), which is described in table 3.4. The cells were 
broken down in a Dounce jhomogeniser > in a hypotonic buffer 
until no more than 90% of the cells were lysed as viewed by 
phase contrast microscopy, taking care to keep the nuclei 
intact. The method then involves centrifugation at 1500G 
(centifuge Sorval RT6000D 3000 r.p.m), for 5 min. at 4*C to 
sediment the membrane fragments and the nuclei: the
supernatant is referred to as the cytosolic fraction. The 
membrane fragments and the nuclei are further separated by 
centrifugation at 150,000G (centrifuge Sorval OTD50, rotor 
AH650, 35.000 r.p.m.), for 30min, at 4*C on a 60% sucrose 
cushion. The membrane fragments float on top of the cushion 
and the nuclei sediment. The cells are thus fractionated 
into cytosolic, membrane and nuclear fractions.
The volume of the cytosolic fraction was 12 ml. The 
membrane fraction was first washed in 1 ml of 5mM NH4CO3 , 
resuspended in RIPA buffer to extract insoluble proteins, 
sonicated, and centrifuged for 10 min. at 13,000 r.p.m. 
(4°C) in an MSE Microcentaur microfuge. The nuclear 
fraction dissolved instantaneously in 1 ml of RIPA buffer. 
All fractions were centrifuged 10 min. at 13,000 r.p.m. 
(4‘C) in an MSE Microcentaur microfuge to pellet insoluble 
material before the i.p. experiment. The radio-activity of 
a one microlitre aliquot of each fraction was measured to 
calculate the total radio-activity of each fraction. The 
total radio-active count of each fraction was as follow: 
cytosolic, 9xl08 ; membrane, 1.4xl07 and nuclear, 3.3xl07 .
An aliquot containing 4xl06 counts of each fraction was
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i.p. with lOul of TBS and the immune-complexes trapped 
with 60ul of Pansorbin.
Figure 3.9 shows the results of these experiments as 
analysed on a 7.5% SDS polyacrylamide gel.
By the method of cell fractionation used in this study, 
there is hardly any 40KD i.p. in the membrane fraction. 
There is a strong 40KD band in the cytoplasm and in the 
nuclear tracks. The result shows that the 40KD protein can 
be purified from the cytoplasmic fraction. The total radio­
active count of the cytoplasmic fraction was 30 times the 
total radio-active count of the nuclear fraction. Although 
the intensity of the band reflects the amount of radio 
activity incorporated and not the total amount, it was 
considered that a large part of the 40KD protein was 
soluble.
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Figure 3.9. Cell fractionation.
Bn5T cells were fractionated into nuclear, cytoplasmic 
and membrane fractions by differential centrifugation. Each 
fraction was i.p. by TBS, The results were analysed on a
7.5% polyacrylamide gel and visualized by autoradiography.
The polypeptides were labelled with[35S] L-methionine.
Although these samples were all run on the same gel only the
relevant tracks were cut from the autoradiograph for
photography.
Track 1 shows the nuclear fraction i.p. with TBS
(labelled p ).
Track 2 shows the cytoplasmic fraction i.p. with TBS
(labelled c ).
Track 3 shows the membrane fraction i.p. with TBS
(labelled m ).
Track 4 shows a control Bn5T cells i.p. with TBS
(labelled i p ).
The position of the 40KD polypeptides is shown by empty 
triangles on the left of the tracks. The position of the U90 
and L90 is shown by two arrows on the right of track 4.
The U90 is i.p. in the nuclear fraction.
A protein with a MW slightly over 40KD is i.p. in the 
cytoplasmic fraction.
The 44KD band labelled "actin" is i.p. in the nuclear 
and cytoplasmic fraction.
U 90 
L 90
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3.4.2.TRIAL OF A BUFFER WITHOUT DETERGENTS.
The previous experiment located the 4'0KD polypeptide to 
the cytoplasmic compartment. It was reasonable to deduce 
that the protein was probably soluble and that the 
detergents present in RIPA buffer were not required for its 
solubilisation. RIPA buffer contains SDS, sodium 
deoxycholate and triton X 100. SDS precludes the use of an 
ion exchange chromatography column.
To use anion exchange chromatography, another buffer 
without SDS had to be found. The 90KD polypeptide 
recognized by the Mab TG7A was reported to be related to 
HSP 90 (La Thangue and Latchmam , 1988). It was assumed
that the TBS: 40 might conceivably be a similar type of 
protein as it was immunologically related to the 90KD 
polypeptide. In addition other HSPs are frequently 
coprecipitated with oncogenes and anti-oncogenes such as 
ras and p53 (Pinhasi-Kimhi, et a l .. 1986).
Therefore buffers used in the extraction of the HSPs 
were tested and the buffer used to successfully purify the 
HSP70 by ion exchange chromatography (Welsh and Feramisco, 
1985) was chosen (20mM tris acetate pH.7,4; 20mM NaCl;
O.lmM EDTA; 15mM beta-mercaptoethanol). It will be referred 
hereafter as the WF buffer. Bn5T cells were extracted with 
this WF buffer. This extract was i.p. by TBS and the result 
compared with a standard i.p in which Bn5T cells were lysed 
in RIPA buffer.
Figure 3.10 compares the results of the i.p. of Bn5T 
cells extracted in WF buffer and in RIPA buffer.
Cells from two 50mm petri dishes seeded with equal 
numbers were radio-labelled with [35S] L-methionine using 
the same conditions. One plate was harvested with WF buffer 
and the other with RIPA buffer. Cells extracted , in WF 
buffer do not contain as high levels of radio-activity as 
similar cells extracted in RIPA buffer (total count per 
50mm dish : WF buffer, 1.6xl06 c.p.m. against 4xl06 c.p.m. 
for RIPA buffer). Total protein from both samples were used 
for an i.p. experiment with TBS. In this experiment only a
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Figure 3.10. Extraction of Bn5T polypeptides in a buffer 
without detergent.
Autoradiograph of a 9% SDS polyacrylamide gel which shows
i.p. experiments performed on f35S] L-methionine labelled 
polypeptides extracted in RIPA buffer (control i.p.) and in 
20mM TrisHCl p H .7.4 (WF) buffer from Bn5T tumour cells. 
Although these samples were all run on the same gel only the 
relevant tracks were cut from the autoradiograph for
photography.
Track 1 shows the MW markers.
Track 2 shows a control Bn5T cells i.p. with TBS.
Track 3 shows Bn5T cells extracted in WF buffer and i.p. 
with TBS.
The MW of the markers is at the left of the gel
The position of the U90 is indicated by arrows and the 
40KD polypeptide by open triangles at the left of the tracks. 
(The TBS used in this experiment does not i.p. the L90).
WF
ripa buffer
90KD and a 40KD polypeptide is i.p. by TBS from Bn5T cells 
extracted in RIPA buffer. A 90KD and a 40KD can also be
i.p. from cells extracted in WF buffer; in addition twelve 
polypeptides were i.p., nine of MW between 90KD and 40KD 
and three of MW inferior to 40KD (fig 3.10). In some 
preparation U90 is well extracted by WF buffer, but 
generally good extraction of the U90 requires the addition 
of detergent. The reason why WF buffer can occasionally 
extract the U90 is not understood.
The WF buffer, which contains no detergent, extracts a 
40KD polypeptide which was i.p. by TBS. To further identify 
the 40KD, the polypeptide band was cut out of the gel and 
digested with Staph. aureus V8 protease together with a 
TBS:40 band extracted by RIPA.
Figure 3.11 shows that by proteolysis the two peptides 
maps were similar therefore the 40KD polypeptide extracted 
in and i.p. from WF buffer was very similar to the TBS:40. 
Bn5T cells were therefore lysed in this WF buffer at the 
start of all further purification experiments.
Figure 3.11. Comparison of the Staph. aureus V8 protease 
digest of the 40KD polypeptides extracted by WF buffer and 
RIPA buffer.
The 40KD [35S] L-methionine labelled polypeptides 
extracted in RIPA and WF buffer and i.p. by TBS (figure 
3.10) were digested with 5ug of Staph, aureus V8 protease. 
The results were analysed on a 15% polyacrylamide gel and 
visualized by autoradiography.
Track 1 shows the MW markers.
Track 2 shows the digest of the control TBS:40.
Track 3 shows the digest of the 40KD polypeptide 
extracted by WF buffer and i.p. by TBS.
The MW of the markers is at the left of the gel
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T A B L E  3.5.
IMMUNOPRECIPITATION OF THE 
A M M O N I U M  SULFATE FRACTIONS.
Extraction pellet 
Resuspend in RIPA, spin,
Resuspend in RIPA,spin
Desalt using a 
Centricon 30 
Resuspend in W F  buffer
Bn5T cell lysate 
in W F  Buffer.
Spin 10,000 r.p.m., lOmin. 
SS34, 4 C.
Add(NH4^ 0 4
Spin as above.
and i.p. with TBS.
30% pellet Add
Spin as above.
and i.p. with TBS.
70% pellet 70% supernatant
Desalt using a 
Centricon 30 
Resuspend in W F  buffer
Spin and i.p. with TBS Spin and i.p. with TBS
3.4.3. Ist PURIFICATION STEP.
AMMONIUM SULPHATE PRECIPITATION.
Precipitation of proteins by a high concentration of 
salt is a well established procedure. This technique is 
therefore applied as a preliminary procedure in protein 
purification. It can be used on a large amount of material, 
the precipitated proteins are extremely stable in (NH4)s C>4 
at 4"C and can be redissolved in a small volume to 
concentrate the protein and this is advantageous for 
stability. Its main drawback is that recovery is limited 
by differential solubility of the protein. The peak of 
recovery of proteins has a leading and a trailing fraction.
In the pilot experiments 2xl09 Bn5T cells (8 roller 
bottles and four 140mm plates labelled with [35S] L- 
methionine ) were lysed in a total volume of 12ml of WF 
buffer. Cells were first disrupted with a Dounce 
homogeniser (40 strokes), and then sonicated in a sonibath 
for at. least 2 min. at 0 “ C .
The lysate was aliquot.ed in 1.5ml tubes and was cleared 
by centrifugation in an MSE Microcentaur microfuge by 
spinning at 13,000 r.p.m. for 10 min. (4"C). The pellet 
hereafter called the extraction pellet, and the supernatant 
were kept.
For the preliminary experiment.,* proteins were 
sequentially precipitated from the supernatant by adding 
NH4S04 to make a 30%, 50% and 70% saturated solution. In
the third experiment which is presented in figure 3.12, 
proteins were precipitated by a 30% saturated solution and 
then (n H4)s 04 was added to make a 70% saturated (n H 4^ S04 
solution. Precipitated proteins were pelleted by 
centrifugation as above, these were the 30% and 70% pellet 
and the supernatant was saved and called the 70% 
supernatant hereafter. The flow chart. of the experiment, is 
shown in table 3.5.
The extraction pellet was resuspended in RIPA buffer 
and sonicated for two minutes to solubilize any membrane 
proteins present.
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An aliquot of the 30% pellet was resuspended in 1ml of 
RIPA buffer and desalted in a Centricon 30 tube. This tube 
is closed by an ultrafiltration membrane retaining protein 
having a molecular weight of over 30,000 Daltons. The 
sample is put in the top chamber and the molecules below 
30KD are forced into the lower chamber by centrifugation. 
The volume of the sample can readily be reduced to 30ul. 
The proteins were desalted twice by adding 1ml of RIPA each 
time, and the final volume was made up to 400 ul. RIPA 
buffer was used because the 30% pellet could contain
aggregated proteins as well as particulate material which 
could be redisolved by the detergents contained in RIPA 
buffer.
The 70% pellet was desalted by the same procedure but 
WF buffer was used instead of RIPA buffer.
The 70% supernatant was desalted by dialysis against 
5mM NH4 C03 and then concentrated by freeze drying. An
aliquot was resuspended in 200 ul of WF buffer.
All samples (resuspended extraction pellet, 30% pellet, 
70% pellet and 70% supernatant) were centrifuged (13,000 
r.p.m., 5 min., 4°C in an MSE microcentaur microfuge) to 
remove insoluble proteins before i.p.. An aliquot of each
sample was saved to run as a control on the gel, and the
remainder was used in the i.p. experiments with 50ul of TBS 
and lOOul of Pansorbin*.
The result of the experiments is shown in figure 3.12.
TBS precipitates a 40KD polypeptide from each fraction. 
To identify which polypeptide was the TBS:40, the bands 
were cut and digested with Staph, aureus V8 protease, and a 
TBS:40 band from an i.p. experiment of Bn5T cell lysate was 
used as a positive control.
A 90KD polypeptide was also present in the extraction 
pellet and in the 30 % pellet when re-extracted with RIPA. 
Digestion with Staph, aureus. V8 protease showed that these 
two polypeptides were similar to the U90 (Data not shown), 
a finding used to aid its purification.
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Figure 3.12. 1st purification step, Ammonium sulphate 
precipitation.
Bn5T cells were lysed in WF buffer, insoluble material 
was pelletted (extraction pellet). The polypeptides of the 
supernatant were precipitated by a 30% and a 70% saturated 
solution of ammonium sulfate, resuspended in RIPA buffer or 
WF buffer, desalted and i.p. with TBS. The results were 
analysed on a 9% polyacrylamide gel and visualized by 
autoradiography. The polypeptides were labelled with [35S] L- 
methionine.
Track 1 shows the MW markers.
Track 2 shows the Bn5T cell polypeptides profile.
Track 3 shows the profile of the extraction pellet which
contains polypeptides insoluble in WF buffer but extracted by
the detergents contained in RIPA buffer.
Track 4 shows the polypeptides of the extraction pellet 
i.p wi th TBS.
Track 5 shows the profile of the polypeptides insoluble 
in a 30% saturated solution of (n H4)s 04 (30% pellet).
Track 6 shows the polypeptides of the 30% pellet i.p.
with TBS.
Track 7 shows the profile of the polypeptides soluble in 
a 30% but insoluble in a 70% saturated solution of^NH^04 
(70% pellet).
Track 8 shows the polypeptides of the 70% pellet i.p.
with TBS.
Track 9 shows the profile of the polypeptides soluble in 
a 70% saturated solution of (n H4)S04 (70% supernatant).
Track 10 shows the polypeptides of the 70% supernatant 
i.p with TBS.
The MW of the markers is at the left of the gel
The position of the U90 is indicated by an arrow and the 
40KD polypeptides is indicated by a triangle.
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Figure 3.13 shows that the peptide maps of the 40KD 
polypeptides i.p. by TBS in the extraction pellet, 30% 
pellet and 70% pellet are significantly different from the 
TBS:40 peptide map. However, there are fainter bands in the 
30% and 70% pellet polypeptides, co-migrating with the 
largest peptides of the TBS:40 and the 70% supernatant 
40KD.
The 40KD polypeptide precipitated by TBS in the 70% 
supernatant and the TBS:40 have similar peptide map 
patterns. The fainter bands observed in digests of the 30% 
and 70% pellets suggest that some of the polypeptide of 
interest may precipitate at a lower ammonium sulphate 
concentration.
These experiments showed that the 70% supernatant 
contains a soluble polypeptide similar to the TBS:40. This 
fraction could then be used for further purification. It 
was realized that the protein i.p. from the pellets could 
be a component of the TBS:40 and that the two proteins 
could interact with each other.
The procedure had to be modified for scaling up the 
purification procedure. When 60 roller bottles were used 
(1.2xl010 cells) the volume of lysate used was 120ml. Fifty 
millilitre polycarbonate tubes were used for 
centrifugation in a Sorval SS34 rotor at 10,000 r.p.m. for 
10 min at 4°C.
The method of desalting had to be changed. In the pilot 
experiments, the samples were desalted by dialysis, which 
resulted in considerable losses in recovery; on one 
occasion only 10% the radio-activity was recovered. In 
addition a lower ammonium sulphate concentration might 
improve the yield of the purified 40KD polypeptide. To 
increase recovery of the 40KD protein, the fractionation 
procedure was modified to 30%, 60% and 80% fractions. The
polypeptide was then recovered in the 80% pellet, from 
which it was desalted on a PD10 column and could be 
immunoprecipitated by TBS. The protein could be preserved 
for three to five days at 4°C in the 80% pellet. In the 
experiments which follow, the 70% supernatant were first
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Figure 3.13. 1st purification step, Staph. aureus V8 
protease digests
The 40KD polypeptides from the NH4 SO4 fraction i.p. by 
TBS were digested by 5ug of Staph. aureus V8 protease. The 
results were analysed on a 15% polyacrylamide gel and
visualized by autoradiography. Although these samples were
all run on the same gel only the relevant tracks were cut
from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 to 5 show the digests of the 40KD polypeptide 
i.p. by TBS from the extraction pellet, the 30% pellet, the 
70% pellet and the 70% supernatant (bands cut from the gel 
shown in figure 3.1JL, tracks 4, 6, 8 and 10).
Track 6 shows the digest of the control TBS:40.
The MW of the markers is at the left of the gel

investigated (figures 3.14 and 3.15). In all further 
experiments the 40KD protein was purified from the 60%-80% 
pellet.
It was verified that the supernatant of the 80% pellet 
contained no 40KD protein. This modification did not result 
in any loss of 40KD protein (Data not shown).
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3.4.4. 2nd PURIFICATION STEP.
3.4.4.1. ION EXCHANGE CHROMATOGRAPHY: Anion exchange
chromatography at p H .8.
Anion exchange chromatography was chosen for the second 
purification step. A prepacked column from the FPLC system 
was used.
The Mono Q prepacked HR 5/5 column was used, hereafter 
referred to as the Mono Q column. This column contains 1ml 
of the Mono Q resin, it is an anion exchange column. The 
capacity of this column is 25mg, and it was used for all 
the experiments. When the sample exceeded the capacity of 
the column, the sample was divided, and two to four runs 
were made.
The charged groups on the matrix of Mono Q are all 
quaternary amines. The ionic charge capacity is totally 
independent of the pH. over the range 2 to 12. The Mono Q 
column separates sample components at a pH. value of 1 pH. 
unit above their isoelectric point (pi.). Negatively 
charged sample components interact with the quaternary 
amines until a rising salt concentration causes the 
component to elute from the column.
Cells from 12 roller bottles and four 140 mm plates 
labelled with [35S] L-methionine were used for the initial 
experiment (2xl09 cells). The 70% supernatant was desalted 
by dyalisis against several washes of lOmM NH4 CO3 and 
concentrated by freeze drying.
Dr A. Darling, a protein chemist working in our 
Institute, supplied the following method of separating 
proteins using the Mono Q column. The polypeptides were 
resuspended in 0.5ml of buffer A (50mM trisHCl p H .8), and 
insoluble material pelleted by centrifugation in an MSE 
Microcentaur centrifuge for 5 min (R T ), at 13,000 r.p.m., 
before loading onto the Mono Q column. The void volume of 
the Mono Q column was set for three millilitres, the 
polypeptides were then eluted by a 13ml gradient of 50% 
buffer B (buffer A + 1M NaCl ) and the Mono Q column was
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finally washed by three millilitres of 100% buffer B.
To avoid overloading the Mono Q column and to set the 
parameters for the detector, the amount of protein applied 
was measured by the Bradford method. The value found was 
1.2 mg, and therefore well within the capacity (25 mg) of 
the column. The amplification was set at 0.1.
For the initial experiments, the fractions obtained
were desalted using a microdyalisis unit (Bethesda Research
Laboratory), against two changes of 10 mM NH4CO3 ,
concentrated by freeze drying before loading on an SDS- 
PAGE. Protein was lost by this method and microdyalisis was 
subsequently replaced by precipitation with 5% 
Trichloroacetic acid (TCA) using a method suggested by Dr 
H.Lankinen of this Institute. In these studies TCA 
precipitation was not found more efficient at protein
recovery but was certainly faster.
In the subsequent experiments the 80% pellet was
desalted by gel filtration using a PD10 column. The PD10 
column was first equilibrated with buffer A. The 80% pellet 
was resuspended in 2.5 ml of buffer A and loaded onto the 
column. The proteins were eluted from the column free of 
(n H4)s 04 , by 3.5 ml of buffer A.
The void volume of the Mono Q column was increased to
6ml to take into account the larger volume (3.5ml) of the
sample loaded onto the Mono Q column, but the volume of the
gradient remained unchanged.
The amount of protein contained in the 80% pellet was 
39 mg. To avoid overloading the column the sample was 
divided into 4 aliquots which were each loaded separately 
on the column.
Figures 3.14a and b show the result of the first 
experiment. The polypeptides were loaded in 0.5ml buffer 
A (50mM trisHCl p H .8). The void volume was three 
millilitres and the polypeptides were eluted by a 13ml 
linear gradient of 50% buffer B (buffer A + 1 M NaCl). The 
column was washed with three millilitres of buffer B.
One millilitre fractions were collected from the 1ml
Mono Q column and the polypeptides analyzed on two separate
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Figures 3.14a and b. 2ndpurification step, anion exchange 
chromatography.(opposite page and next page).
The polypeptides from the 70% supernatant were desalted 
concentrated and loaded in 0.5ml of buffer A (50mM trisHCl 
pH.8) onto the 1ml Mono Q column. The void volume was 3ml, 
and the proteins were eluted with a 13ml gradient of 50% 
buffer B (buffer A + 1M NaC l ). The column was then washed 
with 3 ml buffer B. Each 1ml sample was desalted, 
concentrated and analysed on two 9% polyacrylamide gels. The 
polypeptides which were labelled with [3 5 S ] L-methionine, 
were visualized by autoradiography. The track number is
indicated at the bottom of the gel and the fraction number at 
the top of the gel.
In figure 3.14a
Track 1 shows the MW markers.
Track 2 shows a control Bn5T cells i.p. with TBS,
(labelled ip ) .
Track 13 shows a Bn5T polypeptides profile (labelled B).
Tracks 3-12 show the polypeptides of the 1ml fractions 
eluted from the 1ml Mono Q column numbered 1-10 above the 
gels. They are eluted by:
Fractions 1-3 : Void volume.
Fractions 4-16 : Linear gradient of 50% buffer B.
Fractions 17-19 : 100% buffer B.
The MW of the markers is at the left of the gel
The filled triangle left of track 2 shows the position of
the TBS:40. Another filled triangle on the right of fraction
13 shows the position of 3 40KD band . The position of the 
40KD protein eluting in the void volume is indicated by two 
empty triangles. The position of the 90 doublet is indicated 
by arrows.
AFractions numbers
ip 1 2 3 4 5  6 7 8 9  10 B
200 -  _____
Tracks numbers
In figure 3.14b
Track 14 shows the MW markers.
Track 25 shows a control Bn5T cells i.p. with TBS, 
(labelled i p ).
Track 15 shows a Bn5T polypeptides profile (labelled B).
Tracks 16-24 shows the polypeptides of the 1ml fractions 
eluted from the 1ml Mono Q column numbered 11-19 above the 
gel. They are eluted by:
Fractions 1-3 : Void volume.
Fractions 4-16 : Linear gradient of 50% buffer B.
Fractions 17-19 : 100% buffer B.
The MW of the markers is at the left of the gel
The filled triangle right of track 25 shows the position 
of the TBS:40 band. The position of the 90 doublet is 
indicated by arrows.
200 I
97 %  
69 %
46%
30 t 
KD 
14 15
Fractions numbers
B 11 12 13 14 15 16 17 18 19 ip
16 17 18 19 20 21 22 23 24 25
Tracks numbers
Figure 3.14c, Graph 1.
Graph showing the elution polypeptides from the 1ml Mono 
Q column (anion exchange chromatography at p H .8. Polypeptides 
were loaded in buffer A (50mM trisHCl, p H .8 ) and eluted by a 
gradient of buffer B (buffer A + 1M N a C l ) as follow.
Fractions 1-3 : Void volume (0-3ml).
Fractions 3-16 : Linear gradient of 50% buffer B (3-
16ml ) .
Fractions 17-19 : 100% buffer B (16-19ml).
The line representing the % of buffer B is indicated by 
triangles.
lml fractions.
Flow rate : 1 ml/mn.
Wave length : 260nm
AUFS : 0.1
buffer B
SDS-PAGESrun in parallel, using the same conditions.
There was one polypeptide of 40KD in each of the 19 
fractions collected. Digestion of these 40KD proteins with 
Staph. aureus V8 protease was used to identify the 
polypeptides similar to the TBS:40.
The elution profile is presented in figure 3.14c.
3.4.4.2. DIGESTION WITH STAPH. AUREUS V8 PROTEASE.
Figure 3.15 shows the results of the Staph, aureus V8 
protease digest for all the 40KD bands. A 40KD band from 
each fraction was digested with the exception of fractions 
5 6 and 19 which contained too little radio-activity to be 
able to be analyzed. Polypeptides could be grouped into 
three different patterns of peptide maps according to the 
following fractions: 1-4, 7, 8-18. The slight differences
between the peptides map may be the results of the 
diinerization of proteins (H. Marsden, personal 
communication) .
Unfortunately the positive control TBS:40 did not digest 
correctly. The analysis had therefore to be based on 
controls digested in other gels, which was less accurate 
but essentially feasible.
The peptide map patterns from the fractions 1 to 4, 
i.e. void volume are very similar to those obtained from 
TBS:40. This similarity was verified later. However, the 
polypeptides of these bands migrate with a slightly lower 
molecular weight than the control TBS:40.
The other digests are clearly different from the 
positive control TBS:40 digest.
These experiments showed that the polypeptide eluting 
in the void volume was probably similar to the TBS:40. This 
similarity had to be confirmed by other experiments.
3. 4. 4. 3. CONFIRMATION OF THE SIMILARITY OF TBS:40 WITH 
THE 4OKD ELUTING IN THE VOID VOLUME OF THE ANION EXCHANGE 
COLUMN AT pH.8.
The similarity of the 40KD eluting in the void volume 
and the TBS:40 was further tested by the following
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Figure 3.15. 2nd purification step, Staph, aureus V8 protease 
digests.
The 40KD polypeptides in each fraction eluted from the 
anion exchange chromatography at pH. 8, (shown in figure 
3.14) except fractions 5, 6 and 19 were digested by 5ug of 
Staph, aureus V8 protease. The results were analysed on a 
15% polyacrylamide gel. The polypeptides were labelled with 
[35S] L-methionine and visualized by autoradiography. The 
track number is indicated at the bottom of the gel and the 
fraction number at the top of the gel.
Tracks 1 and 11 show the MW markers.
Tracks 2-9 and 12-19 shows the digest of each 40KD 
polypeptide.
The fraction in which the polypeptide eluted is indicated 
above the gel. Fractions 1-3 are the void volume.
Tracks 10 and 21 show the digest of the control TBS:40 
(labelled i p ).
The MW of the markers is at the left of the gel
Fractions numbers
1 2 3 4 7 8 9 10
2 3  4 5 6 7 8 9
Tracks numbers
Fractions numbers
 1
11 12 13 14 15 16 17 18
12 13 14 15 16 17 18 19 20
Tracks numbers
experiments :
1/ Digestion of the 40KD polypeptides with a variable 
amount of Staph, aureus V8 protease.
2/ Enzymatic digestion with chymotrypsin.
3/ Chemical cleavage with N-chlorosuccinimide.
4/ Immunoprecipitation of the 40KD polypeptides by TBS.
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3.4.4.4. DIGESTION BY AN INCREASING AMOUNT OF STAPH. 
AUREUS V8 PROTEASE.
In the experiments routinely carried out and presented, 
in the thesis, the polypeptides were always digested with 
5ug of Staph. aureus V8 protease. Digestion with lower 
amounts of enzyme will generate less complete digests and 
larger peptides, and this may highlight differences between 
the polypeptides.
Figure 3.16 shows the result of the digestion of four 
TBS:40 and four 40KD polypeptides eluting in the void 
volume of the Mono Q column, using an increasing amount of 
Staph, aureus V8 protease, namely 0.25, 0.5, 1 and 5ug.
When the polypeptide bands digested by the same amount 
of enzyme are compared, all the main bands are the same, 
but the polypeptides immunoprecipitated by TBS produce 
peptides of MW 39,000, 35,000 and 30,000 when digested with 
0.25ug of V8, which have no counter-parts in the 40KD 
purified by FPLC.
All the other bands, used as controls, were digested by 
5ug of Staph, aureus V8 protease.
1/ A 40KD eluting in fraction 8 has a digest clearly 
different from the TBS:40 digest, and therefore this 
polypeptide can be disregarded.
2/ A 40KD band from the 60%-80% pellet was digested for 
comparison with the 40KD purified by FPLC (fig 3.16.). This 
digest is very similar to the digest of the TBS:40, however 
considerable variation can be observed in the Staph, aureus 
digests of the 40KD protein from the flow through, (see 
figure 3.21a tracks 4 and 12).
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Figure 3.16. 2nd purification step, Enzymatic digestion with 
an increasing amount of Staph. aureus V8 protease to 
identify the 40KD protein similar to TBS:40.
The 40KD polypeptides eluting in the void volume of the
anion exchange chromatography experiment at pH.8, and TBS:40 
were digested by 0.25, 0.5, 1 and 5 ug of Staph, aureus V8 
protease. The 40KD polypeptides eluting in fraction 8 of the
anion exchange chromatography experiments and 40KD
polypeptides from a different 70% supernatant was digested 
with 5ug of Staph. aureus V8 protease. The results were 
analysed on a 15% polyacrylamide gel. The polypeptides were 
labelled with [35S] L-methionine and visualized by 
autoradiography.
Track 1 shows the MW markers.
Tracks 2-5 show the digests of the 40KD polypeptides 
eluting in the void volume of the 1ml Mono Q by 0.25, 0.5, 1 
and 5ug of Staph, aureus V8 protease.
Tracks 6-9 show the digests of the TBS:40 by 0.25, 0.5, 1 
and 5ug of Staph, aureus V8 protease.
Track 10 shows the digest of the 40KD polypeptides 
eluting in fraction 8 of the anion exchange chromatography 
experiments.
Track 11 shows the digest of 40KD polypeptides from a70% 
supernatant.
The MW of the markers is at the left of the gel

Aromatic: tryptophane, tyrosine and phenylalanine.
3.4.4.5. DIGESTION BY CHYMOTRYPSIN.
The 40KD polypeptide bands were digested by 
chymotrypsin. Chymotrypsin cleaves the following peptide
Xbonds: X-CO— NH2 -R. X is any amino-acid, R is an aromatic 
amino-acid. This enzyme was used with the same method and 
the same buffer as used for Staph. aureus V8 protease 
digestion. Five microgrammes of enzyme were used in each 
track.
Figure 3.17 shows the results of the experiment.
All the bands found in the FPLC track were also in the 
track of the TBS:40 but the FPLC track had bands with a 
slightly higher molecular weight. The TBS:40 track gives 
more bands than the FPLC:40 almost certainly because it was 
more highly radio-labelled. The lowest band in the i.p. 
track migrates with a lower apparent MW than in the FPLC 
track.By contrast with the i.p. track, no bands can be seen 
in the FPLC track between a 14KD band and the lowest
band. The two peptide maps are nevertheless similar.
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Figure 3.17. 2nd purification step, digestion with 5ug of 
chymotrypsin.
The 40KD polypeptides labelled with [3 5 S ] L-methionine, 
eluting in the void volume of the anion exchange 
chromatography experiment at p H .8, and a TBS:40 were 
digested by 5ug of chymotrypsin. The result was analyzed on a 
15% SDS-PAGE and visualized by autoradiograph. Although these 
samples were all run on the same gel only the relevant tracks 
were cut from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows the digest of the 40KD polypeptides eluting 
in the void volume of the anion exchange chromatography 
experiment at p H .8 (labelled fplc).
Track 3 shows the control digest of a TBS:40 (labelled
i p ) .
The MW of the markers is at the left of the gel
fplc ip
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3.4.4.6. CLEAVAGE BY N-CHLOROSUCCINIMIDE.
The method used was developed by Lisch.WS and Ochs 
(1982).N-chlorosuccinimide cleaves peptide bonds Trp-COO- 
NH2-X, X being any amino-acid. Because tryptophan is a rare 
amino-acid the result enhances similarities.
Figure 3.18 shows the result of digestions with N- 
chlorosuccinimide.
The experiment confirmed the similarity of the TBS:40 
and the 40KD eluting in the void volume of the Mono Q 
column at pH 8. There are only two main bands of 30 and 8 
KD in addition to the 40KD band. The 8KD band is slightly 
higher in the TBS:40 track and may consist of one band as 
opposed to two seen in the FPLC track. Fainter bands of 25, 
16 and 14KD are visible in both tracks. It is of interest 
that the U90 polypeptide did not resemble the FPLC:40 by 
this digestion protocol which shows similarities in protein 
rather than differences (data not shown).
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Figure 3.18. 2nd purification step, cleavage with N-
chlorosuccinimide.
The 40KD polypeptides eluting in the void volume of the
anion exchange chromatography experiment at p H .8, and a
TBS:40 were cleaved with N-chlorosuccinimide. The results 
were analysed on a 15% polyacrylamide gel. The polypeptides 
were labelled with £3 5 S ] L-methionine and visualized by
autoradiography. Although these samples were all run on the 
same gel only the relevant tracks were cut from the 
autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows the cleavage of the 40KD polypeptides 
eluting in the void volume of the anion exchange 
chromatography experiment at p H .8
Track 3 shows the cleavage of the TBS:40.
The MW of the markers is at the left of the gel
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3.4.4.7. IMMUNOPRECIPITATION BY TBS.
Polypeptides from the anion exchange chromatography 
fractions 2 (void volume), 8 and 14 were i.p. by TBS. 
Before freeze drying the three fractions were each divided 
into two tubes, 600 ul were used for i.p. and 400ul were 
analysed on a separate gel, run in parallel, together with 
all the other fractions of the anion exchange 
chromatography experiment at p H .8 (not shown).
Fraction 8 was chosen as a control to further confirm 
that the 40KD band in this fraction was not related to the 
TBS:40, and also because a 34KD band was noticed which 
might be related to the 34KD polypeptide often seen in i.p. 
by TBS from Bn5T cells (Hewitt, 1988).
Fraction 14 was chosen as a second negative control.
Figure 3.19 shows the result of the i.p. experiments.
TBS immunoprecipitated a 40KD polypeptide only in 
fraction 2, which is a fraction of the void volume.
TBS immunoprecipitated a 34KD band in fraction 8, no 
40KD band was immunoprecipitated in either fractions 8 or 
f ract i on 14.
The flow through was therefore considered to contain 
the 40KD protein i.p. by TBS.
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Figure 3.19. 2nd purification step, i.p. by TBS of the 
fractions from the anion exchange chromatography at pH.8.
The fractions 2, 8 and 14 from the anion exchange
chromatography at pH.8 were concentrated, desalted and i.p. 
by TBS. Bn5T tumour cells and RE cell extracts were i.p. by 
TBS as positive and negative controls. The results were 
analysed on a 9% polyacrylamide gel. The polypeptides were 
labelled with [35S] L-methionine and visualized by 
autoradiography. Although these samples were all run on the 
same gel only the relevant tracks were cut from the 
autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows the Bn5T cell polypeptides profile 
(labelled Bn5 T).
Track 3 shows Bn5T cells i.p. with TBS (labelled Bn5T
i p ) .
Tracks 4-6 show the i.p. of fractions 2, 8 and 14
respectively i.p. by TBS.
Track 7 shows RE control cells i.p. with TBS (labelled RE
ip).
Track 8 shows the RE control cell polypeptides profile 
(labelled R E ).
The MW of the markers is at the left of the gel.
The position of the U90 and L90 is shown by arrows. A 
filled triangle shows the position of the TBS:40 and an empty 
triangle the position of the 40KD polypeptide i.p. from 
fraction 2. Two horizontal strokes - indicates the position 
of 34KD polypeptides. (Such proteins have been previously 
i.ped. by TBS from Bn5T cells)
Bn5T Bn5T  
ip
KD 1 2 3 4 5 6 7 8
3.4.4.8. THE 2nd PURIFICATION STEP: CONCLUSIONS
The previously described experiments demonstrated a 
great similarity between the TBS:40 and the 40KD band 
eluting in the void volume (fraction 2) of the Mono Q 
column at p H .8. This band will be called FPLC:40. The 
variable intensity of the peptides generated by Staph. 
aureus V8 protease digestion of the TBS:40 suggested that 
the TBS:40 band was made up of several polypeptides. The 
variation in the intensity of the peptide bands could be 
the result of differences in the relative amounts of these 
40KD polypeptide i.p. by the different TBS samples. To 
confirm this hypothesis the components of the FPLC:40 which 
appears to contain the same polypeptides as the TBS:40 
were further purified.
3.4.5. THE 3rd PURIFICATION STEP.
Four methods were tried to further purify the FPLC:40. 
They are described in the following section.
3.4.5. 1. 3rd PURIFICATION STEP: CATION EXCHANGE
CHROMATOGRAPHY.
The Mono S prepacked HR5/5 (Pharmacia FPLC system)
hereafter referred as the Mono S column contains 1ml of
Mono S beads. Mono S beads share the same matrix as Mono Q
beads but the reactive groups are sulphonyl groups instead
of quaternary amine groups. The sulphonyl groups interact 
Twith poteins having a net positive charge. The Mono S is 
effective in separating sample components with pH. values 
greater than 1 pH. unit below their pi. Attempts were made 
to use the Mono S column to further purify the TBS:40.
The void volume of the anion exchange chromatography 
purification step was desalted by dialysis and concentrated 
by freeze drying. The proteins were resuspended in 500 ul 
of buffer G (50mM sodium phosphate buffer, Na2HP04 
NaH2 PO4 pH 7.2). The protein was loaded onto the 1ml Mono 
S column. The total void volume was 3ml; the proteins were 
then eluted with a 13ml gradient of 50% buffer H (Buffer G 
+ 1M NaCl ) . Any remaining proteins were finally eluted by 
3ml of buffer H.
Most of the polypeptides did not bind to the column 
including the FPLC:40, and no separation was achieved. 
The experiment was repeated twice with the same poor 
results, and finally abandoned- .
Although theoretically it should have been possible to 
lower the pH. of the buffer so that the 40KD would bind to 
the column, this was not done. This decision was made on 
the advice Dr Joe Connor, protein chemist working in this 
Institute who had obtained good separations using the Mono 
Q columnn at higher pH. values. This system will be 
described later (section 3.4.5.3.1).
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3.4.5.2. 3rd PURIFICATION STEP: ELECTROFOCUSING.
Electrofocusing separates proteins according le> their 
isoelectric point (pi.). The aim of this experiment was to 
separate the proteins and obtain an approximation of their 
pi.. The machine Rotofor* (Bio Rad) is sold for preparative 
electrofocusing. This machine consists of a rotating 
horizontal column divided by several porous nylon filters.
The sample (Bn5T polypeptides eluting in the void 
volume of the anion exchange experiment at p H .8), 5.5ml in 
buffer A, 1.5ml of ampholines (Amphoteric molecules used as 
buffer), 6ml of glycerol and 45ml of H 2 0 were loaded in the 
column. When an electric field is applied to the column, a 
pH. gradient forms, and the proteins migrate in the column 
toward the part of the column whose pH. equals their pi.. 
The nylon diaphragm limits the diffusion of the proteins 
and defines chambers which can be harvested separately.
There is no set running time for the experiment, the 
experiment is run at constant power (12 watts) and is 
stopped when the voltage reaches a plateau. In this 
experiment the voltage reached a plateau of 1200 Volts.
The fractions were harvested, the pH. of each fraction 
was measured, a pH. gradient between pH.2 and pH.10 had 
formed. The fractions were desalted by precipitation with 
10 volumes of methanol and loaded onto an SDS-PAGE, with a 
standard TBS i.p. as control. The autoradiograph of the gel 
showed that all the fractions contained the same bands 
including the 40KD band. Therefore the result was merely a 
dilution of the protein.
The experiment was not repeated although the 
experimental conditions could have been adjusted according tb 
the manufacturer’s suggestions. This was not carried out 
because separation at high pH. on a Mono Q column was being 
tested and its result looked promising (see next section).
3.4.5.3. 3rd PURIFICATION STEP: ANION EXCHANGE
CHROMATOGRAPHY AT p H . 9.5.
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3.4.5.3.1. Description and results of the anion
exchange chromatography experiment at pH 9.5.
Anion exchange chromatography was used again, but the 
pH. of the buffer was increased to 9.5 and the ionic 
siength of the buffer was decreased to 20mM to try to
retain the polypeptides on the column.
The buffer A in which the polypeptides of the void 
volume were disolved was changed to buffer C (20 mM 
Ethanolamine pH 9.5) using a PD10 column. The polypeptides 
were loaded on the 1ml Mono Q column in 3,5ml buffer C 
with a total void volume of 6ml, and eluted with a 13ml 
linear gradient of 50% buffer D (buffer C + 1 M NaCl). The
column was then washed with 100% buffer D.
The gradient was linear for the first experiment. (Data 
not shown). Examination of the autoradiograph showed that a 
40KD polypeptide eluted in the void volume and also ahead 
of all the other polypeptides when the salt gradient was 
applied. When the percentage of buffer D reached 15 %, a 
stronger 40KD band, of slightly higher molecular weight, 
was seen which trailed through the remaining fractions. 
Examination of the graph showed that most of the 
polypeptides were eluted by 20% buffer D.
Using these data the gradient was modified to obtain a 
better resolution of the polypeptides. Step gradients using 
3ml of 2.5%, 5% and 7.5% buffer D were introduced between 
the void volume and the linear gradient of buffer D. After 
four preliminary experiments the gradients were fixed as 
follow; 0-5ml void volume, 6-9ml 2.5% buffer D, 10-13ml 5%, 
14-17ml 7.5%, 17-32ml linear gradient of 50% buffer D and 
32-35ml 100% buffer D.
In the experiment presented in figure 3.20a (3rd 
experiment), the void volume is 9ml and the gradient is 
only 6ml with 25% buffer B. The elution profile is 
presented in figure 3.20b.
A 40KD polypeptide eluted in fraction 2 (void volume) 
and from fraction 17 onwards. 40KD bands from this gel were 
cut out and digested with Staph, aureus V8 protease.
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Figure 3.20a. 3rd purification step, anion exchange
chromatography at pH. 9.5.
The polypeptides eluting in the void volume of the anion 
exchange chromatography at pH. 8 were concentrated and the 
buffer was changed to buffer C (20mM Ethanolamine pH 9.5). 
The polypeptides were loaded onto a 1ml Mono Q column in 
3.5ml buffer C (20 mM Ethanolamine pH. 9.5) and eluted by a 
linear gradient of buffer D (Buffer C + 1M NaCl) interupted 
by 3ml steps as follow : Fractions 1-9, void volume; 
fractions 12-14, step of 2.5% buffer D fractions 16-18, step 
of 5% buffer D; fractions 20-22, step of 7.5% buffer D then
fractions 23-28 linear gradient of 25% buffer D . The column
was washed by 4 ml of buffer D. The results were analysed on 
a 9% polyacrylamide gel. The polypeptides were labelled with 
[35SJ L-methionine and visualized by autoradiography.
Track 1 shows the MW markers.
Track 2 shows the fraction 2 (void volume).
Track 3 shows Bn5T cells i.p. with TBS.
Tracks 4-20 show the polypeptides eluted by the gradient 
of buffer D, from fraction 10 onwards. Polypeptides of 40KD 
MW are detected from fraction 15 onwards. The fraction
number is indicated at the top of the gel.
The MW of the markers is at the left of the gel
The position of the 40KD polypeptides is indicated by
empty triangles and the position of the TBS:40 by a filled 
triangle. Two arrows show f ,  the U90 and the L90.
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Figure 3.20b. Graph 2.
Graph showing the elution profile of polypeptides from 
the 1ml Mono Q column (anion exchange chromatography at 
p H .9.5) . Polypeptides were loaded in buffer C (20mM 
ethanolamine pH.9.5) and eluted by a gradient of buffer D 
(buffer C + 1M NaC l ) as follow.
Fractions 1-9 : Void volume (0-9ral).
Fractions 10-11 .’linear gradient of 0% to 2.5% buffer D.
Fractions 12-14 : 2.5% buffer D (ll-14ml).
Fraction 15: linear gradient of 2.5% to 5% buffer D.
Fractions 16-18 : 5% buffer D (15-18ml).
Fraction 19: linear gradient of 5% to 7.5% buffer D.
Fractions 20-22 : 7.5% buffer D (19-22ml).
Fractions 23-28 : linear gradient of 25% buffer D (22- 
28ml).
Fractions 28-32 : 100% buffer D (28-32ml).
The line representing the % of buffer J) is indicated by 
triangles.
lml fractions.
Flow rate : 1.5 ml/mn.
Wave length : 260nm
AUFS : 0.1
100%
buffer 0
*\)£b....0,A 
J \  0. It, i*v fcllEI k c u c d k
28 ml 32 ml11 ml 15 ml 19 ml 22 ml0 ml
3.4.5.3.2. Enzymatic digestion with Staph. aureus V8 
protease.
The results of the anion exchange chromatography 
experiment at p H .9.5 indicated the possible existence of 
two 40KD polypeptides. One polypeptide eluted in the void 
volume at a low salt concentration, and a second 
polypeptide eluted with a salt concentration of 0.15M 
onward. To confirm the existence of two different 
polypeptides the bands were cut out, digested with Staph. 
aureus V8 protease and compared with digests of a TBS:40
Figure 3.21a shows that two polypeptides both eluting 
in the flow through of the anion exchange experiment at 
p H .8 are separated by anion exchange chromatography at pH
9.5.. They are characterized by different peptide maps.
One elutes in the void volume(fraction 2, track 5) and 
is eluted by 5% buffer D (fractions 15 and 17, tracks 6 and 
7). The digest is composed of 3 main bands of molecular 
weight 10, 7 and 5KD.
Another protein elutes from fractions 19 to 23 (tracks 
8, 10 and 11). The peptide map is composed of a group of 3 
bands of molecular weight 14KD and over, and a band of 
about 6KD.
The 40KD protein eluting in the void volume and at low
salt concentration will be referred to hereafter as the
"VOID VOLUME 40" whereas the 40KD protein eluting from the 
column will be referred as the "COLUMN 40".
The peptide maps of the "VOID VOLUME 40" and of the
"COLUMN 40" are both different from the peptide map of the
TBS:40. Four TBS:40 digests are shown in figure 3.21, they 
illustrate the different intensity of the bands discussed 
in section 3.2.1. and allow the comparison with the digests 
of the "VOID VOLUME 40" and "COLUMN 40" digests. This
comparison suggests that each band of both peptide map
could have a homologue in the peptide map of the TBS:40.
The peptide maps of the "VOID VOLUME 40" and the "COLUMN
40" shown in figure 3.21b were superposed and photographed 
but the result was not clear enough to show the homology 
with the peptide map of a TBS:40. The TBS:40 peptide map
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Figures 3.21a and b. 3rd purification step, Staph, aureus V8 
protease digests.(opposite page and next page)
The 40KD polypeptides in fractions eluted from the anion 
exchange chromatography experiment at pH. 9.5 were digested 
by 5ug of Staph. aureus V8 protease. The results were 
analysed on 15% polyacrylamide gels. The polypeptides were 
labelled with [35S] L-methionine and visualized by 
autoradiography.
Figure 3.21a
Track 1 shows the MW markers.
Tracks 2, 3, 9 and 13 show the digests of control TBS:40 
(labelled i p ).
Tracks 4 and 12 show the digests of polypeptides eluted 
from the void volume of the anion exchange experiment at pH. 
8 (FPLC:40, labelled ft).
Tracks 5, 6, 7, 8, 10 and 11 show the digests of the 40KD 
polypeptides eluted from the anion exchange chromatography 
experiments at pH 9.5 in fractions 2, 15, 17, 19, 21 and 23
of the experiment presented in the figures 3.2 0 a and b, as
labelled on top of the gel.
Fraction 2 is one of the fractions of the void volume.
Fraction 15 contains polypeptides eluted by 2.5 to 5%
buffer D.
Fraction 17 contains polypeptides eluted by 5% buffer D.
Fraction 19 contains polypeptides eluted by 5 to 7.5%
buffer D.
Fraction 21 contains polypeptides eluted by 7.5% buffer
D.
Fraction 23 contains polypeptides eluted by over 7.5%
buffer D.
The MW of the markers is at the left of the gel.
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Figure 3.21b
In another experiment the 40KD proteins eluting in the 
void volume and in fraction 20 of an anion exchange 
chromatography experiment at pH. 9.5 were digested by 5ug 
of Staph, aureus V8 protease and compared to the digest of a 
TBS:40, Although these samples were all run on the same gel 
only the relevant tracks were cut from the autoradiograph for 
photography.
Track 1 shows the digest of the 40KD protein eluting in
the void volume (labelled VV 40).
Track 2 shows the digest of the 40KD protein eluting in
fraction 20 (labelled Col. 40).
Track 3 shows the digest of a TBS:40 (labelled TBS:40).
This figure shows that the peptide map pattern of the
TBS:40 could be the result of the combination of the 
patterns of the "VOID VOLUME 40" and the "COLUMN 40".
BVV Col. TBS
40 40 40
!
» n
could nevertheless result from the digestion of a 
combination of the two 40KD proteins which i.p. separately 
or together as a complex with TBS. I.p experiments were set 
up to determine which protein was i.p. by TBS.
3.5.4.3. 3. Immunoprecipitation by TBS of THE "COLUMN 
40" and the "VOID VOLUME 40".
After the experimental conditions of the anion, exchange 
chromatography experiment at pH. 9.5 were definitly set 
up, examination of the Coomassie blue stained gels showed 
that the "VOID VOLUME 40" always eluted in the void 
volume,(but trails in the following fractions). The 
"COLUMN 40" started to elute in fraction 14 (7.5% b uffer D) 
with a maximum in fraction 20.
The early experiments were unfortunately failures, the 
proteins were present in very small amounts and were lost 
on changing the buffer in Centricon tubes to RIPA. I 
decided to i.p. the proteins without changing the buffer 
(Buffer C) or concentrating the sample.
Finally it was verified, in a separate experiment, that 
the 40KD polypeptide was immunoprecipitated by TBS from 
Bn5T cell lysates extracted in buffer C (20 mM Ethanolamine 
pH.9.5). To do this the cells from two 140mm plates were 
labelled with 40ul of [35S] L-methionine. One of the plates 
was harvested in 1ml of RIPA buffer and the other in 1 ml 
of Buffer C. The radio-activity of a lul aliquot of each 
extract was counted. The results were: RIPA buffer, 6xl05 
c.p.m. and buffer C, 4xl05 . I.p. experiments were set up 
with 7.5ul of RIPA extact and llul of buffer C extract and 
5ul of TBS, The immune complexes were captured with 60ul of 
Pansorbin* and analysed as presented in figure 3.22. TBS 
i.p. a 40KD protein in this buffer, however one of the 
proteinSmay not be i.p. in this buffer.
The i.p. experiment was set up using two fractions of 
the anion exchange chromatography at pH. 9.5:
Fraction 2 (void volume) to test the "VOID VOLUME 40".
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Figure 3.22. Immunoprecipitations of Bn5T tumour cells 
polypeptides extracted in RIPA buffer and buffer C (20mM 
ethanolamine pH. 9.5) with TBS.
Autoradiograph of a 9% polyacrylamide gel which shows 
i.p. experiments performed on f35S] L-methionine labelled 
polypeptides extracted in RIPA buffer and in buffer C from 
Bn5T tumour cells with TBS. Although these samples were all 
run on the same gel only the relevant tracks were cut from 
the autoradiograph for photography.
Track 1 shows the MW markers.
Tracks 2 and 3 show the Bn5T cell polypeptides profile
extracted in RIPA buffer and 
Tracks 4 and 5 show the 
in RIPA buffer and buffer C 
TBS.
The position of the 90KD 
triangles and the position 
triangles.
buffer C respectively.
Bn5T cell polypeptides extracted 
respectively, i.p. by the same
doublet is shown by two empty 
of the TBS:40 by two filled
The MW of the markers is at the left of the gel
K D  1 2 3
Fraction 20 to test the "COLUMN 40".
Two positive controls were included:
1/ A Bn5T extract in RIPA for a standard i.p. 
experiment.
2/ A 1ml fraction of the void volume of the anion 
exchange experiment at p H .8., which is the substrate of the 
anion exchange experiment at pH. 9.5.
Fifty microlitres of TBS was added to improve the 
precipitation of the polypeptides because it was estimated 
that the low radio-activity did not reflect the total 
quantity of protein present.
Figure 3.23 shows the result of the experiment. ,
A 40KD is present in both fractions 2 (track 5) and 20 
(track 7), however, the 40KD protein in fraction 2 has a 
slightly lower MW than the protein i.p. from the control 
track.
The i.p. tracks showed:
TBS i.p. a 40KD protein from the two positive controls; 
a Bn5T cell extract (track 2) and a fraction of the void 
volume of the anion exchange experiment at p H . 8 (track 4).
A 40KD protein is i.p. by TBS in fraction 2 but only 
faintly, and at a lower MW than in the protein profile of 
fraction 2.
The "COLUMN 40" in fraction 20 (track 8), is strongly 
i.p. by TBS.
The "VOID VOLUME 40" was identified by AA sequencing 
(see sections 3.5.4. and 3.5.5.) as the mitochondrial 
aspartate aminotransferase and two proteins were identified 
from the "COLUMN 40" 1-6 diphosphate aldolase A and
phosphoglycerate kinase (see section 3.5.8.1.). The 
preparations used for sequencing the "COLUMN 40" were not
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Figure 3.23. 3rd purification step, i.p. by TBS of the 
fractions from the anion exchange chromatography at pH.9.5.
The fractions from the anion exchange chromatography 
experiment at pH. 9.5 2 containing the "VOID VOLUME 40” and 
20 containing the "COLUMN 40" are i.p. by TBS. A fraction 
from the void volume of the anion exchange chromatography
experiment at pH. 8 is i.p. by TBS and a standard i.p. are
used as controls. The results were analysed on a 9% 
polyacrylamide gel. The polypeptides were labelled with [35S] 
L-methionine and visualized by autoradiography. Although 
these samples were all run on the same gel only the relevant 
tracks were cut from the autoradiograph for photography.
Track 1 shows the Bn5T cell polypeptides profile 
(labelled Bn5T).
Track 2 shows Bn5T cells i.p. with TBS (labelled Bn5T 
i.p. ).
Track 3 shows the polypeptides profile of the fraction
from the void volume of the anion exchange chromatography
experiment at pH. 8 (labelled ft). The polypeptides i.p. by 
TBS from this fraction gre shown in track 4 (labelled ft i.p.)
Track 5 shows the polypeptide.\ profile of the fraction 2, 
i.e. void volume of the anion exchange experiment at p H . 9.5 
(labelled 2). The polypeptides i.p. by TBS are shown in track 
6 (labelled 2 i.p.).
Track 7 shows the polypeptides eluting in fraction 20 of 
the anion exchange experiment at pH. 9.5 (labelled 20). The 
polypeptidesi.p . by TBS from fraction 20 are shown in track 8 
(labelled 20 i.p.).
The MW of the markers is at the left of the gel
The position of the TBS:40 is indicated by a filled 
triangle. The position of the 40KD i.p. from the FPLC 
fractions are indicated at the left of track 4 and at the 
right of track 8 by empty triangles. The position of the 90 
KD doublet is indicated by an arrow.
Bn5t ft
Bn5t , p f t i.p. 2 j n 202 ™ 20• p. 2 0  i.p.
■ )0 ;—E /■
actin _
TBS 4 0  ^
>< 4 0  KD
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radiolabelled. It was not possible to say if these proteins 
could be i.p. by TBS.
3. 4. 5. 4. 3rd PURIFICATION STEP: CHROMATOFOCUSING.
Chromatofocusing is an analytical or preparative 
technique for the separation of biomolecules according 
their pi.. The Mono P HR5/20 prepacked column, hereafter
referred as the Mono P column was used, it is part of the
FPLC system.
The Mono P matrix is made of the same monobeads as the 
Mono Q and Mono S but they are substituted with quaternary 
amines and tertiary amines. The quaternary amines are
always charged ensuring sample binding. The tertiary amines 
provide buffering capacity, they are charged or neutral 
depending on the pH..
A molecule has a negative charge above its pi.
Following sample application, the polybuffer is used to
titrate the Mono P and the sample components. Titration of
the Mono P results in the generation of a linear descending 
pH. gradient and titration of the sample molecules results
in focused zones of molecules with different pi. A
polypeptide is eluted from the Mono P column when the pH. 
of the buffer is equal to or lower than its pi.
The polypeptides which elute in the void volume of the 
lml Mono Q at p H .8 would be expected to have a pi above 7. 
A pH. gradient from 9 to 7 was therefore chosen to separate 
them using the Mono P column.
The sample was loaded onto the Mono P column in 7ml of
25 mM diethanolamine p H .9 and eluted by a 34ml linear pH.
gradient created between pH^ 9 and pH. 7. The buffer used 
consists of lml of "Pharmalyte 8-10.5*" and 5.2 ml of 
"polybuffer 96 HC1*M in 100ml of water, and the pH. is 
adjusted to 7.0 with hydrochloric acid,. Polybuffer 
consists of amphoteric buffering substances dissociating at 
different pHs.
Figure 3.24 shows the presence of a 40KD polypeptide 
in fraction 4 (track 3); one of the seven fractions which 
constitute the void volume, the other fractions were saved
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Figures 3.24a and b. 3rd purification step, chromatofocusing.
The polypeptides eluted in the void volume of the anion 
exchange chromatography at pH 8 were loaded onto the Mono P 
column in 25mM diethanolamine p H .9, and eluted by 34ml of a 
buffer consisting of lml pharmalyte 8-10.5 and 5.2ml
polybuffer 96 pH. 7 in 100ml of water, generating a pH. 
gradient from 9 to 7. The results were analysed on two 9% 
polyacrylamide gels. The polypeptides were labelled with 
[3 5 S ] L-methionine and visualized by autoradiography.
Figure 3.24a
Track 1 shows the MW markers.
Track 2 shows a Bn5T polypeptides profile.
Track 3 shows the 40KD polypeptide eluting in 25mM
diethanolamine p H .9. (Only one of the 7 fractions is shown).
Tracks 4-20 show the polypeptides eluted by the pH. 
gradient. 40KD polypeptides are detected from fraction 17
onwards (indicated on top of the gel).
Figure 3.24b (next page)
Track 21 shows the MW markers.
Track 22 shows a Bn5T polypeptides profile.
Tracks 23-35 show the polypeptides eluted by the pH. 
gradient.
Track 36 shows a Bn5T:i.p., the TBS:40 is indicated by an 
empty triangle.
The MW of the markers is at the left of the gel
The position of the 40KD polypeptide eluting in 25 mM
diethanolamine is indicated by a filled triangle, the 40KD 
polypeptides eluted by the pH. gradient are indicated by
arrows. The position of actin is indicated by an empty
triangle.
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bers
A
Fractions 
num
bers
Tracks num
bers
B
for later work. The following tracks show the proteins 
eluted by the pH. gradient. From fraction 17 (track 11) 
onwards a 40KD protein is seen with a maximum at fractions 
21 and 25. Unfortunately the peptides forming the 40KD 
bands could not be digested by Stanh. aureus V8 protease 
because the gel had been enhanced (it was found that after 
enhancement polypeptides did not generate clear proteolytic 
digestion patterns). This result confirms the existence of 
two proteins as shown by anion exchange chromatography at 
pH. 9.5. One elutes with a maximum in fraction 21 and the 
second with a maximum in fraction 25. It is likely that the 
protein which elutes in the void volume is similar to the 
protein eluting in fraction 21. A similar phenomenon is 
observed in the anion exchange chromatography at pH. 9.5. 
where the protein elutes in the void volume but some of it 
is retained by the column and is eluted when the percentage 
of buffer D reached 5% (see figures 3.20a, figure 3.21a for 
the Staph, aureus V8 digests and section 3.5.4.3.2).
3.4.5.5. 3rd PURIFICATION STEP: CONCLUSION.
The polypeptides eluted from the void volume of the lml 
Mono Q column at p H .8 were i.p. by TBS and the digest of
the 40KD protein were indistinguishable from the TBS:40 as
determined by the results of enzymatic and chemical 
digestion (figures 3.15, 16, 17 and 18).
Further purification of the void volume by anion 
exchange chromatography and chromatofocusing experiments 
proved the existence of two polypeptides determined from 
the results of Staph. aureus V8 protease digests. The 
digestion of these polypeptides by Staph. aureus V8 
protease gives peptide maps which individually are
different from the TBS:40 peptide map. Only the "COLUMN 
40" is i.p. by TBS individually but the "VOID VOLUME 40" 
may be complexed to the "COLUMN 40" (protein:protein
interactions) and i.p. with the "COLUMN:40".
It was decided to use anion exchange chromatography at 
pH. 9.5 and not electrofocusing for all further
experiments. Modifications of the conditions used for anion
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T A B L E  3.6.
PURIFICATION QF THE 4QKD PROTEIN S I M M U N Q PRECIPITATED 
B Y  T U M O U R  BEARING SERA (TBS) IN ,Vn5T T U M O U R  CELLS.
Purification step: 
1st Step.
H O M O G E N r IZATON OF Bn5T CELLS. 
Buffer : 20m M  trisCl pH. 7.4, 20 m M  NaCl..
CENTRIFUGE 10.000G, 10 min. 
Retain supernatant.
SALTING O U T  USING A M M O N I U M  SULPHATE. 
Retain 60%-80% fraction .
2nc^ Step. ANION E X C H A N G E  C H R O M A T O G R A P H Y .
1 ml FPLC MonoQ column.
Proteins are loaded in buffer A (50 m M  tris pH. 8) and eluted 
with a linear gradient of 50% buffer B (Buffer A  + 1M NaCl). 
The proteins of interest elute in the flow through.
3rC* Step ANION E X C H A N G E  C H R O M A T O G R A P H Y .
1 ml FPLC monoQ column.
Proteins are loaded in buffer C (20 m M  ethanolamine pH. 9.5) and 
eluted with a step gradient of buffer D  (Buffer C + 1 M  NaCl).
3 ml with 2.5% buffer D.
3 ml with 5% buffer D.
3 ml with 7.5% buffer D.
19 ml of a linear gradient of 50% buffer D.
1 ml fractions are collected.
"VOID V O L U M E  40” 
elutes in the flow-through.
" C O L U M N  40" 
elutes in fraction 20.
exchange chromatography permitted the elution of the 
polypeptides in a reduced number of fractions. These 
modifications were impossible with electrofocusing
because a fixed volume of buffer is required to produce the 
pH.gradient.
The purification method used in all further experiments 
is summarized in a flow chart, table 3.6.
Using anion exchange chromatography, the polypeptide 
eluting in the void volume and at low salt will be called 
"VOID VOLUME 40". The polypeptide eluting from 15% buffer D 
onward will be called "COLUMN 40" as previously stated.
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3.5. PREPARATION FOR SEQUENCING.
After anion exchange chromatography at pH.9.5, the 
polypeptides were further purified to obtain amino acid 
sequence data. Two methods are generaly described to 
prepare polypeptides for N-terminus sequencing. High 
performance liquid chromatography (HPLC) with a reverse 
phase column and SDS-PAGE, followed by electoblotting onto 
a polyvinyl difluoride membrane (Problott*). The samples 
were sent to Dr G. Currie and Dr M. Cussak, Department of 
Geology, University of Glasgow. Protein sequencing was 
carried out using an ABI 477A pulse liquid protein 
sequencer and an ABI 420-H amino acid analyser complete 
with automatic hydrolysis head. This sequencer uses the 
chemistry developed by Edman (1950). Nine samples 
generated by digestion with Staph. aureus V8 protease were 
sent to Dr Keen of the SERC sequencing source, Department 
of Biochemistry, University of Leeds.
3.5.1. REVERSE PHASE HPLC.
The method recommended by the technical department of 
Applied Biosystems and by Professor Fothergill and Dr 
Dunbar (Department of Biochemistry, University of Aberdeen) 
was a final purification by High Performance Liquid 
Chromatography using a reverse phase column (RP-HPLC). The 
system I used was an Applied Biosystem 130A separation 
system with a Aquapore RP 300 C 8 , microbore column and a 
50ul loop.
Reverse phase chromatography separates the proteins 
according to their hydrophobicity. The polypeptides were 
loaded on the column in 0,1% trifluoroacetic acic (TFA) and 
were eluted by a gradient of 0-70% acetonitrile. The 
polypeptides were recovered in a small volume of 
acetonitrile in 0.1% TFA. Both acetonitrile and TFA are 
volatile and do not interfere with the sequencing reaction, 
therefore the sample can be concentrated easily by 
evaporation to 30ul and applied to the sequencer. This 
method is not universaly applicable because the solvents
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usually denature the polypeptides. The immunological 
reactivity is also usually destroyed. It was verified that 
extraction of Bn5T cells in 0.1% TFA and exposure to TFA 
for 30 minutes destroyed the immunogenic response as 
measured by immunoprecipitation of the 40KD by TBS.
3.5.2. ELECTROBLOTTING ON PVDF.
The proteins were separated by SDS-PAGE, and then 
electroblotted onto a PVDF membrane Problott* using 3- 
cyclohexylamino-1-propanesulfonic acid (CAPS) buffer at pH. 
1 1.
This method may result in blockage of the N-terminus of 
the polypeptide by reaction with free radicals generated 
during the polymerisation of the gels. To minimize N- 
terminus blockage, there is a general agreement that gels 
should be cast at least a day in advance i.e. aged. Some 
authors advise pre-running the gel with "radical 
scavengers" (Speicher, 1989) such as thioglycolic acid with 
the addition of another "radical scavenger", glutathione to 
the tank buffer (Moos et a l .. 1989). Some authors do not
use these precautions (Le Gendre and Matsudaira, 1989). I 
set the resolving gels at least a day in advance and I 
pre-ran the gels with 0.1 M thioglycollate for 2 hours at 
20 milliAmp. in quarter strength resolving buffer.
A Bio-Rad Mini-Protean II electophoresis cell (mini-gel 
kit) was used for the isolation of the "VOID VOLUME 40". A 
Bio-Rad Mini Trans Blot Cell was used for electroblotting. 
Large gels used for the isolation of the "COLUMN 40" and 
for the separation of the fragments generated by Staph. 
aureus V8 protease digestion were cut to fit the size of 
the Mini Trans-Blot Cell.
The tank buffer used for electrophoresis contains 
glycine. The first experiments on sequencing polypeptides 
separated by this system and electroblotted on Problot* 
gave spurious peak of glycine in the first sequencing 
cycles (D. McNab personal communication). To avoid the use 
of glycine, two other gel systems were tried but found 
unsatisfactory. The system used by Moos et a l . (1989)
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uses the same buffer for the stacking and the resolving 
gels. The entire gel can therefore be pre-run with lOmM 
glutathione or O.lmM thioglycolate 14 hours, at 
lOmilliAmp.. The reagents used for the buffers were 2- 
2{[2-hydroxy-l,1-
bis(hydroxymethyl)ethyl]amino}ethanesulfonic acid, (T E S ); 
and 2 f bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane- 
1,3-diol, (BisTris). The composition of the buffers was:
Constituent Upper buffer Lower buffer Gel buffer
TES (g)
1M HC1 (ml) 
BisTris (g ) 
Final
volume (m l ) 
pH. (25 ° C )
10.07
23.66
1000
7.25
50
13.10
1000
5.9
21.6 
10.31
100
6.61
The resolution of the buffer was poor and the "VOID 
VOLUME 40” and "COLUMN 40" could not be separated.
The system developed by Schragger and von Jaggow (1987) 
uses the following buffers :
Anode buffer : 0.2M tris H C 1 , pH. 8.9
Cathode buffer : 0.1M tris HC1
0.1M tricine, pH. 8.25, adjust
with tricine if necessary.
0.1% SDS
Gel buffer : 3M tris H C 1 . pH. 8.45
0.3% SDS
This system is optimized for separation of protein of 
MW less than 20KD. Separation of the 40KD proteins took an 
excessive length of time, which resulted in a low AA yield 
(sequence dated 11/10, section 3.5.4.2).
The final system used a buffer where glycine was
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replaced by tricine weight for weight in a Laemmli system 
(Laemmli 1970). The system gave good results in the 
purification of the 90KD polypeptide (M. Grassie personal 
communication) . In the case of the 40KD polypeptide the 
gel frequently showed distortion phenomena probably because 
the buffering power was lower. The buffering power is lower 
because the pKa2 of tricine is 8.15 as against 9.6 for 
glycine, and the molarity is lower since glycine has a MW = 
76, whereas tricine has a MW = 179. The polypeptide was, 
nevertheless, separated (Figure 3.27) and sequenced.
The system resolved peptides well of the 90KD digested 
by Staph. aureus V8 protease (M. Grassie personal 
communication). Therefore this system was chosen to obtain 
internal sequence of the polypeptides.
To concentrate the polypeptide, three systems were 
used. Precipitation by 5% trichloroacetic acid, 
precipitation with 4 volumes of acetone and precipitation 
with 10 volumes of methanol after concentration on the 
Speedy Vac. Precipitation by 5% TCA was the most frequently 
used because of its speed and the possibility of 
precipitating the protein from concentrated salt solutions. 
It is a harsh method leading to losses, but it w a s _ 
previously successfully used for preparation of 
polypeptides for sequencing (Matsudaira, 1989). The other 
methods dilute the polypeptides which also leads to losses.
The polypeptides were separated on a 9% acrylamide 
gel. The polypeptides were electroblotted on Problott* with 
CAPS buffer pH. 11. After staining with Coomassie brillant 
blue R250 (Coomassie blue) the bands of interests were cut 
out and sent for sequencing.
3.5.3. AMINO ACID ANALYSIS.
AA analysis were performed in the department of Geology 
by Dr G. Currie and Dr M. Cussak with a ABI 920A analyzer 
module on aliquots of protein sent for sequencing on 
Problott*, as a preliminary analysis. The results presented 
in table 3.7. showed that the AA composition of the "VOID 
VOLUME 40" and the "COLUMN 40" are different. AA analysis
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gave estimates of the amounts of polypeptide loaded on the 
sequencer (See sections 3.5.4.3. and 3.4.5.6.).
TABLE 3.7. RESULTS OF THE AA ANALYSIS OF THE "VOI
VOLUME 40" AND THE "COLUMN 40".
PROTEIN Void vol. Column Void v o l . Column
40 40 40 40
Composition by picomoles by
molecular we i ght height of the peak
Aspartic acid 28, 7 24. 7 176.70 259.78
Glutamic acid 91 .3 34. 7 561.93 366.18
Serine 14.5 23.4 89.56 247.10
Glycine 32.5 32.0 199.84 337.82
Histidine 2.9 9.9 18.39 105.06
Arginine 11.5 17.2 70.72 181 .62
Threoni ne 10.5 17.1 64.44 180.25
Alanine 31 . 8 28.3 195.85 298.27
Proline 18.3 19.3 113.04 203.53
Tyrosine 6.4 10.4 39.88 109.50
Valine 31 . 7 34.0 195.16 358.35
Methionine 0.6 6.33
Cysteine 10.1 106.87
Isoleucine 10.3 29.6 106.86 311.97
Leucine 37.2 38.3 228.96 403.83
Phenylalanine 14.7 11.9 90.81 125.32
Lysine 14.9 27.0 91 .88 285.20
When the "VOID VOLUME 40" was identified as th'
mitochondrial aspartate aminotransferase (See section 
3.5.6), the published AA composition (Huynh et a l . 1988) 
was compared to the result obtained. They were found to be 
different. Two peptides one matching the sequence of the 
fructose 1-6 diphosphate aldolase A and the other the 
sequence of the phosphoglycerate kinase were sequenced from 
the Staph aureus V8 digest of the "COLUMN 40" (See section 
3.5.8). The AA composition of the two proteins was 
calculated from the published AA sequence (Ciccarese et 
a l ., 1989; Joh et a l ., 1985). It was compared to the result 
obtained for the "COLUMN 40" but the comparison was no help 
in distinguishing the two proteins sequenced.
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3.5.4. N-TERMINUS SEQUENCE OF THE "VOID VOLUME 40"
POLYPEPTIDE.
3.5.4.1. PURIFICATION USING RP-HPLC.
RP-HPLC was used successfully to prepare the "VOID 
VOLUME 40" for sequencing.
The Aquapore RP-300 column is a silica based column, 
and therefore unstable at a pH. above 8. The ethanolamine 
buffer pH. 9.5, was changed to buffer E (0.1% TFA in 
water), and each fraction of the void volume was 
concentrated using a Centricon 30 tube. The polypeptides 
were loaded on the column in buffer E and were eluted by a
gradient of buffer F (70% acetonitrile in buffer E).
The 40KD polypeptide was eluted by 63 ^  of buffer F in 
a well individualised peak, after most of'^other proteins. 
The peak, however, frequently showed a shoulder. It is 
known that acetonitrile can duplicate peaks (Kamp, 1986), 
but it also may be that the peak may not contain a pure 
polypeptide. To try to separate these peaks a shallower 
gradient of 45% to 75% buffer B was used . This failed to
separate the peaks completely but it was retained because
it reduced the contamination by trailing from other peaks.
The elution profile is presented in figure 3.25.
To confirm the purity of the polypeptide, an aliquot 
was loaded on a SDS-PAGE where it gave a clear 40KD band as 
seen in figure 3.26. The polypeptide was sent for N- 
terminus sequencing. The results of the sequencing 
experiments are presented in table 3.8.
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Figure 3.25. Graph 3.
Graph showing the elution of polypeptides from the 
microbore reverse phase column. The polypeptides from the 
void volume of the anion exchange experiment at pH 9.5 were 
concentrated using a Centricon 30 and the buffer changed to 
buffer E (0.1 % TFA in water). The proteins were eluted from 
the column using buffer F (70 % acetonintrile in buffer E).
The polypeptides were eluted by the following gradient.
time in min. 
0 
3 
8
45
48
53
55
% of buffer F 
0 
0
45
75
100
100
0
The injection is shown by the bottom arrow (labelled 
’’start") and the peak containing the "VOID VOLUME 40" is 
shown by the arrow at the left of the Graph.

Figure 3.26. Reverse phase HPLC.
The fractions of the void volume of the anion exchange 
chromatography experiment at pH. 9.5 were concentrated, the 
buffer changed to buffer E (0.1% TFA) and loaded onto the 
microbore reverse phase column. The peak eluting at 64% in 
buffer F (70% acetonitrile in buffer E) was saved and sent 
for sequencing. An aliquot was taken to be analysed on a 9% 
gel. The polypeptides were labelled with [35S] L-methionine 
and visualized by autoradiography. Although these samples 
were all run on the same gel only the relevant tracks were 
cut from the autoradiograph for photography.
Track 1 shows the MW markers.
Track 2 shows the "VOID VOLUMW 40" purified by RP-HPLC
(labelled fplc ) .
Track 3 shows a control standard i.p (labelled i.p.).
The MW of the markers is at the left of the gel
The position of the "VOID VOLUME 40" is indicated by an 
an empty triangle at the left of track 2 and the TBS:40 by a 
filled triangle at the right of track 3.
d« TBS 40
TABLE 3.8. AA SEQUENCE OF THE SAMPLES OF THE "VOID
VOLUME 40" PURIFIED BY RP-HPLC.
Date 30/6 17/8 24/8
AA N • pmoles pmoles pmoles
1 SER 55 SER 25 ALA 20
2 SER 29 SER 24 -
3 ASP 7 TRY 49 SER 2
4 SER 4 TRY 47 ARG 8
5 THR 135 THR 36 ARG 15
6 THR 98 HIS 9 ALA
7 TRP 12 VAL 41
8 TRP 11 GLU 10
9 TRP 15 MET 39
10 ASP 2 GLY 22
11 PRO 25
12 PRO 30
13 ASP 10
14 ARG 1
15 ILE 13
The theoretical initial yield Were 42, 48 and
picomoles respectively.
3.5.4.2. PURIFICATION USING SDS-PAGE.
Figure 3.27 shows a Coomassie blue stained Problott* 
membrane. The polypeptides of a 1 ml sample of the void 
volume were divided in three and analysed on a 9% minigel 
together with a void volume sample of another experiment. 
The actin band of the Bn5T cell extract localizes the ’’VOID 
VOLUME 40” , it migrates with a molecular weight just lower 
than actin (43KD). No TBS i.p. was run in parallel because 
it would not have helped in the localization of the 40KD 
protein.
Six samples were prepared using SDS-PAGE and 
electroblotting. The initial theoretical yields are shown 
in table 3.9.
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Figure 3.27. Electroblot of the void volume of the anion 
exchange chromatography at pH,9.5.
The fractions of the the void volume of the anion 
exchange chromatography at pH 9.5 were concentrated and 
loaded on a 9% SDS polyacrylamide mini-gel. After 
electrophoresis, the gel was electroblotted in CAPS buffer 
onto Problott* membrane, and the peptides visualized by 
Coomasie blue staining.
Track 1 shows a Bn5T cells polypeptides profile.
Tracks 2-5 shows aliquotsof void volume fractions.
Track 6 shows the MW markers identified at the right of 
the gel.
The MW of the markers is at the left of the gel
The position of the "VOID VOLUME 40” is indicated by 
arrows.
The fraction analyzed in track 5 has not been purified 
in the same experiment as the other fractions. This explains 
the different intensity of the bands.
actin
TABLE 3.9. INITIAL SEQUENCING YIELD OF THE SAMPLES
PURIFIED BY SDS PAGE.
Dates Yields in pmoles
4/9 48
25/9 5
1/10 17
11/10 14
8/11 54
20/12 48
The three best results with the highest and most 
consistant AA yield are presented in table 3.10 AA are 
shown in brackets when computer analysis failed to give a 
result. The AA was then deduced from the direct analysis of 
the chromatograms by me.
TABLE 3.10. AA SEQUENCE OF THE SAMPLES OF THE "VOID 
VOLUME 40" PURIFIED BY SDS PAGE AND ELECTROBLOTTING.
Dates 4/9 8/11 20/12
AA N° pmoles pmoles pmoles
1 Ser 44 Ser 63
2 ( Ser ) 38 Ser 52
3 Trp 41 Trp 91
4 ( Trp ) 38 Trp 80
5 Thr 25 Thr 43
6 Lys 6 His (Ala) 2
7 Val 47 Val 80
8 Glu 21 Glu 39
9 Met 33 Met 65
10 Val(G1y ) Met(G1 y ) 114 Gly 93
11 ( Pro ) 38 Pro 106
12 ( Pro ) 52 Pro 167
13 ( Asp ) 18 Asp 81
14 - Thr 25
15 H e 26 lie 7 7
16 lie 29 Leu 119
17 Gly 39 Leu 133
18 Val 34 Val 96
19 Thr 1 3 Thr 45
20 Val 32 Glu 64
21 Ala 115
22 Phe 84
23 Lys 87
24 -
25 Asp 69
26 Thr 45
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The data obtained after computer analysis were 
carefully scrutunized by me by eye to make sure that they
e
were genuinly the result of the N-terminus sequencing of a 
polypeptide. Once some experience of the interpretation of 
sequencing data was acquired, early data were ignored 
because the yields were too low (less than 10 picomoles).
To validate the data the following criteria were used.
The AA proposed was matched with the peak on the
chromatogram. It was essential that the peak was 
signi f icant,
its height was compared to the control to detect any
erroneous yield. Moreover, its position relative to the DMP
and DPT peak was checked to detect a possible shift in the
chromatogram resulting in an erroneous identification.
The picomole amount of each AA proposed by the computer
were compared to the values in the previous and in the
following sequencing cycles. To be significant the value
must be low in the previous cycle, and significantly lower
in the following cycle. The transient increase of one peak
0
is more important than the abslute pmoles value.
In addition to be sure that the data selected by the 
computer really represent the sequencing of a polypeptide 
the yield of each AA in the sequence should be grossly 
similar.
The following figures (3.28, 29 and 30) show three
chromatograms of cycles 6, 7 and 8 from an experiment of 
17/8/90. The valine derivative elutes at 19.17 min. Its 
amount rises from 7.27 pmoles in cycle 6 to 49.18 picomoles 
in cycle 7 to decrease to 21.98 pmoles in cycle 8.
The two strong peaks are N-dimethyl-N*-phenylthiourea 
(DMP) and N - N ’diphenylthiourea (DPT) which elute at 8.85 
min. and 20.75 min. respectively. They are by products of 
the Edman chemistry.
142
Figures 3.28, 29 and 30.
These three figures show the chromatograms of sequencing 
cycle 6, 7 and 8 respectively of the sequence of 17/8/90. The 
peak of valine appears in the cycle 6 and decreases in cycle 
7.
The AA identified in cycle 6 is histidine 12.3 min.
7 is valine 19 min.
8 is glutamine 8.3 min.
The height of the peak and the values in picomoles are
written under the chromatogram.
- Applied Biosvstens ^77H Protein Sequencer Chronatoqran Report -
SAMPLE : LUC.170890
C Initiated 17 Aug 1990 2:17pm 1
CYCLE SUMMARY :
Reaction cycle : NORMAL 
Conversion cycle : NORMAL 
Gradient : NORMAL
Data col 1 ect t me 
Data interval 
Inject volume
m i n0.0 to 29.
1.0 sec 
50 of 150 uL
AMINO ACID # 
Basshnt Corrected data
[ 17 Auc '90 7:55pm 0.0100 AU
10.0 1S.C ?0.0
Retention 7i M i nu t e s
PEAK TABULATION : ( 100Z injection ) Calibration : 1 G0890
Peak R. Time C.Time Helght Pmol Peak R. Tlme C . Time Helght Pmol
ID ( min) ( min) ( uAU) ID (min) (min) ( uAU )
ASP 5.05 5.07 3G15 9.81 DPT 20.75 20.75 S87570 1125.3G
ASN 5.42 5.52 939 2.G5 TRP 22.03 22.05 l 2852 2 5.82
SER G . 37 G . 47 525 2.El rHE 22.87 22.65 1 269 4.04
GLN 6.G3 G. 75 785 2 .79 : l e 25.50 2 3.45 1 1 37 4 .06
THR 7.28 7.40 2274 1 4 .02  ^YS 23.92 25.36 2280 4 . 93
GLY 7.G5 7.75 3408 13.84 L E U 24 .32 24 .28 4593 15.21
6LU 8.52 8.47 90*9 2.77
DMP 8.85 8.95 301809 1259.85
ALA 11.18 1 1 .28 1 473 5.28
HIS 12.18 12.30 1548 10.03
TYR 14.75 14.82 507 1 .57
ARG 16.98 17.05 987 1 1 .56
PRO 17.78 17.80 2127 7.69
MET 18.77 18.78 555 1 .58
UAL 19.15 19.17 2553 7.27
Tabulation threshold : 999 uAU
— Applied Biosvstcws ^77fl Protein Sequencer Chronatoqran Report -
SAMPLE : LUC.170890
[ Initiated 17 Aug 1990 2:17pr 1
CYCLE SUMMARY :
Reaction cycle : NORMAL Data collect tine : 0.0 to 29.0 nin
Conversion cycle : NORMAL Data interval : 1.0 sec
Gradient : NORMAL Inject volune : 50 of 150 uL
AMINO ACID 0 7 [17 Auc '590 S:3Spn 1 0.010*0 AU
Basehnr Corrected Data
20.010.0 25.0
Retention 'me: Minutes 
PEAK TABULATION : ( 1CK5Z injection ) Calibration : 160390
Peak R. Tine C. T me Height Pnol Peak R.Tine C.Tine Helght Pnol
ID (nin) (nin) ( uAU) ID (nin) (nin) ( uAU)
ASP S. 07 5.07 287J 7.60 DPT 20.77 20.75 1010157 1151.10
ASN 5.43 5.52 624 1 .76 TRP 22 .05 22.05 1 l 550 26.80
SER G.40 6 . 47 423 2.11 FHE 22 .88 22 .85 1 "7 I £ 5.46
GLN G. 65 6.75 771 2.74 1LE 25.52 23.45 1 476 5.30
THR 7.50 7. 40 720 4.44 LYS 2 j . 9 j 25.88 2316 5.01
GLY 7.65 7.75 4329 17.56 LEU 24.33 24 .26 3554 1 1 . 90
GLU 8.32 8 . 47 897 2.73
DMP 8.85 8.95 Z78973 1164.52
ALA 1 1 .20 1 1 . 28 1596 5.72
HIS 12.25 12.30 546 3.54
TYR 14.77 14.82 552 1 .7!
ARG 17.05 17.05 533 7.4 1
PRO 17.80 17.80 2016 7.25
MET 18.78 18.78 723 2.06
UAL 19.17 19.17 17283 49.16
Tabulation threshold : 999 uAU
- Applied Biosvstens i77R Protein Sequencer Chronatoqran Report —
2 '• 1 7 p m 1
SAMPLE : LUC.170690
[ Initialed 17 Aug 1993
CYCLE SUMMARY : 
Reaction cycle 
Conversion cycle 
Gradient
AMINO ACID U 8
Baseline Corrected Bata
NORMAL Data collect tine
NORMAL Data interval
NORMAL Inject volune
1 17 Aug 1590 9:22pm J
0.0 to 29.0 nin 
!.0 sec 
50 of 150 uL
0.0100 AU
20.0 2S.0
Retention Time: Minutes
PEAK TABULATION : ( 1 002 injection ) Calibration : 160890
Peak R.Tine C.Tine Height Pnol Peak R.Tlne C.Tine Height Pnol
ID (nin) (nin) ( uAU) ID (nin) (nin) ( uAU)
ASP 5.05 5.07 2043 5.54 DPT 20.72 20.75 1109241 12G4.01
ASN 5.42 5.52 666 1 . 86 TRP 22.02 22.05 12807 29.71
SER 6.38 6.47 444 2.21 PhE 22.83 22.85 1 908 6 .07
6LN 6.63 6.75 723 2.57 ILE 23.48 23.45 1380 4.95
THR 7.28 7.40 303 1 .87 LYS 23.88 23.88 2040 4.41
6LY 7.65 7.75 3267 13.27 LEU 24.28 24.28 3255 10.78
GLU 8.30 8 .47 4566 13.85
DMP 8.85 8.95 29154G 1217.01
ALA 11.18 1 1 .26 2835 10.17
HIS 12.23 12.30 256 1 .67
TYR 1 4 .75 14.82 504 1 .65
ARG 16 . 98 1 7.05 555 6.50
PRO 17.75 17.80 1756 6.35
MET 18.75 18.78 735 2.09
UAL 19.13 19.17 7725 21 .93
Tabulation threshold : 999 uAU
3.5.4.3. CONCLUSION OF THE N-TERMINUS SEQUENCING 
EXPERIMENTS OF THE "VOID VOLUME 40".
The AA sequence data were examined, The sequence 
obtained from samples purified by RP-HPLC dated 30/6 and 
24/8 were disregarded because of the low and inconsistent 
AA yield. The sequence obtained on 17/8 was considered to 
be the sequence of the polypeptide because the AA yield 
remained throughout between 45 and 13 picomoles, a 
significant figure.
The AA sequence of the sample electroblotted on 20/9 
had to be established by examination of the chromatograms, 
because a shift in the analysis of the cycle 10 incorrectly 
identified the peak of DPT as valine.
The sequence of the sample of 8/11 started at AA N ‘10 
because of a technical problem on the sequencer which 
prevented identification of earlier AA.
A total of nine samples were sequenced, three prepared 
by RP-HPLC and six by electroblotting. The results of the 
four best sequences, selected because of their high and 
consistent AA yields are compared using the single letter 
code for A A , X denotes that the AA was undetermined.
10 20 
RP-HPLC SSWWTHVEMG PPDRI
Electroblotting 20/9 SSWWTKVEMG PPDXIIGVTV
8/11 X PPDTILLVTE AFKXDT
20/12 SSWWTHVEMG
The sequence data confirm each other except for AA N°6, 
14, 16, 17 and 20.
The AA 6 and 14 detected were different for the five 
other samples sequenced and the yields were much lower than 
for the other cycles. It was concluded that these AA could 
be either phosphorylated, glycosylated or might be 
cysteine. The cysteine residue must be modified to be
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detectable with the HPLC procedure used with the sequencer 
(Dr M. Cussak, personal communication). Cysteinfcresidue can 
be detected after S-pyridylation of the protein. S- 
pyridvlation was carried out using the method developed by 
Amons (1987) but no cysteine was detected (Sequence dated 
20/12, section 3.5.4.2).
The chromatograms of AA N°16 17 and 20 were examined,
it was decided that AA 16 was most probably a leucine, AA 
N°17 a glycine and AA N°20 a glutamic acid residue.
The sequence was therefore most probably the following: 
10 20
SSWWTXVEMG PPDRILGVTE AFKXDT
The sequence was compared to the sequences of the NBRF 
data base using a VAX computer with the GCG package 
developed in the University of Wisconsin. It was found to 
be the N-terminus sequence of the rat mitochondrial 
aspartate aminotransferase (mAspAT) , (The complete AA 
sequence of rat mAspAT is presented in section 3.5.5).
I was not confident that the rat mAspAT was the right 
protein. The intensity of the Coomassie blue staining of 
the bands sent for sequencing suggested that the sequencing 
yield was very low. The result obtained could represent the 
sequence of a minor protein co-migrating with a major 
protein whose N-terminus was blocked. N-terminus of 
eukaryotic protein blockage is a common occurence (Brown 
and Roberts, 1976). The N-terminus of the protein of 
interest could have been blocked during the electrophoresis 
or by modification.
Pinpointing accurately the "VOID VOLUME 40" polypeptide 
on a minigel was not very easy because of the large
amount of material loaded. At the beginning an aliquot was 
run on a normal size gel. On the blot shown in figure 3.27, 
a Bn5T cell extract was run in parallel with the flow 
through fraction. The position of the actin band could be 
clearly seen and the position of the "VOID VOLUME 40" was 
thereafter deduced.
144
Two experiments were set up to estimate the efficiency 
of the gel system and the blotting technique.
To evaluate the potential recovery of AA, a quality 
control protein provided by Applied Biosystems was also put 
through the same experiments as the unknown samples. One 
hundred picomoles of beta lactoglobulin were loaded on a 
mini gel electrophoresed and blotted exactly as the "VOID 
VOLUME 40". The initial sequencing yield was 78.5 picomole, 
which is higher than expected from published data (Wilson 
and Yuan, 1989). Therefore the gel system used does not 
appear to block the N-terminus of proteins.
The amount of protein blotted was measured as part of 
the AA analysis. When the 4 bands, shown in figure 3.29, 
together with four other bands (not shown) were sent for N- 
terminus sequencing, an aliquot of a quarter of one band 
was used for AA analysis. The others bands were used for 
sequencing. The result of the sequencing experiment has 
already been presented (experiment dated 8/11, table 3.10, 
section 3.5.4.2); the yield of the first AA was 111 pmoles. 
The amount recovered from the AA analysis was 0.25ug of 
protein i.e. 6 pmoles. An exact quantification was not 
possible, because the amount of the protein blotted on the 
membrane was not necessarily the same for each band, but it 
indicates that approximatively 120 pmoles of purified 40KD 
proteins were loaded on the sequencer. According ft) Dr M. 
Cussak who sequenced the protein and supervised the AA 
analysis, the results showed that the recovery of AA by the 
sequencer was high. A percentage of recovery from PVDF 
membrane of 50% is usual (Wilson and Yuan, 1989).
The yield of the control, protein and the AA sequencing 
showed that the rat mAspAT is not a contaminant. Further 
confirmation was obtained by internal AA sequence data.
3.5.5. INTERNAL SEQUENCE OF THE "VOID VOLUME 40".
As the N-terminus of the "COLUMN 40" was blocked (See 
section 3.5.6) it was digested by Staph, aureus V8 protease 
to obtain internal sequence data. The "VOID VOLUME 40" was
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digested in the same experiment on a parallel track, and 
used as a control to distinguish between fragments of both 
40KD proteins and fragments of the enzyme. Five peptides 
were sent to Dr Keen, Department of Biochemistry, 
University of Leeds, for sequencing. Some of these were 
peptides from the Staph. aureus V8 protease, but two 
fragments were not. They were matched by Dr Keen as 
fragments of the rat mAspAT. Their sequence is presented in 
Table 3.11.
TABLE 3.11. AA SEQUENCE OF TWO PEPTIDES GENERATED BY
DIGESTION OF THE "VOID VOLUME 40" BY STAPH. AUREUS V8 
PROTEASE.
Peptide 3 (5KD ) : Peptide 4 ( 14KD):
AA pmoles AA pmoles
1 Ala 5 —
2 Phe 8 Gin 5
3 Gly? 2 Leu 9
4 - Pro? 1
5 Asp 10 H e 2
6 Thr 5 Leu 5
7 Asn 4 lie 2
8 Ser 2 -
9 - Pro 2
10 - Leu 5
11 Met 4 Tyr 4
12 Asn 4 Ser 0
13 Leu 3 Asn 5
14 Gly 2 Pro 2
15 Val 3 Pro 2
16 Gly 1 Leu 1
17 Ala 3 Asn 1
18 Tyr 4 Gly 2
19 - Ala 1
20 Asp 5 -
21 Asp 4 lie 0
22 Asn 2 Ala 0
23 Gly 1
24 -
25 Pro 0
26 Tyr 0
2 7 Val 1
28 Leu 1
29 Pro 0
30 Ser 0
The sequence of rat mAspAT was published by Huynh et 
a l . (1980). It is presented here and compared with the
fragments sequenced. The N-terminus fragment sequenced (AA 
1-26) is shown over the published sequence of the protein. 
The two internal peptides sequenced are shown underneath 
(AA 21-50 and AA 277-298). The strokes ! denote common AA.
SSWWTXVEMG PPDXILGVTE AFKXDT
i i i i i i i i i ii i i i i i i i i i  ti
i i i i i i i i i i i  i i i i i i i i i  i i
1 SSWWTHVEMG GPDPILGVTE AFKRDTNSKK MNLGVGAYRD DNGKPYVLPS
iif" i i i i i i i i i i i i i i i i  i i i i i i
II; I I I I I I I I I I I I I I I I  I I I I I I
AFGXDTNSXX MNLGVGAYXD DNGXPYVLPS 
51 VRKAEAQIAG KNLDKEYLPI GGLADRCKAS AELALGENSE VLKSGRFVTV
101 QTISGTGALR VGASFLQRFF KFSRDVFLPK PSGGNHTEIA RDAGMQLEGY
151 RYYDPKTCGF DFSGALEDIS KIPEQSVLLL HACAHNPTGV DPRPEQWDEM
201 AAYVKKNNLF AFFDMAYQGF ASGDGNKDAW AVRHFIEQGI NVCLCQSYAK
251 NMGLYGERVG AFTVVCKDAE EAKRVESQLK ILIRPLYSNP PLNGARIAAT
i i  i i  i i i i i i i i i i i i i
ii ii i i i i i i i i i i i ii
XQLP ILIXPLYSNP PLNGAXIA 
301 ILTSPDLRQG WLQEVKGMAD RIGSMRTQLV SNLKKEGSSR NWQHITDQIG
351 MFCFTGIKPE QVERLTKEFS IYMTKDGRIS VAGVTSGNVG YLAHAIHQVT
401 K
The results match the published sequence of the rat
mitochondrial aspartate amino-transferase well. There are, 
however, discrepancies for three amino-acids :
AA 11 a glycine is replaced by a proline.
AA 23 a lysine is replaced by a glycine in the fragment 
of internal sequence, but the identification given is only 
tentative, the recovered yield of glycine is only 2 pmoles 
(AA 3, peptide 3 (5KD)).
AA 280 a 1 (?y$ine is replaced by a ppo^ine.
3.5.6 N-TERMINUS SEQUENCE OF THE "COLUMN 40"
POLYPEPTIDE.
Experiments using Coomassie blue stained gels showed
that the "COLUMN 40M elutes in four fractions namely 19-23 
with a maximum in fraction 20. It was not possible to 
isolate the "COLUMN 40" in a pure form from fraction 20 by
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RP-HPLC. The resolution was insufficient, and the peak 
collected always contained contaminants when examined on 
SDS-PAGE (Data not shown). The polypeptide was therefore 
separated using SDS-PAGE. It was impossible to cut out the 
"COLUMN 40" protein by aligning it with a TBS:40 in a mini 
gel because the abundance of a contaminating protein 
overloaded the gel. Normal size gels (140x140 mm) of 
normal thickness (1.5 mm) were used. The "COLUMN 40" was 
separated on SDS-PAGE, electroblotted on Problott*, located 
using A Bn5T i.p. and a Bn5T cell extract and sent for N- 
terminus sequencing twice. The results are shown in table
3.12.
TABLE 3.12. RESULTS OF THE ATTEMPTS OF THE N-TERMINUS 
SEQUENCING OF THE "COLUMN 40".
Date 23/10 10/12
lA n ° AA pmoles AA pmo
1 Trp 14 Ser 28
2 - Thr 3
3 Arg 4 Val 4
4 Tyr 4 Glu 2
5 Phe 2 Tyr 3
6 Ala 6 Leu 12
7 Ser 6 Phe 8
8 Thr 3 Lys 2
9 Pro 3 Val 3
10 Pro 5 Ser/Lys
The sequences are completly different, the initial 
yields were low (5 and 8 picomoles). One of the bands sent 
for AA sequencing the 10/12 was used for AA analysis. The 
amount of polypeptide recovered from the band used for AA 
analysis indicated that around 60 pmoles of polypeptide had 
been loaded on the sequencer. Thus it was concluded that 
the N-terminus was most probably blocked and the sequences 
obtained represented non specific background. The protein
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had therefore to be fragmented to obtain internal sequence 
data.
3.5.7. ENZYMATIC DIGESTION WITH STAPH. AUREUS V8 
PROTEASE.
The same method of enzymatic digestion with Staph. 
aureus V8 protease as used for identification of the 
FPLC:40 was again used; but with some modifications taking 
into account the experience gained from the sequencing of 
the U90 (M. Grassie, personal communication).
The stain used to visualize the bands contained only 
10% methanol and 1% acetic acid to speed up destaining and 
facilitate electroelution from the gel slices. The gels 
were stained for only 15 min, and destained in the same 
solution minus stain until the bands were visible.
The bands excised were first dried to be packed into a 
normal sized gel; but the gel used was only 0.75 mm thick 
because electroelution proved to be difficult using 16.5% 
polyacrylamide gel of 1.5 mm thickness.
The pH. of the buffer was increased to 8, to decrease 
the number of fragments produced, because Staph, aureus V8 
protease cleavage is restricted to glutamyl residues at 
pH.8 (Houmard and Drapeau^1972).
Since the amount of polypeptide to be digested was 
considerably larger than for analytical TBS:40 digests, 50 
ug of protease was used initially. However this was 
excessive, and it was later reduced to 10 or 15 ug.
The same amount of protease was run on a separate track in 
the gel, to detect the Staph. aureus V8 protease and any 
fragments generated although the technical department of 
the manufacturer (Sigma) indicated that the enzyme should 
not autodigest.
The gels were cast one day in advance, they were not 
pre-run and no "radical scavengers" (Thioglycolate or 
glutathione) were used. The concentration of the gels was 
16.5%.
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3.5.8. DIGESTION OF THE "VOID VOLUME 40" AND "COLUMN
40" INDIVIDUALLY.
This experiment was repeated three tiroes. The fragments 
generated in the first two experiments were sent to the 
Department of Geology, University of Glasgow, but the 
levels were found to be too low for sequencing and Dr M. 
Cussak aborted the experiments.
The yield of peptides had to be increased to be 
successful. It was noticed that not only the peptide bands 
but also the whole track was stained with Coomassie Blue; 
this smear was attributed to protein degradation which 
could occur during the drying of the gel. To try to reduce 
protein degradation, in the third experiment the 
polypeptides were first analysed on 0.75mm thick gels 
instead of the normal 1.5mm gels. After staining the gel 
slices were equilibrated for 15 min. in the digestion 
buffer and stored at -70°C. The gel slice could then be 
inserted in the wells of the digesting gel without first 
drying the slice.
The "VOID VOLUME 40" and the "COLUMN 40" were digested 
in separate tracks. Twelve gel slices were loaded in each 
track. After staining the blot, five bands were cut out and 
sent for sequencing.
Figure 3.31. shows the result of the digestion of the 
two proteins blotted on Problott* and stained with 
Coomassie blue.
In one experiment [35S] L-methionine labelled TBS:40 
bands were loaded and digested in parallel, to compare the 
Coomassie blue stained and radio-active peptide map 
patterns. Unfortunately protein degradation prevented any 
significant comparison.
3.5.8.1. The "COLUMN 40"
The sequences of the peptides of the "VOID VOLUME 40" 
sent to Dr Keen Department of Biochemistry, University of 
Leeds have already been presented in section 3.5.5.
Five peptides of the "COLUMN 40" were sent to Dr Keen.
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Figure 3.31. Electroblot of the digests of "VOID VOLUME" and 
the "COLUMN 40".
The bands containing the "VOID VOLUME 40" and the 
"COLUMN 40" were pooled from the fractions of two anion 
exchange experiments at p H .9.5 using cells from a total of 
120 roller bottles. They were digested with lOug of Staph. 
aureus V8 protease. The results were analysed on a 16.5% 
polyacrylamide gel. The polypeptides were electroblotted onto 
Problott* membranes and visualized by Coomasie blue staining.
Track 1 shows the digest of the "COLUMN 40" (labelled C).
Track 2 shows the digest of the "VOID VOLUME 40" 
(labelled V V ).
Track 3 shows the MW markers.
The MW of the markers is at the right of the gel
c vv
1 2 3 KD
Two fragments were successfully sequenced although the 
levels of AA were low. The results are presented in Table
3.13.
TABLE 3.13. AA SEQUENCE OF TWO PEPTIDES GENERATED BY 
DIGESTION OF THE "COLUMN 40” BY STAPH. AUREUS V8 PROTEASE.
Fragment 3 Fragment 4
AA pmoles AA pmoles
1 - -
2 Leu? 1 Asn 1
3 Pro? 1 Tyr 4
4 Tyr 2 Phe 2
5 Pro? 0 Ala 3
6 Ala 2 -
7 Leu 1 Ala 2
8 Thr? 0 Leu 2
9 Asn 1 Glu 1
10 Glu 1 Ser 0
11 Gin 0 -
12 - Glu 1
13 Leu 0 -
14 Glu 0 -
15 Leu 0 Phe 1
16 Ala 2 Leu 1
1 7 Asp? 0 Ala 1
18 H e 0 lie 1
19 Ala 0 Leu 0
20 -
21 -
22 Ala 1
23 -
24 -
25 Ala 0
26 Asn? 1
27 -
28 lie? 0
29 Gin 0
30 Leu 0
The fragments were identified by Dr Keen as belonging 
to two different proteins . The fragment 3 matches the N- 
terminus of the rat fructose biphosphate aldolase A (Muscle 
specific), two of the 19 AA of this sequence are not 
identified. The fragment 4 matches the internal sequence 
of rat X-linked phosphoglycerate kinase (this gene is 
carried on the X chromosome), in this fragment 20 out of 30 
AA were identified.
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The AA sequence of the X-linked phosphoglycerate kinase 
(Ciccarese et a l ., 1989) and the fructose biphosphate
aldolase A (Joh et a l .. 1985) have been published
3.5.8.2. Fructose 1-6 biphosphate aldolase.
The published AA sequence of rat fructose biphosphate 
aldolase (Joh et a l .. 1985) is presented with the sequence 
of the fragment 3 written under the sequence of the protein 
(AA 1-19) :
1 PHPYPALTPE QKKELADIAH RIVAPGKGIL AADESTGSIA KRLQSIGTEN
i i I i i i i i i i i i i iii(iii i * i i i i i i
XLPYPALTNE QXLELADIA 
51 TEENRRFYRQ LLLTADDRVN PCIGGVILFH ETLYQKADDG RPFPQVIKSK
101 GGVVGIKVDK GVVPLAGTNG ETTTQGLDGL SERCAQYKKD GADFAKWRCV
151 LKIGEHTPSS LAIMENANVL ARYASICQQN GIVPIVEPEI LPDGDHDLKR
201 CQYVTEKVLA AVYKALSDHH VYLEGTLLKP NMVTPGHACT QKFSNEEIAM
251 ATVTALRRTV PPAVPGVTFL SGGQSEEEAS INLNAINKCP LLKPWALTFS
301 YGRALQASAL KAWGGKKENL KAAQEEYIKR ALANSLACQG KYTPSGQSGA
351 AASESLFISN HAY
Three AA of fragment 3 are different from the published 
sequence, AA N°2 leucine a tentative identification, AA N°8 
asparagine and AA N°13 leucine. A total of 14 out of 19 AA 
of fragment 3 fit the published sequence.
3.5.8.3. Rat phosphoglycerate kinase.
The AA sequence of rat phosphoglycerate kinase (EC 
2.7.2.3) is the following (Ciccarese et a l ., 1989)., the 
sequence of the fragment 4 is written underneath. Strokes 
show the similarity between the A A .
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1 SLSNKLTLDK LDVKGKRVVM RVDFNVPMKN NQITNNQRIK AAVPSIKFCL
51 DNGANSVVLM SHLGRPDGVP MPDKYSLEPV AAELKSLLGK DVLFLKDCVG 
101 SEVENACANP AAGTVILLEN LRFHVEEEGK GKDASGNKVK AEPAKIDAFR
151 ASLSKLGDVY VNDAFGTAHR AHSSMVGVNL PQKAGGFLMK KELNYFAKAL
i i i i ii i i i i ii
XNYFAXAL
201 ESPERPFLAI LGGAKVADKI QLINNMLDKV NEMIIGGGMA FTFLKVLNNM
ii i i i i i i i ii i ii
i i i i i i i i i i i  i i i
ESXEXXFLAI LXXAXXADXI QL 
251 EIGTSLYDEE GAKIVKDLMT KAEKNGVKIT LPVDRVTADK FDENAKTGQA
301 TVASGIPAGW MGLDCGTESS KKYAEAVARA KQIVWNGPVG VFEWEAFARG
351 TKSLMDEVVK ATSRGCITII GGGDTATCCA KWNTEDKVSH VSTGGGASLE
401 LLEGKVLPGV DALSNV
Twenty AA out of 29 were identified in fragment 4, They 
all fit the published sequence of the rat phosphoglycerate 
kinase.
The amount of AA recovered is low but 14 and 20 AA have 
been identified and matched with the published sequences. 
This gives confidence in the accuracy of the
identification.
3.5♦9. SUMMARY OF THE SEQUENCING EXPERIMENTS.
Altogether these purification experiments summarized in 
table 3.14 identified three different AA sequences.
The N-terminus of "VOID VOLUME 40", the protein which 
is not i.p. by TBS, is identical to the N-terminus of the 
rat mitochondrial aspartate aminotransferase.
Two peptides were sequenced from the digestion of the
"COLUMN 40", the protein which is i.p. by TBS, one is
similar to the N-terminus sequence of rat fructose
biphosphate aldolase and the second is very similar to 
internal sequences of rat phosphoglycerate kinase.
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3.6.IMMUNOLOGICAL EXPERIMENTS.
The Staph, aureus V8 protease digest of the 40KD band 
eluting from the anion exchange chromatography experiment 
at p H . 9.5 showed that the FPLC:40 is made up of two 
proteins.
The "VOID VOLUME 40" was identified as a protein with 
sequence homologies to the rat mAspAT.
the "COLUMN 40" was digested with Staph. aureus V8 
protease; two peptides were successfully sequenced one 
showed homology to the N-terminal sequence of rat fructose 
1-6 diphosphate aldolase A and the other showed homology to 
the internal sequence of rat phosphoglycerate kinase-1.
3.6.1.IMMUNOPRECIPITATION EXPERIMENTS WITH AN ANTIBODY 
TO RAT MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE.
The "VOID VOLUME 40", shown to have sequence homologies 
with the rat mAspAT, is not i.p. by TBS. Its apparent MW 
(40KD, as compared with the MW markers, fig 3.20 and 3.26) 
is less than the published result (44KD) (Huynh et a l .. 
1980) .
To test an immunological relationship between the "VOID 
VOLUME 40" and the mAspAT, a polyclonal antiserum against 
rat mAspAT was obtained from Professor Mattingly, Division 
of Molecular Biology and Biochemistry, University of 
Missouri-Kansas City. It was raised in goat, and recognized 
rat mAspAT in Western Blotting experiments (Mattingly et 
a l . 1987). This antiserum was used in i.p. experiments.
Bn5T and RE cells radiolabelled with [35S] L-methionine 
were extracted in RIPA buffer, incubated with lOul of TBS 
or lOul of mAspAT antiserum for 1 h . ; 60ul of Pansorbin* 
was then added and the mixture was incubated for a further 
hour.
Figure 3.32 shows the result of the experiment.
TBS i.p. a 40KD protein from the Bn5T cell extract as 
expected (track 3).
The mAspAT antiserum i.p. two proteins of approximate 
apparent MW 44KD and 40KD. The 40KD protein has an apparent
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Figure 3.32. Immunoprecipitation of Bn5T polypetider by an 
antiserum specific of the rat mAspAT.
Autoradiograph of a 9% SDS polyacrylamide gel which shows 
i.p. experiments performed on f35S] L-methionine labelled 
polypeptides extracted in RIPA buffer from Bn5T tumour cells 
with TBS and rat mAspAT antiserum. Although these samples 
were all run on the same gel only the relevant tracks were 
cut from the autoradiograph for photography.
Track 1 shows the Bn5T cell polypeptides profile.
Track 2 shows the RE control cell polypeptides profile.
Track 3 shows Bn5T cells i.p. with TBS.
Track 4 shows Bn5T cells i.p. with mAspAT antiserum.
Track 5 shows RE control cells i.p. with mAspAT 
anti serum.
The position of the TBS:40 is shown by an empty triangle. 
The mAspAT antiserum i.p. a polypeptide of an apparent MW 
slightly inferior to the TBS:40 in both Bn5T tumour cells and 
RE control cells shown by two filled triangles. The position 
of the U90 is indicated by an arrow.
actin
MW slightly lower than the TBS:40. Both the 44KD and the 
40KD are present in the Bn5T and the RE cell extracts 
(tracks 4 and 5). The 44KD band is stronger in the RE track 
than in the Bn5T track and comigrates with a faint band in 
the TBS i.p. track and the strong bands labelled "actin’' in 
the Bn5T and RE cell extract (tracks 1 and 2).
This antibody does not selectively i.p. a 40KD protein 
in Bn5T cells extract.
3.6.2. SLOT BLOT EXPERIMENTS.
The TBS:40 is increased by HSV-2 infection (Macnab et 
a l . 1992). Slot blot experiments were set up to investigate 
if mAspAT expression was increased by HSV-2 infection. Bn5T 
cells were infected with HSV-2 HG52 (1 p .f .u ./cells). The 
growth of one roller bottle of uninfected and infected 
cells were harvested in 2ml of WF buffer. The cell extracts 
were ly$ed with a Dounce homogenizer (50 strokes) followed 
by sonication as for the purification procedure. The 
protein concentration was measured and the Bn5T extract was 
diluted by a factor 2 to equalize the protein 
concentrations in Bn5T and RE cells extracts. Twelve 
doubling dilutions (1/2 to 1/4096) were made up and loaded 
on the slot blot manifold. After aspiration, the 
nitrocellulose was blocked in 3% gelatin in TBuS, probed 
with mAspAT antibody diluted 1/1000 in TTBuS at 37*C for 
lh, washed three times with TTBuS, the blot was incubated 1
h. at RT with HRP conjugated rabbit anti-goat antibody 
after three washes with TTBuS, the chemoluminescence 
reagent was added.
Figure 3.33. shows that the HSV-2 infected extract 
gives a positive signal up to a titre of 1/1024 and the 
Bn5T extract a positive signal to a titre of 1/256. There 
is a difference of two doubling dilutions which is 
generally considered as the minimum increase to be- 
signi f icant.
This result was repeated twice showing that HSV-2 
infection significally increases the expression of the 
mAspAT as detected by this antibody.
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Figure 3.33. Slot blot experiment.
Twelve doubling dilutions (1/2 to 1/4096) of Bn5T and 
HSV-2 infected Bn5T cell extracts were loaded on
nitrocellulose and then blotted with an antibody specific for 
mAspAT. The reaction was visualized with the 
chemoluminescence reagent.
Track 1 contains the uninfected Bn5T extract doubling 
dilutions.
Track 2 contains the infected Bn5T extract doubling 
dilutions.
■ 1 ■
-1/2
—  | > -1/4
-1/8
-1/16
-1/32
-1/64
-1/128
-1/256
-1/512
f i g -1/1024
-1/2048
M U -1/4096
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3.6.3. WESTERN BLOTTING EXPERIMENT.
A Western blot experiment was set up with two aims.
1/ To further identify the proteins detected by the 
antibody specific to mAspAT in Bn5T cells extracts whose 
expressions were increased upon HSV-2 infection. The cell 
extracts were prepared as for the slot blot experiment.
2/ To test the immunological relationship between the 
two 40KD proteins purified ("VOID VOLUME 40" and "COLUMN 
40") and the mAspAT.
A 0.75mm thick SDS-PAGE was loaded with:
Track 1: A sample containing the "VOID VOLUME 40".
Track 2: A sample containing the "COLUMN 40" (fraction 
23 of an ion exchange chromatography experiment at pH. 
9.5 ) .
Track 3: An enlarged i.p. using 4.107 c.p.m. of Bn5T 
extracts and incubated 1 h. with 50ul TBS. the immune 
complexes were trapped by lOOul of pansorbin*.
The gel was cut to fit the size of a mini gel kit, the 
proteins were blotted onto nitrocellulose in CAPS buffer 
with 10% methanol pH. 11. The voltage was set at 50 Volts 
for lh. 45 min.. The blot was probed with mAspAT antibody 
as described in section 3.6.2.. After development of the 
chemiluminescence reaction, the blot was exposed to detect 
the r 3 5 S ] L-methionine labelled proteins.
The chemiluminescence signal and the autoradiography of 
the blot are shown in figure 3.34a and b.
Figure 3.34a. is the chemiluminescence signal.
The "VOID VOLUME 40" is recognized by mAspAT antibody 
(track 1 ) .
No protein is recognized in the column fraction 23 
(track 2). Therefore the "COLUMN 40" is not recognized by
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Figure 3.34. Immunoblotting with the mAspAT antiserum.
Two fractions of an ion exchange experiment at p H . 9.5 
containing the "VOID VOLUME 40" and the "COLUMN 40", a 
control Bn5T i.p., were loaded onto a 9% polyacrylamide gel 
after completion of the electrophoresis, the polypeptides 
were blotted onto nitrocellulose.
The Western blotting experiment (figure 34a) and the 
autoradiographic control (figure 34b) are presented together.
Track 1 contains a fraction of the void volume and the 
"VOID VOLUME 40",
Track 2 contains the fraction 23 and the "COLUMN 40".
Track 3 shows the control Bn5T i.p.
The MW is indicated at the left of the gel,
Figure 34a is the Western blotting experiment with an 
antibody raised against mAspAT.
The "VOID VOLUME 40"is shown by a filled triangle in 
track 1.
Figure 34b is the autoradiograph of the blot.
The "VOID VOLUME 40" is shown by a filled triangle in 
track 1. The column 40 is shown by an arrow in track 2 and 
the TBS:40 by an empty triangle in track 3.

mAspAT antibody.
Figure 3.34b is the autoradiography of the blot.
It confirms the presence of the "COLUMN 40" in track 2 
(arrow), which comigrates with the TBS:40 in track 3 (empty 
triangle). The mAspAT in track 1 (filled triangle) has a 
lower apparent MW than the TBS:40.
This result shows that the "VOID VOLUME 40" is
immunologicaly related to the mAspAT.
The "COLUMN 40" is not recognized by this mAspAT 
antibody.
3.7. SUMMARY OF THE RESULTS.
The attempt of raising monoclonal antibodies by
immunizing mice against Bn5T cell lysates was a failure,
but the screening experiments showed that mouse did not 
recognize the 40KD protein which TES did.
Purification and sequencing experiments identified 
three rat proteins: mitochondrial aspartate
aminotransferase, fructose 1-6 diphosphate aldolase and 
phosphoglycerate kinase. The relevance of these data to
transformation will be addressed in the "Discussion".
The purified "VOID VOLUME 40", was related to mAspAT by 
its sequence, it was recognized in Western blotting 
experiment by an antibody specific to mAspAT. The "VOID 
VOLUME 40" was not i.p. by TBS but was part of a complex
i.p. by T B S .
An antibody specific to rat mAspAT i.p. a 40KD protein 
in both RE and Bn5T cell, hence failing to detect a 40KD 
protein specificaly i.p. in Bn5T cells.
Slot blot experiments using doubling dilutions and the 
same antibody specific to mAspAT showed that the 
expression of mAspAT is increased by HSV-2 infection.
Two proteins, namely rat fructose 1-6 diphosphate 
aldolase and phosphoglycerate kinase were identified as 
components of the "COLUMN 40" by sequencing. The "COLUMN"
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40 was always i.p. by TBS, but this was not checked for the 
samples sent for sequencing. It is also not known which of 
the two enzymes is i.p. by TBS.
Aldolase A and PGK are normal cellular proteins.
Explanation for their i.p. in Bn5T cells and not in RE
control cells and the relevance of these results to
transformation will be discussed in the "Discussion''
following. Further experiments to confirm these results 
will be suggested.
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PART 4
DISCUSSION.
The aim of the project was to purify and obtain AA 
sequence for a polypeptide of 40 KD i.p. by TBS from a Bn5T 
cell extract but not from an RE control cell extract. 
Moreover infection with HSV increased the amount of 
polypeptide i.p.. The 40 KD polypeptide was characterized 
by its digestion pattern with the enzyme Staph, aureus V8 
protease. The initial characterization was carried out on 
Bn5T cells and not on infected cells.
In these experiments TBS was found to i.p. more than 
one polypeptide. It was decided to purify and identify each 
polypeptide in turn and lastly to test the effect of HSV-2 
infection on its expression. Two candidate polypeptides 
were purified and AA sequences belonging to three proteins 
were obtained namely, rat mitochondrial aspartate 
aminotransferase, rat phosphoglycerate kinase-1 and rat 
fructose 1-6 diphosphate aldolase A, but HSV-2 increased 
only the expression of the mAspAT as tested in slot blot 
experiments.
Attempts to raise antibodies in mice and rabbits were 
carried out. In rabbit there was no immunological response. 
To raise Mabs twelve mice were immunized against Bn5T 
tumour cells. The 90KD polypeptide i.p. by mouse antisera 
and the U90 i.p. by TBS were similar, in respect of the 
Staph, aureus V8 protease peptide map. By contrast the 40KD 
polypeptide i.p. by the serum of the mice and the TBS:40 
had different peptide maps. Therefore, in this instance the 
immune system of the rat and the mouse recognized different 
40KD proteins. Unfortunately attempts to raise Mabs against 
the 90KD and the 40KD polypeptide failed. Although the 
40KD polypeptide did initially raise Mabs, these were 
unfortunately subsequently lost.
The discussion will be divided in three parts, the 
first part will cover specific points of the purification 
procedure, the second part will propose a mechanism for the 
different specificity of the mouse antisera and TBS and
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the third part will review the biochemical properties of 
the proteins identified and discuss their identification as 
the TBS:40.
4.1. THE PURIFICATION PROCEDURE.
4.1.1. PRECIPITATION BY AMMONIUM SULPHATE.
This experiment confirmed that the TBS:40 and the U90 
could be i.p. independently of each other (Macnab et a l .. 
1985; Hewitt et a l . . 1991) and were not merely recognized 
as part of a complex. They were i.p. in different ammonium 
sulphate fractions, the U90 in both the extraction pellet 
and the 30% pellet, and the TBS:40 in the 70% supernatant.
Two 40KD proteins i.p. by TBS were separated in this 
experiment which were distinguished by their Staph, aureus 
V8 protease peptide map.
The 40KD polypeptide i.p. in the extraction pellet, 30% 
pellet and 70% pellet was i.p. independently from the U90 
since no U90 was i.p from the 70% pellet, (figure 3.12). 
The 40KD in the extraction pellet was not studied further 
because its peptide map after digestion by Staph, aureus 
V8 protease was different from the peptide map of the 
T B S :40
However although most of the 40KD protein precipitated 
in the pellet is not soluble, a fraction of it may be 
soluble and be present in the 70% ammonium sulphate 
supernatant. Therefore the 40KD polypeptide in the pellet 
could be one of the polypeptides making up the final 
pattern of the i.p. TBS:40 band, (figure 3.13).
4.1.2. ANION EXCHANGE CHROMATOGRAPHY.
4. 1.2.1. RESOLUTION AT p H .8.
The peptide maps of the TBS:40 and the FPLC:40 are 
undistinguishable (figures 3.16, 17, 18), as identitified
by radiolabelled peptides detected by autoradiography.
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4.1.2.2. RESOLUTION AT pH 9.5.
The Staph, aureus V8 protease digests showed that the 
FPLC:40 was made of two proteins (figure 3.21a and b). 
Comparison of the two peptide map patterns to all the 
peptide maps previously made suggested that the pattern of 
the "COLUMN 40" was highly similar but close to the pattern 
of the TBS:40. Because it is i.p. by TBS, it is probably 
the most intersting component of the TBS:40.
The "VOID VOLUME 40" is not i.p. by TBS and has a 
Staph. aureus V8 protease peptide map which differs 
considerably from the TBS:40 (see figures 3.21). Because 
the peptide maps of the TBS:40 and the FPLC:40 were 
undistinguishable, the "VOID VOLUME 40" had to be a 
component of the TBS:40. The "VOID VOLUME 40" identified as 
sequence related to the mAspAT may be i.p. by TBS from Bn5T 
cells extract as part of a complex, and the complex could 
have been disrupted as a result of this purification step. 
Therefore both proteins had to be purified and sequenced.
4.1.3. RP-HPLC.
The method used was adapted after consultation with the 
technical departmemt of Applied Biosystem and was described 
in the litterature as the method of choice to prepare 
proteins for N-terminus sequencing. However, the results 
obtained with RP-HPLC were disapointing. Out of the 3 
samples sequenced, only one gave a good result. The other 
two were disregarded because of low or irregular levels of 
AA recovery. The reasons for the poor recovery is not 
known. No satisfactory explanation could be found in the 
literature. It is possible that RP-HPLC was degrading the 
"VOID VOLUME 40" since the protein became totally insoluble 
if dried, whereas this was not the case before separation 
on the RP-HPLC column.
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4.2. HYPOTHESIS TO EXPLAIN THE DIFFERENT SPECIFICITY OF
TBS AND MOUSE ANTISERUM.
The lack of reactivity of mice to proteins with a 
peptide map similar to the TBS:40 is surprising. Bn5T 
cells injected into a mouse act as a xenoantigen. 
Xenoantigens are expected to stimulate the immune response 
strongly. The lack of immune response of the mouse to the 
TBS:40 can be explained by the similarity of the rat and 
the mouse protein.
PGK-1 could be such a protein. The AA sequences of the 
rat and mouse PGK-1 differ by three AA. Could such a small 
difference in the AA sequence prevent an effective 
stimulation of the immune response? There is no answer to 
this in the current study but an attempt at raising 
antibody against another well conserved protein, aldolase 
A, suggests it is possible. A rabbit failed to make 
antibodies to human aldolase A (Okajima et a l .. 1990). 
Comparison of the published sequences of the rabbit and 
the human aldolases, using the GCG Bestfit programm, found 
only six different AA.
I
4.3. THE BIOCHEMICAL ROLE OF THE ENZYMES ISOLATED FROM 
THE 40KD BAND AND THEIR RELEVANCE TO TRANSFORMATION.
Aspartate aminotransferases are involved in the 
synthesis of AA from oxaloacetate and L-glutamate. Two 
forms of enzyme exist a cytosolic and a mitochondrial form 
(cAspAT and mAspAT).
The two enzymes fructose 1-6 diphosphate aldolase and 
phosphoglycerate kinase are part of the glycolytic cycle. 
The glycolytic pathway plays a critical role in the 
production of adenosine triphosphate and therefore in the
energy metabolism
4.3.1. FRUCTOSE 1-6 DIPHOSPHATE ALDOLASE.
Fructose 1-6 diphosphate aldolase, also called aldolase 
(EC 4.1.2.13) catalyses the following reaction:
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fructose 1-6 dihydroxy acetone glyceraldehyde
diphosphate phosphate * 3-phosphate
Two types of this enzyme are known designated class I 
and class II. The enzymes of class I function by imino 
formation between the substrate and a catalyticaly 
essential lysine residue in the active site. The class II 
enzymes utilize a divalent metal ion.
The enzymes of eukaryotes generally fall into class I 
and are tetrameric (Mr 160.000). They consist of four 
identical subunits which have an apparent MW of 40KD, and 
which occurs as three isozymes namely A,B and C. The 
nucleotide and the AA sequences of the three aldolase 
isozymes have been determined (Tsutsumi et a l .. 1984; Joh 
et al . . 1985: Kukita et a l . . 1988). The AA sequences of
the isozymes are homologous especially in the region of 
imine forming lysine residue (Reviewed by Perham, 1990). 
The different isozymes occur in different tissues.
Aldolase A is a foetal form of aldolase, it is present 
in large amounts in muscle and in much smaller amounts in 
kidney.
Aldolase B is found predominantly in kidney.
Aldolase C is found mainly in the brain and is composed 
of subunits C and A (reviewed by Asaka, 1983).
The peptide called fragment 3 was generated by 
digestion of the "COLUMN 40" with Staph Aureus V8 
protease.The AA sequence of fragment 3 was found to be 
similar to the N-terminus of the rat aldolase A sequence. 
This result contradicts the previous result i.e. failure 
to obtain N-terminal sequences from the "COLUMN 40" (see 
section 3.5.6). Dr Keen who sequenced the protein could not 
give an explanation. The sequence of fragment 3 was 
compared with the sequences of aldolase A, B and C, to 
confirm the isozyme identification. The AA differences 
between aldolase A and aldolase B and C are shown below in 
bold characters. The AA of fragment 3 which do not fit 
the aldolase A sequence are underlined.
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Fragment 3 - Leu Pro Tyr Pro Ala Leu Thr
9
Asn
10
Glu Gin -
Aldolase A Pro His Pro Tyr Pro Ala Leu Thr Pro Glu Gin Lys
Aldolase B Ala His Arg Phe Pro Ala Leu Thr Ser Glu Gin Lys
Aldolase C Pro His Ser Tyr Pro Ala Leu Ser Ala Glu Gin Lys
? ? ? 19
Fragment 3 Leu Glu Leu Ala Asp lie Ala
A Lys Glu Leu Ala Asp lie Ala
B Lys Glu Leu Ser Glu lie Ala
C Lys Glu Leu Ser Asp lie Ala
? : querry AA.
The sequence of fragment 3 differs from aldolase A by 
two A A , AA 2 a leucine replaces a histidine, and AA 9 an 
asparagine replaces a proline, but in this case the 
asparagine is only a tentative identification. This result 
is not surprising, allelic variants of aldolase A have been 
reported previously (Joh et a l .. 1985).
In this region aldolase A differs from aldolases B by 
five AA, four of them identified, from aldolase C by four 
AA. Therefore the isoenzyme identification is not 
ambiguous.
Aldolase levels were investigated as possible markers 
of various cancers.
The high glycolytic activity of tumoral tisssues was 
discovered by Warburg (1930). High aldolase levels have 
been observed in rat tumour tissues (Sibley and Lehninger, 
1955) and in the venous blood from a rat tumour (Warburg 
and Christian, 1943; Sibley and Lehninger, 1955), 
histologically classified as a sarcoma like the tumours 
induced by injection of Bn5T cells (J.C.M. Macnab, personal 
communication ) .
More recently elevated aldolase levels have been 
reported in the sera of patients with cervical cancer 
(Yeshorwardana and Sangita, 1985), ovarian cancer 
(Yeshorwardana and Singh, 1984) and in bronchial cancer
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(Dalliige et a l . 1984), but a raised aldolase level is also 
associated with chronic liver diseases and muscle diseases 
(Reviewed by Asaka et a l .. 1983).
An identification of the aldolase A as the 40KD protein 
recognized by TBS is compatible with some properties known 
for the TBS:40.
Aldolase A is a protein expressed at high level in 
embryo and in tumour tissues (Reviewed by Asaka et a l .. 
1983) and is also capable of inducing auto-antibodies 
(Brown et a l .. 1984). These properties fit with the TBS:40 
which is located in the cytoplasm and is detected by i.p. 
in early embryo cells (12 days), disappears at 15-19 days 
(J.C.M. Macnab, unpublished results) and is again detected 
by i.p. in all lines of transformed and immortalized cells 
tested (Macnab et a l ., 1985).
The Aldolase A monomer has a predicted MW of 39,125 
which fits with the MW of the TBS:40.
The pi. of Aldolase A is 8.9, thus it would not be 
retained by a anion exchange column at pH.8. The published 
purification procedure for aldolase A is not however 
directly comparable (Reviewed by Horeker et a l .. 1970).
In contrast to the TBS:40, the bulk of aldolase A is 
precipitated by a 60% saturated ammonium sulphate solution. 
HSV-2 infection induces an 8 fold decrease of the
expression of aldolase A as tested with doubling dilutions
in a slot blot experiment (data not shown). Moreover, the 
sequencing of the N-terminus is difficult to conciliate 
with the N-terminus blockage of the "COLUMN 40". In 
conclusion, aldolase A is unlikely to be the "COLUMN 40", 
it may be a contaminating protein.
4.3.2. PHOSPHOGLYCERATE KINASE.
Phosphoglycerate kinase (P G K ) is a monomeric enzyme
which catalyzes the following reaction :
1-3 Diphosphoglycerate ^ 3-phosphoglycerate
+   +
MgADP MgATP
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In mammals PGK is encoded by two genes, pgk-1 and pgk-
2. Pgk-1 is X chromosome linked and is expressed in somatic 
cells (Vandeberg et a l ., 1976). Pgk-2 is expressed only in 
meiotic and haploid male germ cells.
The peptide called fragment 4 was generated by the
digestion of the "COLUMN 40” by Staph, aureus V8 protease. 
The AA sequence of fragment 4 was found similar to a region 
of the rat X-linked phosphoglycerate kinase (PGK-1) 
sequence.
The nucleotide and the AA sequences of PGK-1 and PGK-2
in mouse (Boer et a l ., 1989) and rat PGK-1 (Ciccarese et
a l .. 1989) have been published. To make sure that the 
isozyme identification is correct, the sequence from the
purified peptide obtained in this study (top line) is 
compared with the sequence of rat PGK-1 and of mouse PGK-2, 
the sequence of rat and mouse PGK-1 is the same for the 
region in which the polypeptide fits. The AA which differs 
in PGK-2 (from PGK-1) are written in bold characters. The 
sequence of the purified peptide starts at AA 193, and 
contains 30 A A .
Fragment 4 - Asn Tyr Phe Al a - Ala Leu Glu
10
Ser - Glu
PGK1 (rat) Leu Asn Tyr Phe Ala Lys Ala Leu Glu Ser Pro Glu
PGK2 (mouse) Leu Asp Tyr Phe Ser Lys Ala Leu Glu Lys Pro Glu
Fragment 4 - - Phe Leu Ala
9
lie Leu
20
- Ala - -
PGK1 Arg Pro Phe Leu Ala lie Leu Gly Gly Ala Lys Val
PGK2 Arg Pro Phe Leu Ala lie Leu Gly Gly Ala Lys Val
Fragment 4 Ala Asp -
?
H e Gin
30
Leu
PGK1 Ala Asp Lys lie Gin Leu
PGK2 Lys Asp Lys lie Gin Leu
The sequences of PGK-1 and PGK-2 differ by 4 AA which 
have been all identified in this fragment. Therefore the 
identification of fragment 4 as PGK-1 is not ambiguous
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although the molar levels of AA in the purified peptide are 
low.
PGK-1 has been identified as the primer recognition 
protein 2 (PRP2). (Jindal and Vishwanatha, 1990). PRP are 
proteins important for the efficiency of DNA replication. 
Purified PRP is made up of two subunits PRP1 and PRP2 of MW 
of 36,000 and 41,000 on SDS gel.
Evidence from studies of SV40 DNA replication in vitro, 
has led to to the proposal that DNA polymerase delta is the 
leading strand replicase while DNA polymerase alpha 
functions as a lagging strand replicase. For polymerase 
alpha to function on the lagging strand it must be capable 
of extending On RNA primer of 6-9 bases utilizing a 
template of 40-300 bases of ssDNA, i.e. working on 
substrates with a low primer to template ratio. Polymerase 
alpha is very ineffective at using substrates where the 
primer to template ratio is low. PRP are cofactors of 
polymerase alpha which increase the efficiency of the 
enzyme (Jindal and Vishwanatha, 1990).
The two subunits of PRP are tightly bound, they co­
elute from a MonoQ column at pH. 6.9 (Tsurimoto and 
Stillman, 1989). The i.p. of the two subunit of PRP could 
explain the existence of a 34KD polypeptide which is i.p. 
by TBS (Hewitt, 1988). A 34KD is also purified in the same 
experiment as the TBS:40, however, it does not co-elute 
with the TBS:40 from the 1ml Mono Q column at p H .8, but it 
can be i.p. by TBS in fraction 8 (see figure 3.21). The 
identification of such a 34KD protein has not been further 
pursued.
Published properties of PGK-1 suggests that it could be 
one of the constituents of the TBS:40.
PGK-1 showed properties similar to the TBS:40 in a 
published purification procedure (Hiremath and Rothstein, 
1982). As for the TBS:40, PGK-1 was precipitated in a 54%- 
80% ammonium sulphate pellet, and it did not stick to an 
anion exchange resin at p H .8.
PGK-1 calculated molecular weight is 44,596 Daltons,
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but it is reported to migrate faster in SDS gels (Mas et 
a1» » 1986). The apparent mobility of PGK-1 is variable in 
different rat tissues and minor isoforms exists (reviewed 
by VandeBerg, 1985). PGK-1 isoforms can be induced by 
transformation} (Tollefsbol and Gracy} 1980). Some isoforms 
could therefore be i.ped by TBS.
PGK-1 expression is decreased 8 fold, but not shut-off 
by HSV-2 infection as detected by slot blots (data not 
shown). Since the TBS:40 is made of several proteins, PGK-1 
could be a component of the TBS:40 whose expression is not 
increased by HSV-2 infection. Moreover the slot blots 
experiment used measured the abundance of the proteins 
reacting with an antibody and not of an individual isoform.
A Western blotting experiment with the antiserum 
raised against PGK-1 could show an immunological 
relationship between the "COLUMN 40” . and PGK-1.
4^3.3. RAT MITOCHONDRIAL ASPARTATE AMINOTRANSFERASE.
Aspartate aminotransferases are dimeric enzymes which 
catalyze the following reaction.
L-aspartate oxaloacetate
+ x  ^  +
2-oxaloglutarate L-glutamate
/(or oxoglutarate)
Aspartate aminotransferases use pyridoxal phosphate as 
co-enzyme. Both the cytoplasmic and the mitochondrial 
aspartate aminotransferases are synthesized in the 
cytoplasm. The mAspAT precursor migrates to the 
mitochondria, where it is cleaved to form the mature 
enzyme.
The rat mAspAT has been purified (Huynh et a l .. 1980) 
sequenced (Huynh et a l .. 1981) and the gene cloned
(Mattingly et a l ., 1987). The subunit of the rat mAspAT has 
a predicted MW of 44,358 (Huynh et a l .. 1981), which
matches its apparent MW on SDS-PAGE (Huynh et a l .. 1980).
The N-terminus sequence and the sequence from two 
internal peptides from the "VOID VOLUME 40" matched the 
published sequence of the rat mAspAT.
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Two AA of the peptides sequenced differ from the 
published sequence of rat mAspAT. The glycine, AA 11, is 
replaced by a proline. This substitution was also observed 
in the clone of the mAspAT gene isolated and sequenced by 
Mattingly et a l .. (1987). The second difference is a
lysine, AA 280, replaced by a proline but from my 
purification the identification of the proline was only 
tentative, because of the low level of AA recovered from 
the sequencer. These differences could be confirmed by 
cloning the gene and sequencing it.
Aspartate aminotransferases are the subject of 
considerable studies because they are markers of myocardial 
infarction and of liver diseases. No report of their 
involvement in cancer has been found in the literature. 
There is, however, extensive evidence of mitochondrial 
derangement in cancer but it is not clear whether these 
derangements are a factor initiating transformation or a 
consequence of it (Reviewed by Shay and Werbin, 1987). 
Mitochondria are the site of the cellular respiration. 
However the oxidative metabolism of cancer cells is 
impaired. Cancer cells can obtain approximate^ the same 
amount of energy from fermentation as from respiration, 
whereas normal cells obtain much more energy from 
respiration than from fermentation. Warburg (1956), 
therefore, proposed that an impairement of mitochondrial 
function was essential to the transformed phenotype. These 
results also showed that mitochondria were unimportant for 
the energy metabolism of cancer cells and genes coding 
mitochondrial proteins could become non-functional without 
modification of the phenotype of the cell, and therefore 
the importance of the modification of such genes is in 
doubt (Howard Jacobs, personal communication).
Mitochondrial proteins are also known to induce auto­
antibodies. The proteins responsible have been studied in 
primary liver biliary cirrhosis. Mitochondrial aspartate 
aminotransferase has not been identified as one of the 
components of the mitochondrial autoantigens in the
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published literature.
The biochemical properties of the purified mAspAT 
(Huynh et a l ., 1980) are compatible with the results
presented in this thesis. The mAspAT is precipitated by 
ammonium sulphate in the 40%-80% fraction and it is not 
retained by an anion exchange column at p H .8.
The mAspAT was reported to be functional, associated 
with glutamate dehydrogenase, the alpha ketoglutarate 
dehydrogenase complex and the mitochondrial malate 
dehydrogenase (Fahien et a l ., 1989); the mAspAT associates
with lipids and with a binding protein on the internal 
membrane of the mitochondrion (Teller et a l .. 1990). It is 
possible that TBS i.p. one of these proteins and the mAspAT 
as a consequence. The complex could be disrupted by the 
purification procedure. This explanation is compatible with 
the results of the i.p. experiments. The "VOID VOLUME" may 
be i.p. as a complex with the "COLUMN 40" at p H . 8. But co­
precipitation of the "VOID VOLUME 40" and the "COLUMN 40" 
is not the only possible explanation. The "VOID VOLUME 40" 
could co-precipitate with another protein (see figure, 
3.19) .
The purification of the "COLUMN 40" was repeated using 
radiolabelled extracts. Four preparations using the growth 
of 60 roller bottles were used. One fraction .of each 
preparation was us^ct for an i.p. experiment with TBS to 
verify the presence of the "COLUMN 40". The experiment was 
carried out as described in section 3.5.8.. Six bands from 
this digest were sent for sequencing to Dr Keen. No 
sequence could be obtained from one of the bands sent 
because of insufficient material. More than one sequence 
was obtained from the other bands. Nine sequences having an 
initial yield of 10 to 50 picomoles matched the sequence of 
the mAspAT.
The internal peptides sequenced are shown underneath. The 
strokes J denote common A A .
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1 SSWWTHVEMG GPDPILGVTE AFKRDTNSKK MNLGVGAYRD DNGKPYVLPS
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
AFGRDTNSKK MNLGV 
51 VRKAEAQIAG KNLDKEYLPI GGLADRCKAS AELALGENSE VLKSGRFVTV
i i i i i i i i i i i i i i i i i i
i i i i i i i t i i t i i i i i i i
LALGENSE VLKSGRFVTV
101 QTISGTGALR VGASFLQRFF KFSRDVFLPK PSGGNHTEIA RDAGMQLEGY
i i i i i i i i ii i i i i i i i
QTISGTGAL
151 RYYDPKTCGF DFSGALED1S KTPEQSVLLL HACAHNPTGV DPRPEQWDEM
i i i i i i i i i i i i i i i i i
i i i i i i i i i i i i i i i i i
QSVLLL HACAHNPTGV M
201 AAYVKKNNLF AFFD.MAYQGF ASGDGNKDAW AVRHFIEQGI NVCLCQSYAK
ii iii iii i i i i i i iii iii iii i i i i i i i
AAVVKKKNLF AFFDMAY 
251 NMGLYGERVG AFTVVCKDAE EAKRVESQLK ILIRPLYSNP PLNGARIAAT
i i i i i i i i i i i i i i
i i i i i i i i i i i i i i
SQLK ILIRPLYSNP 
301 ILTSPDLRQG WLQEVKGMAD RIGSMRTQLV SNLKKEGSSR NWQHITDQIG
35 1 MFCFTGIKPE QVERLTKEFS IYMTKDGRIS VAGVTSGNVG YLAHAIHQVT
401 K
In total 89 AA were identified. The sequences obtained are 
identical to the sequence of mAspAT except for AA 203 and 
207. This result suggested that the "COLUMN 40" could be 
also related to the mAspAT.
4.4. CONCLUSION AND FUTURE WORK.
The "VOID VOLUME 40" is immunological1y and sequence 
related to the mAspAT. The mechanism of the i.p. of the 
"VOID VOLUME 40" by TBS should be investigated.
HSV-2 infection increases the expression of mAspAT as 
detected in slot blot experiments. In common with most 
house keeping gene the mAspAT contains neither CAAT nor 
TATA boxes (Setoyama et a l ., 1990) therefore the mechanism
of induction by HSV-2 is not by transactivation. Several 
mechanisms of induction of cellular genes by HSV have been 
documented (Reviewed by Everett, 1987). These includes
transactivation by Vmwl75 and VmwllO, the formation of
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complexes of TAATGARAT with Vmw65 (Kemp et a l . 1986), the 
induction by adsorption of the virus to the cell surface 
and induction without any protein synthesis (Patel et a l .. 
1986). So far we have not investigated these mechanisms, 
but it is known that the TBS:40 activates at least seven 
and a half hour later than the U90 (Hewitt, 1988), and 
moreover the U90 is increased by those proteins which 
regulates protein synthesis (Macnab, personnal
communication ) .
In the second experiment the sequences obtained from 
the "COLUMN 40" were matching the sequences of the mAspAT. 
A contamination of the "COLUMN 40" by the "VOID VOLUME 40" 
must be ruled out. Other methods of purification must be 
used such as chromatofocusing, cation exchange 
chromatography or two dimension gel electrophoresis. If 
the sequences obtained are identical to the mAspAT 
sequences, the relationship between the "COLUMN:40" and the 
mAspAT would be confirmed.
Finally which of the 40KD proteins is i.p. by the sera 
of cervical cancer patientS could be determined. Its gene 
could be cloned and the entire protein sequenced. Its 
function could be investigated.
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